Classification criteria for psoriatic arthritis: Developme international study

Arthritis and Rheumatism 54, 2665-2673 DOI: 10.1002/art.21972

Citation Report

#	Article	IF	CITATIONS
1	The locus ceruleus and dementia in Parkinson's disease. Neurology, 1993, 43, 986-986.	1.5	160
2	Management of psoriatic arthritis: The therapeutic interface between rheumatology and dermatology. Current Rheumatology Reports, 2006, 8, 348-354.	2.1	37
3	Other seronegative spondyloarthropathies. Medicine, 2006, 34, 401-404.	0.2	1
4	Lack of genetic association of the interleukin-4 receptor single-nucleotide polymorphisms I50V and Q551R with erosive disease in psoriatic arthritis. Arthritis and Rheumatism, 2006, 54, 4023-4024.	6.7	4
5	Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis, than rheumatoid arthritis. Annals of the Rheumatic Diseases, 2006, 66, 113-117.	0.5	62
6	Clinical, radiological, and functional assessment in psoriatic arthritis: is it different from other inflammatory joint diseases?. Annals of the Rheumatic Diseases, 2006, 65, iii22-iii24.	0.5	36
7	Psoriatic disease—from skin to bone. Nature Clinical Practice Rheumatology, 2007, 3, 698-706.	3.2	81
8	Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. Annals of the Rheumatic Diseases, 2007, 67, 672-676.	0.5	149
9	Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Annals of the Rheumatic Diseases, 2007, 67, 717-719.	0.5	49
10	Psoriatic Arthritis-New Insights Give New Options for Treatment. Current Medicinal Chemistry, 2007, 14, 359-366.	1.2	7
11	Psoriatic arthritis is a joint-damaging disease a call for action!. Rheumatology, 2007, 46, 1747-1748.	0.9	3
13	The clinical spectrum of psoriasis. Clinics in Dermatology, 2007, 25, 510-518.	0.8	158
14	Psoriatic arthritis: clinical spectrum and diagnostic procedures. Clinics in Dermatology, 2007, 25, 519-523.	0.8	21
18	Are the classification criteria for psoriatic arthritis better than existing criteria for diagnosing psoriatic arthritis? Comment on the article by Taylor et al. Arthritis and Rheumatism, 2007, 56, 699-700.	6.7	17
19	Psoriatic arthritis: Current concepts on pathogenesis-oriented therapeutic options. Arthritis and Rheumatism, 2007, 56, 1051-1066.	6.7	53
20	TNF polymorphisms in psoriasis: Association of psoriatic arthritis with the promoter polymorphismTNF*-857 independent of thePSORS1 risk allele. Arthritis and Rheumatism, 2007, 56, 2056-2064.	6.7	88
21	Development of psoriasis after B cell depletion with rituximab. Arthritis and Rheumatism, 2007, 56, 2715-2718.	6.7	231
22	Classification criteria in rheumatic diseases: A review of methodologic properties. Arthritis and Rheumatism. 2007. 57. 1119-1133.	6.7	122

ATION REDO

#	Article	IF	CITATIONS
23	Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis and Rheumatism, 2007, 57, 1560-1563.	6.7	129
25	Diagnostic du rhumatisme psoriasique de forme périphérique : élaboration de recommandations pour la pratique clinique, à partir d'une analyse systématique de la littérature et de l'opinion d'experts. Revue Du Rhumatisme (Edition Francaise), 2007, 74, 15-22.	0.0	4
26	Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case?control study. British Journal of Dermatology, 2007, 157, 68-73.	1.4	543
27	Multidisciplinary evaluation of patients with psoriasis presenting with musculoskeletal pain: a dermatology: rheumatology clinic experience. British Journal of Dermatology, 2007, 157, 1050-1051.	1.4	35
28	Psoriasis and psoriatic arthritis: separate or one and the same?. British Journal of Dermatology, 2007, 157, 850-860.	1.4	51
29	Apsoriatic psoriatic arthritis. APLAR Journal of Rheumatology, 2007, 10, 264-269.	0.2	4
30	A case of psoriatic arthritis without the appearance of psoriatic skin or nail lesions for 21 years. APLAR Journal of Rheumatology, 2007, 10, 306-309.	0.2	1
31	Psoriatic arthritis: Is it for real?. Joint Bone Spine, 2007, 74, 311-312.	0.8	7
32	Recommendations of the French Society for Rheumatology regarding TNFα antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine, 2007, 74, 638-646.	0.8	98
33	A Comparison of the Efficacy and Safety of Celecoxib 200 mg and Celecoxib 400 mg Once Daily in Treating the Signs and Symptoms of Psoriatic Arthritis. Seminars in Arthritis and Rheumatism, 2007, 37, 164-173.	1.6	37
35	Sensitivity and specificity of plain radiographic features of peripheral enthesopathy at major sites in psoriatic arthritis. Skeletal Radiology, 2007, 36, 1061-1066.	1.2	22
36	Genetik der Psoriasis. Medizinische Genetik, 2007, 19, 350-355.	0.1	2
37	T cells in psoriatic arthritis. Current Rheumatology Reports, 2007, 9, 437-441.	2.1	18
38	Psoriatic arthritis: Current topics. Current Rheumatology Reports, 2007, 9, 442-448.	2.1	10
39	Psoriatic arthritis epidemiology. Current Rheumatology Reports, 2007, 9, 449-454.	2.1	41
40	Axial disease in psoriatic arthritis. Current Rheumatology Reports, 2007, 9, 455-460.	2.1	110
43	Clinical evaluation and comparison of different criteria for classification in Turkish patients with psoriatic arthritis. Rheumatology International, 2008, 28, 959-964.	1.5	3
44	Joint and nail involvement in Turkish patients with psoriatic arthritis. Rheumatology International, 2008, 29, 223-225.	1.5	24

	CHATON R	EPORT	
#	Article	IF	CITATIONS
47	Altered bone remodeling in psoriatic arthritis. Current Rheumatology Reports, 2008, 10, 311-317.	2.1	28
48	Can we identify psoriatic arthritis early?. Current Rheumatology Reports, 2008, 10, 419-421.	2.1	8
49	Fast spin echo-T2-weighted sequences with fat saturation in toe dactylitis of spondyloarthritis. Clinical Rheumatology, 2008, 27, 1141-1145.	1.0	21
50	Classification and categorisation of psoriatic arthritis. Clinical Rheumatology, 2008, 27, 1211-1216.	1.0	12
51	Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis. Arthritis and Rheumatism, 2008, 58, 1796-1802.	6.7	33
52	Tumor necrosis factor $\hat{I}\pm$ drives cadherin 11 expression in rheumatoid inflammation. Arthritis and Rheumatism, 2008, 58, 3051-3062.	6.7	54
53	Erosive arthritis in a patient with pycnodysostosis: An experiment of nature. Arthritis and Rheumatism, 2008, 58, 3394-3401.	6.7	13
54	Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis and Rheumatism, 2008, 59, 1322-1331.	6.7	126
55	Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis and Rheumatism, 2008, 58, 3705-3709.	6.7	122
57	Immunopathogenesis of psoriatic arthritis: Recent advances. Open Medicine (Poland), 2008, 3, 245-253.	0.6	0
58	Anti–tumour necrosis factorâ€Î± therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 341-344.	1.3	166
59	Clinical expression, but not disease outcome, may vary according to age at disease onset in psoriatic spondylitis. Joint Bone Spine, 2008, 75, 544-547.	0.8	27
60	Insights Into the Pathology and Treatment of Spondyloarthritis: From the Bench to the Clinic. Seminars in Arthritis and Rheumatism, 2008, 38, 83-100.	1.6	27
61	Developments in psoriasis and psoriatic arthritis. Drug Discovery Today Disease Mechanisms, 2008, 5, e47-e54.	0.8	1
62	Successful treatment of psoriatic arthritis with rituximab. Annals of the Rheumatic Diseases, 2008, 67, 1647-1648.	0.5	27
63	National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. Journal of the American Academy of Dermatology, 2008, 58, 1031-1042.	0.6	383
64	Guidelines of care for the management of psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology, 2008, 58, 851-864.	0.6	456
65	The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy. Cytokine, 2008, 41, 16-23.	1.4	98

#	Article	IF	CITATIONS
66	Rheumatoid Arthritis Synovium Contains Two Subsets of CD83â^'DC-LAMPâ^' Dendritic Cells with Distinct Cytokine Profiles. American Journal of Pathology, 2008, 172, 940-950.	1.9	129
68	MRI changes in psoriatic dactylitis extent of pathology, relationship to tenderness and correlation with clinical indices. Rheumatology, 2008, 47, 92-95.	0.9	125
69	Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate. Annals of the Rheumatic Diseases, 2008, 67, 1648-1649.	0.5	27
70	Psoriatic arthritis: genetic susceptibility and pharmacogenetics. Pharmacogenomics, 2008, 9, 195-205.	0.6	13
71	The occurrence of psoriatic arthritis in Denmark. Annals of the Rheumatic Diseases, 2008, 67, 1422-1426.	0.5	37
72	On the applicability of the CASPAR criteria in psoriatic arthritis. Annals of the Rheumatic Diseases, 2008, 67, 1495-1496.	0.5	8
73	On the heritability of psoriatic arthritis. Disease concordance among monozygotic and dizygotic twins. Annals of the Rheumatic Diseases, 2008, 67, 1417-1421.	0.5	71
74	What is the primary lesion in SpA dactylitis?. Rheumatology, 2008, 47, 561-562.	0.9	18
75	Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. Rheumatology, 2008, 47, 1160-1167.	0.9	145
76	Rapid improvement of nailfold capillaroscopy after intense immunosuppression for systemic sclerosis and mixed connective tissue disease. Annals of the Rheumatic Diseases, 2008, 67, 1057-1059.	0.5	73
77	Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma. Annals of the Rheumatic Diseases, 2008, 67, 1056-1057.	0.5	70
79	Involvement, satisfaction and unmet health care needs in patients with psoriatic arthritis. Rheumatology, 2008, 48, 53-56.	0.9	38
80	Very low prevalence of anti-CCP antibodies in rheumatoid factor-negative psoriatic polyarthritis. Rheumatology, 2008, 48, 315-316.	0.9	19
81	Do all anti-citrullinated protein/peptide antibody tests measure the same? Evaluation of discrepancy between anti-citrullinated protein/peptide antibody tests in patients with and without rheumatoid arthritis. Annals of the Rheumatic Diseases, 2008, 67, 542-546.	0.5	37
83	Epstein-Barr Virus (EBV) Prevalence and the Risk of Reactivation in Patients with Inflammatory Arthritis Using Anti-TNF Agents and in those who are Biologic Naive. Open Rheumatology Journal, 2009, 3, 30-34.	0.1	21
84	Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Annals of the Rheumatic Diseases, 2009, 68, 497-501.	0.5	170
85	Early Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2009, 83, 26-27.	2.2	11
86	The diagnosis and treatment of early psoriatic arthritis. Nature Reviews Rheumatology, 2009, 5, 634-641.	3.5	61

#	Article	IF	CITATIONS
87	Epidemiology of Psoriatic Arthritis. Journal of Rheumatology, 2009, 36, 213-215.	1.0	6
88	Psoriatic arthritis in Asia. Rheumatology, 2009, 48, 1473-1477.	0.9	47
89	Occurrence and correlates of fatigue in psoriatic arthritis. Annals of the Rheumatic Diseases, 2009, 68, 1553-1558.	0.5	77
90	Psoriatic Arthritis Spondylitis Radiology Index: A Modified Index for Radiologic Assessment of Axial Involvement in Psoriatic Arthritis. Journal of Rheumatology, 2009, 36, 1006-1011.	1.0	47
91	Familial aggregation of psoriatic arthritis. Annals of the Rheumatic Diseases, 2009, 68, 664-667.	0.5	154
92	Testing an OMERACT MRI Scoring System for Peripheral Psoriatic Arthritis in Cross-sectional and Longitudinal Settings. Journal of Rheumatology, 2009, 36, 1811-1815.	1.0	29
93	Treatment guidelines for psoriatic arthritis. International Journal of Clinical Rheumatology, 2009, 4, 329-342.	0.3	5
94	Established Psoriatic Arthritis: Clinical Aspects. Journal of rheumatology Supplement, The, 2009, 83, 21-23.	2.2	18
95	Magnetic Resonance Imaging of the Hand in Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2009, 83, 39-41.	2.2	16
96	Inflammatory Arthritis: An Overview for Primary Care Physicians. Postgraduate Medicine, 2009, 121, 148-162.	0.9	8
97	Psoriatic Arthritis sine Psoriasis. Journal of rheumatology Supplement, The, 2009, 83, 28-29.	2.2	34
98	A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Annals of the Rheumatic Diseases, 2009, 68, 1303-1309.	0.5	84
99	Evaluation for Psoriatic Arthritis in Dermatology Clinics. Journal of Cutaneous Medicine and Surgery, 2009, 13, S88-S92.	0.6	2
100	Psoriasis Comorbidities. Journal of Cutaneous Medicine and Surgery, 2009, 13, S77-S87.	0.6	35
101	Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis, and Recommendations for Study Design. Journal of Rheumatology, 2009, 36, 1792-1799.	1.0	38
102	Investigation of association of genes NAT9, SLC9A3R1 and RAPTOR on chromosome 17q25 with psoriatic arthritis: Table 1. Annals of the Rheumatic Diseases, 2009, 68, 292-293.	0.5	6
103	Juvenile Psoriatic Arthritis: Bathwater or Baby?. Journal of Rheumatology, 2009, 36, 1861-1863.	1.0	18
104	Update in treatment options for psoriatic arthritis. Expert Review of Clinical Immunology, 2009, 5, 779-788.	1.3	4

#	Article	IF	CITATIONS
105	Sensitivity of the Classification of Psoriatic Arthritis Criteria in Early Psoriatic Arthritis. Journal of Rheumatology, 2009, 36, 368-370.	1.0	48
106	Psoriatic Arthritis: A Review. Journal of Pharmacy Practice, 2009, 22, 86-103.	0.5	1
107	The Challenge and Need of Defining Axial Psoriatic Arthritis. Journal of Rheumatology, 2009, 36, 2633-2634.	1.0	16
108	High blood levels of chromogranin A in giant cell arteritis identify patients refractory to corticosteroid treatment. Annals of the Rheumatic Diseases, 2009, 68, 293-295.	0.5	21
109	Time Trends in Epidemiology and Characteristics of Psoriatic Arthritis Over 3 Decades: A Population-based Study. Journal of Rheumatology, 2009, 36, 361-367.	1.0	161
110	Prevalence of spondyloarthritis in 504 Chinese patients with HLAâ€B27â€associated acute anterior uveitis. Scandinavian Journal of Rheumatology, 2009, 38, 84-90.	0.6	46
111	Diagnosis of peripheral psoriatic arthritis: Recommendations for clinical practice based on data from the literature and experts opinion. Joint Bone Spine, 2009, 76, 532-539.	0.8	19
112	Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A populationâ€based study. Arthritis and Rheumatism, 2009, 61, 233-239.	6.7	470
113	Evaluation of ankylosing spondylitis spinal mobility measurements in the assessment of spinal involvement in psoriatic arthritis. Arthritis and Rheumatism, 2009, 61, 386-392.	6.7	44
114	Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. Arthritis and Rheumatism, 2009, 60, 966-975.	6.7	136
115	In vitro spontaneous osteoclastogenesis of human peripheral blood mononuclear cells is not crucially dependent on T lymphocytes. Arthritis and Rheumatism, 2009, 60, 1020-1025.	6.7	15
116	International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis and Rheumatism, 2009, 61, 1235-1242.	6.7	104
117	The prevalence of psoriatic arthritis in people with psoriasis. Arthritis and Rheumatism, 2009, 61, 1373-1378.	6.7	203
118	Serum levels of tissue inhibitor of metalloproteinase-1 and periarticular bone loss in early rheumatoid arthritis. Clinical Rheumatology, 2009, 28, 285-291.	1.0	14
119	Imaging of the sacroiliac joint involvement in seronegative spondylarthropathies. Clinical Rheumatology, 2009, 28, 1007-1019.	1.0	39
120	Macroscopic features of knee synovitis in early untreated Behçet disease and psoriatic arthritis. Clinical Rheumatology, 2009, 28, 1053-1057.	1.0	12
123	Clinical evaluation and comparison of different criteria for classification in Turkish patients with psoriatic arthritis. Rheumatology International, 2009, 29, 365-370.	1.5	8
124	Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. British Journal of Dermatology, 2009, 160, 1040-1047.	1.4	341

#	Article	IF	CITATIONS
125	Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice. Clinical and Experimental Dermatology, 2009, 34, 469-475.	0.6	15
126	Genetic Variants of the IL-23R Pathway: Association with Psoriatic Arthritis and Psoriasis Vulgaris, but No Specific Risk Factor for Arthritis. Journal of Investigative Dermatology, 2009, 129, 355-358.	0.3	97
127	Semiâ€quantitative assessment of the distribution of skin lesions in patients with psoriasis and psoriasis arthritis. Skin Research and Technology, 2009, 15, 451-458.	0.8	2
128	Psoriatic arthritis. Dermatologic Therapy, 2009, 22, 40-55.	0.8	106
129	Psoriasis and systemic inflammation: underdiagnosed enthesopathy. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 3-8.	1.3	57
132	Topical treatments for chronic plaque psoriasis. , 2009, , CD005028.		43
133	Treatment strategies for early psoriatic arthritis. Expert Opinion on Pharmacotherapy, 2009, 10, 271-282.	0.9	16
135	Managing Comorbidities in Psoriasis. Actas Dermo-sifiliográficas, 2009, 100, 22-27.	0.2	9
136	Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. Journal of Hepatology, 2009, 51, 758-764.	1.8	217
137	Comorbidities in Patients with Psoriasis. American Journal of Medicine, 2009, 122, 1150.e1-1150.e9.	0.6	161
139	Comorbidities in Dermatology. Dermatologic Clinics, 2009, 27, 137-147.	1.0	35
140	Treatment recommendations for psoriatic arthritis. Annals of the Rheumatic Diseases, 2009, 68, 1387-1394.	0.5	483
141	Psoriatic arthritis: from pathogenesis to therapy. Arthritis Research and Therapy, 2009, 11, 214.	1.6	110
142	Developments in the scientific and clinical understanding of the spondyloarthritides. Arthritis Research and Therapy, 2009, 11, 208.	1.6	41
143	Distinct synovial immunopathology in Behçet disease and psoriatic arthritis. Arthritis Research and Therapy, 2009, 11, R17.	1.6	51
144	MRI bone oedema scores are higher in the arthritis mutilans form of psoriatic arthritis and correlate with high radiographic scores for joint damage. Arthritis Research and Therapy, 2009, 11, R2.	1.6	48
145	Epidemiological and clinical characteristics of psoriatic arthritis in northern Norway. Scandinavian Journal of Rheumatology, 2009, 38, 251-255.	0.6	73
146	Ustekinumab for psoriatic arthritis. Lancet, The, 2009, 373, 605-606.	6.3	19

#	Article	IF	CITATIONS
147	Espondiloartritis. Concepto. Clasificación. Etiopatogenia. Formas clÃnicas. Criterios diagnósticos. Medicine, 2009, 10, 1987-1993.	0.0	0
148	Artritis psoriÃ _i sica. Medicine, 2009, 10, 2001-2007.	0.0	0
149	Diagnóstico de Artritis Psoriática. Revista Colombiana De ReumatologÃa, 2009, 16, 342-351.	0.0	4
150	New insights into the pathogenesis and genetics of psoriatic arthritis. Nature Clinical Practice Rheumatology, 2009, 5, 83-91.	3.2	112
151	Psoriatic arthritis assessment and treatment update. Current Opinion in Rheumatology, 2009, 21, 348-355.	2.0	24
152	Diagnosis and Management of Psoriatic Arthritis. Journal of the Dermatology Nurses' Association, 2009, 1, 283-293.	0.1	1
153	Psoriatic Arthritis from Wright's Era Until Today. Journal of rheumatology Supplement, The, 2009, 83, 4-8.	2.2	27
154	Environmental risk factors for the development of psoriatic arthritis: results from a case–control study. Yearbook of Dermatology and Dermatologic Surgery, 2009, 2009, 150-151.	0.0	0
155	Time Trends in Epidemiology and Characteristics of Psoriatic Arthritis Over 3 Decades: A Population-based Study. Yearbook of Dermatology and Dermatologic Surgery, 2010, 2010, 141-142.	0.0	0
156	Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Yearbook of Dermatology and Dermatologic Surgery, 2010, 2010, 142-144.	0.0	0
157	Variation in Eligibility Criteria From Studies of Radiculopathy due to a Herniated Disc and of Neurogenic Claudication due to Lumbar Spinal Stenosis. Spine, 2010, 35, 803-811.	1.0	84
158	Genetic susceptibility factors for psoriatic arthritis. Current Opinion in Rheumatology, 2010, 22, 152-156.	2.0	21
159	How early should psoriatic arthritis be treated with a TNF-blocker?. Current Opinion in Rheumatology, 2010, 22, 393-396.	2.0	6
160	Advantages in early recognition and treatment of psoriatic arthritis. International Journal of Clinical Rheumatology, 2010, 5, 461-473.	0.3	1
163	Jaccoud's arthropathy and psoriatic arthritis, a rare association. Rheumatology International, 2010, 30, 1081-1083.	1.5	11
164	Antibodies to human tissue transglutaminase and alterations of vitamin D metabolism in ankylosing spondylitis and psoriatic arthritis. Rheumatology International, 2010, 30, 1559-1563.	1.5	23
165	Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clinical Rheumatology, 2010, 29, 399-403.	1.0	77
166	Hepatitis C- and Human Immunodeficiency Virus-Induced Hypersensitivity Vasculitis. HSS Journal, 2010, 6, 102-107.	0.7	0

		LEPUKI	
#	Article	IF	CITATIONS
167	Update on Biomarkers in Psoriatic Arthritis. Current Rheumatology Reports, 2010, 12, 288-294.	2.1	35
168	Application of the GRAPPA Psoriatic Arthritis Treatment Recommendations in Clinical Practice. Current Rheumatology Reports, 2010, 12, 264-271.	2.1	4
169	Where Do We Stand With the Genetics of Psoriatic Arthritis?. Current Rheumatology Reports, 2010, 12, 300-308.	2.1	8
170	Development of Screening Tools to Identify Psoriatic Arthritis. Current Rheumatology Reports, 2010, 12, 295-299.	2.1	34
171	Other seronegative spondyloarthropathies. Medicine, 2010, 38, 190-193.	0.2	4
172	The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskeletal Disorders, 2010, 11, 98.	0.8	104
173	Disease measurement – enthesitis, skin, nails, spine and dactylitis. Best Practice and Research in Clinical Rheumatology, 2010, 24, 659-670.	1.4	31
174	Classification criteria for psoriatic arthritis and ankylosing spondylitis/axial spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2010, 24, 589-604.	1.4	76
175	Seronegative spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2010, 24, 747-756.	1.4	79
176	Classification of rheumatologic opinion on early inflammatory arthritis: Harmonization of a heterogeneous standard. Arthritis Care and Research, 2010, 62, 1407-1414.	1.5	6
177	CD248 and its cytoplasmic domain: A therapeutic target for arthritis. Arthritis and Rheumatism, 2010, 62, 3595-3606.	6.7	60
178	Rhumatisme psoriasiqueÂ: critères de classification, de diagnostic et de réponse thérapeutique. Revue Du Rhumatisme Monographies, 2010, 77, 67-73.	0.0	5
179	Psoriatic arthritis. Dermatologic Therapy, 2010, 23, 123-136.	0.8	27
180	Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 31-35.	1.3	124
181	Psoriatic disease: concepts and implications. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 627-630.	1.3	24
182	Psoriatic arthritis – what the dermatologist needs to know. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1270-1277.	1.3	18
183	EADV preceptorship: advances in dermatology. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 2-24.	1.3	11
184	Antibodies against cyclic citrullinated peptide in Japanese psoriatic arthritis patients. Journal of Dermatology, 2010, 37, 339-345.	0.6	20

#	Article	lF	CITATIONS
185	Analysis of clinical, radiological and laboratory variables in psoriatic arthritis with 25 Japanese patients. Journal of Dermatology, 2010, 37, 647-656.	0.6	8
186	The Role of microRNA-146a (miR-146a) and its Target IL-1R-Associated Kinase (IRAK1) in Psoriatic Arthritis Susceptibility. Scandinavian Journal of Immunology, 2010, 71, 382-385.	1.3	103
187	Evaluation of nail disease in psoriatic arthritis by using a modified nail psoriasis severity score index. International Journal of Dermatology, 2010, 49, 901-906.	0.5	50
188	Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nature Genetics, 2010, 42, 996-999.	9.4	334
189	Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nature Genetics, 2010, 42, 991-995.	9.4	331
190	The Self-Administered Psoriasis and Arthritis Screening Questionnaire (PASQ): A Sensitive and Specific Tool for the Diagnosis of Early and Established Psoriatic Arthritis. Psoriasis Forum, 2010, 16a, 9-16.	0.1	14
191	Update of the management of chronic psoriasis: new approaches and emerging treatment options. Clinical, Cosmetic and Investigational Dermatology, 2010, 3, 25.	0.8	4
192	Value of Entheseal Ultrasonography and Serum Cartilage Oligomeric Matrix Protein in the Preclinical Diagnosis of Psoriatic Arthritis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 2010, 3, CMAMD.S4461.	0.3	20
193	Which Psoriasis Patients Develop Psoriatic Arthritis?. Psoriasis Forum, 2010, 16a, 17-25.	0.1	37
194	Soluble Biomarkers of Cartilage and Bone Metabolism in Early Proof of Concept Trials in Psoriatic Arthritis: Effects of Adalimumab Versus Placebo. PLoS ONE, 2010, 5, e12556.	1.1	34
195	Pesquisa de autoanticorpos em pacientes com artrite psoriásica sob terapia anti-TNFα. Revista Brasileira De Reumatologia, 2010, 50, 225-234.	0.8	16
196	Inflammatory Polyarthritis in a Patient with Psoriasis: Is It Psoriatic Arthritis or Rheumatoid Arthrirtis?. Korean Journal of Internal Medicine, 2010, 25, 224.	0.7	17
197	Time and predictors of response to tumour necrosis factor-Â blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort. Rheumatology, 2010, 49, 1361-1366.	0.9	29
198	Mortality in Psoriatic Arthritis – A Single-center Study from the UK. Journal of Rheumatology, 2010, 37, 2141-2144.	1.0	70
199	Early-Onset Obesity and Risk for Psoriatic ArthritisOBESITY AND RISK FOR PSORIATIC ARTHRITIS. JAMA - Journal of the American Medical Association, 2010, 304, 787.	3.8	7
200	Minimally Important Difference for Patient-reported Outcomes in Psoriatic Arthritis: Health Assessment Questionnaire and Pain, Fatigue, and Global Visual Analog Scales. Journal of Rheumatology, 2010, 37, 1024-1028.	1.0	50
201	Evaluation of the CASPAR criteria for psoriatic arthritis in the Chinese population. Rheumatology, 2010, 49, 112-115.	0.9	28
202	Effect of Psoriatic Arthritis According to the Affected Categories of the International Classification of Functioning, Disability and Health. Journal of Rheumatology, 2010, 37, 1885-1891.	1.0	33

#	Article	IF	CITATIONS
203	Updated Turkish Guidelines for the Management of Psoriasis with Biologic Agents. Turkderm, 2010, 44, 105-112.	0.0	7
204	Shedding of Large Functionally Active CD11/CD18 Integrin Complexes from Leukocyte Membranes during Synovial Inflammation Distinguishes Three Types of Arthritis through Differential Epitope Exposure. Journal of Immunology, 2010, 185, 4154-4168.	0.4	45
205	Diagnostic performance of anti-citrullinated peptide antibodies for the diagnosis of rheumatoid arthritis: the relevance of likelihood ratios. Clinical Chemistry and Laboratory Medicine, 2010, 48, 829-34.	1.4	16
206	Synovial tissue hypoxia and inflammation in vivo. Annals of the Rheumatic Diseases, 2010, 69, 1389-1395.	0.5	198
207	Identification of Risk Factors for Psoriatic Arthritis. Archives of Dermatology, 2010, 146, 785-8.	1.7	24
208	TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade. Annals of the Rheumatic Diseases, 2010, 69, 301-304.	0.5	54
209	Comparison of interferon Î ³ release assays and conventional screening tests before tumour necrosis factor α blockade in patients with inflammatory arthritis. Annals of the Rheumatic Diseases, 2010, 69, 181-185.	0.5	72
210	Current Controversies in Spondyloarthritis: SPARTAN. Journal of Rheumatology, 2010, 37, 2617-2623.	1.0	11
211	Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 671-676.	0.5	104
212	Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?. Annals of the Rheumatic Diseases, 2010, 69, 2160-2164.	0.5	66
213	Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Annals of the Rheumatic Diseases, 2010, 69, 624-625.	0.5	75
214	The Role of Dynamic Contrast-Enhanced MRI in the Differential Diagnosis of Psoriatic and Rheumatoid Arthritis. American Journal of Roentgenology, 2010, 194, 715-720.	1.0	49
215	The Diagnostic and Therapeutic Challenge of Early Psoriatic Arthritis. Dermatology, 2010, 221, 6-14.	0.9	18
216	Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis. Annals of the Rheumatic Diseases, 2010, 69, 934-935.	0.5	33
217	Management of psoriatic arthritis. Indian Journal of Dermatology, Venereology and Leprology, 2010, 76, 645.	0.2	5
218	Co-morbidity and Age-related Prevalence of Psoriasis: Analysis of Health Insurance Data in Germany. Acta Dermato-Venereologica, 2010, 90, 147-151.	0.6	265
219	Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis. Rheumatology, 2010, 49, 1578-1589.	0.9	24
220	Imaging in Psoriasis and Psoriatic Arthritis: GRAPPA 2008. Journal of Rheumatology, 2010, 37, 448-452.	1.0	18

#	Article	IF	CITATIONS
221	Methods of Outcomes Measurement in Nail Psoriasis. Dermatology, 2010, 221, 23-28.	0.9	67
222	C-Reactive Protein and Markers for Thrombophilia in Patients with Chronic Plaque Psoriasis. International Journal of Immunopathology and Pharmacology, 2010, 23, 1195-1202.	1.0	31
223	Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology, 2010, 49, 1399-1405.	0.9	142
224	Testing scaling assumptions, reliability and validity of medical outcomes study short-form 36 health survey in psoriatic arthritis. Rheumatology, 2010, 49, 1495-1501.	0.9	44
227	Longitudinal Analysis of Fatigue in Psoriatic Arthritis. Journal of Rheumatology, 2010, 37, 1878-1884.	1.0	32
228	Variants in linkage disequilibrium with the late cornified envelope gene cluster deletion are associated with susceptibility to psoriatic arthritis. Annals of the Rheumatic Diseases, 2010, 69, 2199-2203.	0.5	36
229	Folate Pathway Enzyme Gene Polymorphisms and the Efficacy and Toxicity of Methotrexate in Psoriatic Arthritis. Journal of Rheumatology, 2010, 37, 1508-1512.	1.0	45
233	Psoriatic Arthritis: What the Dermatologist Needs to Know, Part 1. Actas Dermo-sifiliogrÃjficas, 2010, 101, 578-584.	0.2	1
234	Clinical Management of Psoriatic Arthritis in Spain: The CALIPSO Study. Actas Dermo-sifiliográficas, 2010, 101, 629-636.	0.2	3
235	Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Annals of the Rheumatic Diseases, 2010, 69, 618-623.	0.5	125
236	Risk Factors for Axial Inflammatory Arthritis in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2010, 37, 809-815.	1.0	94
237	Recognizing psoriatic arthritis in the dermatology clinic. Journal of the American Academy of Dermatology, 2010, 63, 733-748.	0.6	23
238	Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. Journal of Autoimmunity, 2010, 34, J314-J321.	3.0	403
239	A reliability study of biomechanical foot function in psoriatic arthritis based on a novel multi-segmented foot model. Gait and Posture, 2010, 32, 619-626.	0.6	29
240	Expression of MDC/CCL22 and its receptor CCR4 in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Cytokine, 2010, 49, 24-29.	1.4	67
241	Treatment of Psoriatic Arthritis with Biological Agents. Seminars in Cutaneous Medicine and Surgery, 2010, 29, 56-62.	1.6	11
242	Artritis psoriásica: lo que el dermatólogo debe saber (Parte 1). Actas Dermo-sifiliográficas, 2010, 101, 578-584.	0.2	6
243	Manejo clÃnico de la artritis psoriásica en España: estudio Calipso. Actas Dermo-sifiliográficas, 2010, 101, 629-636.	0.2	8

#	Article	IF	CITATIONS
244	The Medici syndrome: a medicoâ€historical puzzle. International Journal of Rheumatic Diseases, 2010, 13, 125-131.	0.9	13
245	Psoriatic arthritis: a systematic review. International Journal of Rheumatic Diseases, 2010, 13, 300-317.	0.9	91
246	El pie en las espondiloartropatÃas. EMC - PodologÃa, 2010, 12, 1-11.	0.1	0
247	Management of Psoriatic Arthritis. , 2010, , 55-69.		1
248	Silencing the Expression of Ras Family GTPase Homologues Decreases Inflammation and Joint Destruction in Experimental Arthritis. American Journal of Pathology, 2010, 177, 3010-3024.	1.9	17
249	Focus on: le spondiloartriti. La diagnosi precoce può modificare il decorso della malattia?. Italian Journal of Medicine, 2010, 4, 277-283.	0.2	0
250	Molecular Dissection of Psoriasis: Integrating Genetics and Biology. Journal of Investigative Dermatology, 2010, 130, 1213-1226.	0.3	253
251	Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-1± blockade in the knee joint. Arthritis Research and Therapy, 2010, 12, R148.	1.6	62
252	Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. Arthritis Research and Therapy, 2010, 12, R164.	1.6	87
253	Remission in psoriatic arthritis: is it possible and how can it be predicted?. Arthritis Research and Therapy, 2010, 12, R94.	1.6	77
254	Flow cytometric characterization of freshly isolated and culture expanded human synovial cell populations in patients with chronic arthritis. Arthritis Research and Therapy, 2010, 12, R15.	1.6	46
255	Pharmacological Therapies for Osteoarthritis of the Hand. Drugs and Aging, 2010, 27, 729-745.	1.3	20
256	Spondyloarthritides: evolving therapies. Arthritis Research and Therapy, 2010, 12, 221.	1.6	13
257	Socioeconomic Burden of Psoriatic Arthritis in Hong Kong: Direct and Indirect Costs and the Influence of Disease Pattern. Journal of Rheumatology, 2010, 37, 1214-1220.	1.0	42
258	Psoriatic Arthritis: A Dermatologist's Perspective. American Journal of Clinical Dermatology, 2010, 11, 19-22.	3.3	3
259	Determinants of psoriatic arthritis in patients with psoriasis. Expert Review of Dermatology, 2010, 5, 67-77.	0.3	2
260	Incidence and prevalence of psoriatic arthritis, ankylosing spondylitis, and reactive arthritis in the first descriptive population-based study in the Czech Republic. Scandinavian Journal of Rheumatology, 2010, 39, 310-317.	0.6	57
261	Hepatoprotective effect of tumour necrosis factor \hat{i}_{\pm} blockade in psoriatic arthritis: a cross-sectional study. Annals of the Rheumatic Diseases, 2010, 69, 1148-1150.	0.5	34

#	Article	IF	CITATIONS
262	Small joint involvement in psoriatic arthritis is associated with onycholysis: the Reykjavik Psoriatic Arthritis Study. Scandinavian Journal of Rheumatology, 2010, 39, 299-302.	0.6	40
263	Experiences on the use of biological drugs in psoriatic arthritis-associated amyloidosis. Scandinavian Journal of Rheumatology, 2011, 40, 236-238.	0.6	7
264	Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Research and Therapy, 2011, 13, S4.	1.6	86
265	Lack of effect of the MEFV E148Q polymorphism on IL-1β in Henoch–Schönlein purpura. Scandinavian Journal of Rheumatology, 2011, 40, 238-239.	0.6	0
266	Adalimumab or Cyclosporine as Monotherapy and in Combination in Severe Psoriatic Arthritis: Results from a Prospective 12-month Nonrandomized Unblinded Clinical Trial. Journal of Rheumatology, 2011, 38, 2466-2474.	1.0	52
269	Assessment of Synovitis in Erosive Osteoarthritis of the Hand using DCE-MRI and Comparison with that in its Major Mimic, the Psoriatic Arthritis. Academic Radiology, 2011, 18, 804-809.	1.3	30
270	Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in Spondyloarthritis except for Psoriatic Arthritis. ReumatologÃa ClAnica (English Edition), 2011, 7, 113-123.	0.2	10
271	Consensus statement of the Spanish Society of Rheumatology on the management of biologic therapies in psoriatic arthritis. ReumatologÃa ClÃnica (English Edition), 2011, 7, 179-188.	0.2	8
272	Connective Tissue Diseases and Psoriasis. Actas Dermo-sifiliográficas, 2011, 102, 487-497.	0.2	6
273	MR Imaging Assessment of Inflammatory, Crystalline-Induced, and Infectious Arthritides. Magnetic Resonance Imaging Clinics of North America, 2011, 19, 339-363.	0.6	9
277	Association between the PTPN22+1858 C/T polymorphism and psoriatic arthritis. Arthritis Research and Therapy, 2011, 13, R45.	1.6	18
278	Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy - a single centre, open-label study. Arthritis Research and Therapy, 2011, 13, R7.	1.6	41
279	Bone mineral density and body composition in postmenopausal women with psoriasis and psoriatic arthritis. Arthritis Research and Therapy, 2011, 13, R16.	1.6	83
280	Follistatin-like protein 1 is elevated in systemic autoimmune diseases and correlated with disease activity in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2011, 13, R17.	1.6	63
281	Diagnostic properties of metabolic perturbations in rheumatoid arthritis. Arthritis Research and Therapy, 2011, 13, R19.	1.6	115
284	Increased serum TWEAK levels in Psoriatic arthritis: Relationship with disease activity and matrix metalloproteinase-3 serum levels. Cytokine, 2011, 53, 289-291.	1.4	28
285	Whole-body MR imaging in psoriatic arthritis: Additional value for therapeutic decision making. European Journal of Radiology, 2011, 77, 149-155.	1.2	83
286	Combination systemic therapies in psoriatic arthritis. Journal of Dermatological Treatment, 2011, 22, 276-284.	1.1	22

#	Article	IF	Citations
288	Le rhumatisme psoriasique en Afrique subsaharienne. Revue Du Rhumatisme (Edition Francaise), 2011, 78, 412-415.	0.0	0
289	JUVENILE PSORIATIC ARTHRITIS. , 2011, , 287-297.		3
290	Synovial Tissue Response to Treatment in Psoriatic Arthritis. Open Rheumatology Journal, 2011, 5, 133-137.	0.1	5
292	Seronegative Spondyloarthropathies: Evolving Concepts Regarding Diagnosis and Treatment. Journal of Spine, 2011, 01, .	0.2	2
293	CONVENTIONAL THERAPY OF PSORIATIC ARTHRITIS: EVIDENCE-BASED REVIEW. Reumatismo, 2011, 59, 81-4.	0.4	0
294	Cardiovascular involvement in psoriatic arthritis. Reumatismo, 2011, 63, 148-54.	0.4	22
295	PsorÃase moderada a grave tratada com infliximabe em 53 pacientes: perfil dos pacientes, eficácia e efeitos adversos. Anais Brasileiros De Dermatologia, 2011, 86, 257-263.	0.5	22
296	Cardiovascular and metabolic risk profile in German patients with moderate and severe psoriasis: a case control study. European Journal of Dermatology, 2011, 21, 761-770.	0.3	32
297	EPIDEMIOLOGY OF PSORIASIS AND PSORIATIC ARTHRITIS. Reumatismo, 2011, 59, 19-24.	0.4	13
298	THE DIAGNOSIS OF PSORIATIC ARTHRITIS. Reumatismo, 2011, 59, .	0.4	1
299	Classification criteria for spondyloarthropathies. World Journal of Orthopedics, 2011, 2, 107.	0.8	52
300	Uveitis in Rheumatic Diseases. Current Rheumatology Reviews, 2011, 7, 24-38.	0.4	4
301	Psoriatic arthritis: from a dermatological perspective. European Journal of Dermatology, 2011, 21, 660-666.	0.3	23
302	Differential major histocompatibility complex class I chainâ€related A allele associations with skin and joint manifestations of psoriatic disease. Tissue Antigens, 2011, 77, 554-561.	1.0	27
303	Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 1409-1414.	1.3	97
304	Association between the leptin gene 2548G/A polymorphism, the plasma leptin and the metabolic syndrome with psoriasis. Experimental Dermatology, 2011, 20, 715-719.	1.4	44
305	Validation of Psoriatic Arthritis Diagnoses in Electronic Medical Records Using Natural Language Processing. Seminars in Arthritis and Rheumatism, 2011, 40, 413-420.	1.6	24
306	Stratification by age of onset with 30 years as age limit is an effective means of identifying PSORS1-associated psoriasis in patients with psoriatic arthritis. Joint Bone Spine, 2011, 78, 581-583.	0.8	8

#	Article	IF	CITATIONS
307	Pharmacogenetics of psoriasis. Pharmacogenomics, 2011, 12, 87-101.	0.6	24
310	Antigens from Leishmania amastigotes inducing clinical remission of psoriatic arthritis. Archives of Dermatological Research, 2011, 303, 399-415.	1.1	7
311	Spondyloarthritis in women: differences in disease onset, clinical presentation, and Bath Ankylosing Spondylitis Disease Activity and Functional indices (BASDAI and BASFI) between men and women with spondyloarthritides. Clinical Rheumatology, 2011, 30, 121-127.	1.0	92
312	The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. Clinical Rheumatology, 2011, 30, 1063-1067.	1.0	39
313	Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts. Clinical Rheumatology, 2011, 30, 877-885.	1.0	66
314	Evaluation of spinal mobility measurements in predicting axial psoriatic arthritis. Clinical Rheumatology, 2011, 30, 1157-1162.	1.0	11
315	Vitamin D level: is it related to disease activity in inflammatory joint disease?. Rheumatology International, 2011, 31, 493-499.	1.5	64
316	Synovitis in Psoriatic Arthritis: Immunohistochemistry, Comparisons With Rheumatoid Arthritis, and Effects of Therapy. Current Rheumatology Reports, 2011, 13, 353-359.	2.1	44
317	The Perspective on Psoriatic Arthritis in Asia. Current Rheumatology Reports, 2011, 13, 369-375.	2.1	13
318	Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care and Research, 2011, 63, 195-202.	1.5	165
319	Incidence of arthritis in a prospective cohort of psoriasis patients. Arthritis Care and Research, 2011, 63, 619-622.	1.5	81
320	Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care and Research, 2011, 63, 1062-1067.	1.5	76
321	Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care and Research, 2011, 63, 1091-1097.	1.5	112
322	Seasonal variation in vitamin D levels in psoriatic arthritis patients from different latitudes and its association with clinical outcomes. Arthritis Care and Research, 2011, 63, 1440-1447. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity	1.5	30
323	Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI),	1.5	277
324	Psoriatic Arthri. Arthritis Care and Research, 2011, 63, S64-85. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis and Rheumatism, 2011, 63, 633-639.	6.7	425
325	Abatacept in the treatment of patients with psoriatic arthritis: Results of a sixâ€month, multicenter, randomized, doubleâ€blind, placeboâ€controlled, phase II trial. Arthritis and Rheumatism, 2011, 63, 939-948.	6.7	264
326	Tumor necrosis factor blocking therapy alters joint inflammation and hypoxia. Arthritis and Rheumatism, 2011, 63, 923-932.	6.7	52

#	Article	IF	CITATIONS
327	Deletion of LCE3C and LCE3B is a susceptibility factor for psoriatic arthritis: A study in Spanish and Italian populations and meta-analysis. Arthritis and Rheumatism, 2011, 63, 1860-1865.	6.7	31
328	Reduction of in vitro invasion and in vivo cartilage degradation in a SCID mouse model by loss of function of the fibrinolytic system of rheumatoid arthritis synovial fibroblasts. Arthritis and Rheumatism, 2011, 63, 2584-2594.	6.7	30
329	How can misclassification be prevented when using the 2010 American College of Rheumatology/European League Against Rheumatism rheumatoid arthritis classification criteria? Comment on the article by van der Linden et al. Arthritis and Rheumatism, 2011, 63, 2544-2546.	6.7	14
330	Nerve growth factor: A key local regulator in the pathogenesis of inflammatory arthritis. Arthritis and Rheumatism, 2011, 63, 3243-3252.	6.7	50
331	Impaired dendritic cell proinflammatory cytokine production in psoriatic arthritis. Arthritis and Rheumatism, 2011, 63, 3313-3322.	6.7	30
332	Tumor necrosis factor promoter polymorphism TNF*-857 is a risk allele for psoriatic arthritis independent of the PSORS1 locus. Arthritis and Rheumatism, 2011, 63, 3801-3806.	6.7	25
334	Evidence to support <i>IL-13</i> as a risk locus for psoriatic arthritis but not psoriasis vulgaris. Annals of the Rheumatic Diseases, 2011, 70, 1016-1019.	0.5	68
335	Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Annals of the Rheumatic Diseases, 2011, 70, 1641-1644.	0.5	103
337	Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Annals of the Rheumatic Diseases, 2011, 70, 1068-1073.	0.5	87
338	Genetics of susceptibility and treatment response in psoriatic arthritis. Nature Reviews Rheumatology, 2011, 7, 718-732.	3.5	55
339	Coronary Flow Reserve and Asymmetric Dimethylarginine Levels: New Measurements for Identifying Subclinical Atherosclerosis in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2011, 38, 1661-1664.	1.0	46
340	Carotid Intima-Media Thickness in Psoriatic Arthritis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 705-712.	1.1	111
341	Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?. Annals of the Rheumatic Diseases, 2011, 70, 2152-2154.	0.5	183
342	Preliminary Evidence That Subclinical Enthesopathy May Predict Psoriatic Arthritis in Patients with Psoriasis. Journal of Rheumatology, 2011, 38, 2691-2692.	1.0	86
343	Recent Advances in Imaging in Psoriatic Arthritis. Therapeutic Advances in Musculoskeletal Disease, 2011, 3, 43-53.	1.2	20
344	Management of Psoriasis in Africa and the Middle East: A Review of Current Opinion, Practice and Opportunities for Improvement. Journal of International Medical Research, 2011, 39, 1573-1588.	0.4	14
345	Prologue: 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Journal of Rheumatology, 2011, 38, 522-525.	1.0	11
346	Minimal Important Difference and Responsiveness to Change of the SF-36 in Patients with Psoriatic Arthritis Receiving Tumor Necrosis Factor-1± Blockers. Journal of Rheumatology, 2011, 38, 2077.2-2079.	1.0	12

#	Article	IF	Citations
347	Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. Annals of the Rheumatic Diseases, 2011, 70, 712-714.	0.5	27
348	Presence of lymphocyte aggregates in the synovium of patients with early arthritis in relationship to diagnosis and outcome: is it a constant feature over time?. Annals of the Rheumatic Diseases, 2011, 70, 700-703.	0.5	55
349	Linear Pitting and Splinter Haemorrhages Are More Commonly Seen in the Nails of Patients with Established Psoriasis in Comparison to Psoriatic Arthritis. Dermatology, 2011, 223, 370-373.	0.9	21
350	Patients with Psoriasis Have a Higher Prevalence of Parental Cardiovascular Disease. Dermatology, 2011, 222, 330-335.	0.9	11
351	The Electronic Psoriasis and Arthritis Screening Questionnaire (ePASQ): A Sensitive and Specific Tool to Diagnose Psoriatic Arthritis Patients. Journal of Cutaneous Medicine and Surgery, 2011, 15, 143-149.	0.6	23
352	A Pathogenetic Approach to Autoimmune Skin Disease Therapy: Psoriasis and Biological Drugs, Unresolved Issues, and Future Directions. Current Pharmaceutical Design, 2011, 17, 3176-3190.	0.9	21
353	Development of a preliminary composite disease activity index in psoriatic arthritis. Annals of the Rheumatic Diseases, 2011, 70, 272-277.	0.5	184
354	Rapidly progressive destructive arthritis in psoriatic arthritis sine psoriasis: do bone resorption marker levels predict outcome of bone destruction in psoriatic arthritis?. Modern Rheumatology, 2011, 21, 106-108.	0.9	4
355	Prevalence of spondyloarthritis and its subtypes in southern Sweden. Annals of the Rheumatic Diseases, 2011, 70, 943-948.	0.5	104
356	The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Annals of the Rheumatic Diseases, 2011, 70, 25-31.	0.5	1,302
357	Diagnostic accuracy of enthesis ultrasound in the diagnosis of early spondyloarthritis. Annals of the Rheumatic Diseases, 2011, 70, 434-439.	0.5	95
358	Patient Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA and OMERACT Study. Journal of Rheumatology, 2011, 38, 898-903.	1.0	101
359	High Prevalence of Subclinical Left Ventricular Dysfunction in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2011, 38, 1363-1370.	1.0	53
360	A comparative study of periarticular bone lesions in rheumatoid arthritis and psoriatic arthritis. Annals of the Rheumatic Diseases, 2011, 70, 122-127.	0.5	121
361	Patient Preferences for Psoriasis Treatments. Archives of Dermatology, 2011, 147, 1285.	1.7	84
362	Incidence and prevalence of psoriatic arthritis in Buenos Aires, Argentina: a 6-year health management organization-based study. Rheumatology, 2011, 50, 729-734.	0.9	62
364	Prevalence of Thyroid Autoimmunity in Patients with Spondyloarthropathies. Journal of Rheumatology, 2011, 38, 1371-1377.	1.0	24
365	Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study. Annals of the Rheumatic Diseases, 2011, 70, 1091-1094.	0.5	37

#	Article	IF	CITATIONS
366	The Spondyloarthritis Research Consortium of Canada Registry for Spondyloarthritis. Journal of Rheumatology, 2011, 38, 1343-1348.	1.0	16
367	An overview and update of psoriasis. Nursing Standard (Royal College of Nursing (Great Britain):) Tj ETQq1 1 0.78	4314 rgB ⁻ 0.1	T /Overlock
368	Repair of Radiographic Joint Damage Following Treatment with Etanercept in Psoriatic Arthritis Is Demonstrable by 3 Radiographic Methods. Journal of Rheumatology, 2011, 38, 1066-1070.	1.0	20
369	Is Remission a More Realistic Goal in Psoriatic Arthritis?. Therapeutic Advances in Musculoskeletal Disease, 2011, 3, 3-7.	1.2	2
370	A Pilot Study of the Association of Tumor Necrosis Factor Alpha Polymorphisms with Psoriatic Arthritis in the Romanian Population. International Journal of Molecular Sciences, 2011, 12, 5052-5059.	1.8	14
371	Clinical and Ultrasound Examination of the Leeds Enthesitis Index in Psoriatic Arthritis and Rheumatoid Arthritis. ISRN Rheumatology, 2011, 2011, 1-5.	1.9	46
372	The ClASsification for Psoriatic ARthritis (CASPAR) Criteria – A Retrospective Feasibility, Sensitivity, and Specificity Study: Table 1 Journal of Rheumatology, 2012, 39, 154-156.	1.0	125
373	Dynamic Contrast-enhanced Magnetic Resonance Imaging of Articular and Extraarticular Synovial Structures of the Hands in Patients with Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2012, 89, 44-48.	2.2	27
374	On Defining Musculoskeletal Inflammation: A Report from the GRAPPA 2011 Annual Meeting. Journal of Rheumatology, 2012, 39, 2214-2215.	1.0	3
375	The association between smoking and the development of psoriatic arthritis among psoriasis patients. Annals of the Rheumatic Diseases, 2012, 71, 219-224.	0.5	75
376	Biomarkers of Subclinical Atherosclerosis in Patients with Autoimmune Disorders. Mediators of Inflammation, 2012, 2012, 1-8.	1.4	32
377	Does the change in season affect disease activity in patients with psoriatic arthritis?. Annals of the Rheumatic Diseases, 2012, 71, 1370-1373.	0.5	9
378	Dermal Distribution of Hyaluronan in Psoriatic Arthritis; Coexistence of CD44, MMP3 and 9. Acta Dermato-Venereologica, 2012, 92, 372-377.	0.6	22
379	Prevalence of Monoclonal Gammopathy Among Patients with Psoriatic Arthritis. Journal of Rheumatology, 2012, 39, 564-567.	1.0	17
381	Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma. Case Reports in Rheumatology, 2012, 2012, 1-3.	0.2	4
382	Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology, 2012, 51, 552-556.	0.9	120
383	Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study. Biologics: Targets and Therapy, 2012, 6, 201.	3.0	41
384	Biomarkers for Comorbidities in Psoriasis: A Report from the Grappa 2011 Annual Meeting. Journal of Rheumatology, 2012, 39, 2193-2195.	1.0	2

#	Article	IF	CITATIONS
386	Increase in ventricular-arterial stiffness in patients with psoriatic arthritis. Rheumatology, 2012, 51, 2215-2223.	0.9	40
387	Irrigation Development: A Process of Land Degradation and Marginalisation of the Land Poor. Social Change, 2012, 42, 31-47.	0.1	2
389	The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis. Rheumatology, 2012, 51, 2058-2063.	0.9	116
390	The new ASAS classification criteria for axial and peripheral spondyloarthritis: promises and pitfalls. International Journal of Clinical Rheumatology, 2012, 7, 675-682.	0.3	27
391	TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology, 2012, 51, 2091-2098.	0.9	56
392	Psoriasis and Psoriatic Arthritis in Peruvian Aborigines: A Report from the GRAPPA 2011 Annual Meeting. Journal of Rheumatology, 2012, 39, 2216-2219.	1.0	13
393	Risk variants for psoriasis vulgaris in a large case–control collection and association with clinical subphenotypes. Human Molecular Genetics, 2012, 21, 4549-4557.	1.4	79
394	Hepatic Steatosis and Disease Activity in Subjects with Psoriatic Arthritis Receiving Tumor Necrosis Factor-α Blockers. Journal of Rheumatology, 2012, 39, 1042-1046.	1.0	38
395	Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. Rheumatology, 2012, 51, 721-729.	0.9	166
397	CASPAR criteria in early psoriatic arthritis. Nature Reviews Rheumatology, 2012, 8, 503-504.	3.5	9
398	Cardiovascular Risk in Rheumatic Patients: The Link between Inflammation and Atherothrombosis. Seminars in Thrombosis and Hemostasis, 2012, 38, 497-505.	1.5	46
399	Construct Validity of the Modified Numeric Rating Scale of Patient Global Assessment in Psoriatic Arthritis. Journal of Rheumatology, 2012, 39, 844-848.		16
		1.0	16
400	Rituximab in psoriatic arthritis: an exploratory evaluation. Annals of the Rheumatic Diseases, 2012, 71, 1868-1871.	1.0	51
400	Rituximab in psoriatic arthritis: an exploratory evaluation. Annals of the Rheumatic Diseases, 2012, 71,		
	Rituximab in psoriatic arthritis: an exploratory evaluation. Annals of the Rheumatic Diseases, 2012, 71, 1868-1871. Exploring Priority Research Areas in Psoriasis and Psoriatic Arthritis from Dermatologists' Perspective: A Report from the GRAPPA 2011 Annual Meeting. Journal of Rheumatology, 2012, 39,	0.5	51
401	 Rituximab in psoriatic arthritis: an exploratory evaluation. Annals of the Rheumatic Diseases, 2012, 71, 1868-1871. Exploring Priority Research Areas in Psoriasis and Psoriatic Arthritis from Dermatologists' Perspective: A Report from the GRAPPA 2011 Annual Meeting. Journal of Rheumatology, 2012, 39, 2204-2210. Future Trends in Research in Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2012, 89, 	0.5 1.0	51 3
401 402	Rituximab in psoriatic arthritis: an exploratory evaluation. Annals of the Rheumatic Diseases, 2012, 71, 1868-1871. Exploring Priority Research Areas in Psoriasis and Psoriatic Arthritis from Dermatologists' Perspective: A Report from the GRAPPA 2011 Annual Meeting. Journal of Rheumatology, 2012, 39, 2204-2210. Future Trends in Research in Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2012, 89, 106-110. Psoriatic Arthritis in Canadian Clinical Practice: The PsA Assessment in Rheumatology. Journal of	0.5 1.0 2.2	51 3 4

#	Article	IF	CITATIONS
407	FCGR2A/CD32AandFCGR3A/CD16AVariants and EULAR Response to Tumor Necrosis Factor-α Blockers in Psoriatic Arthritis: A Longitudinal Study with 6 Months of Followup. Journal of Rheumatology, 2012, 39, 1035-1041.	1.0	29
408	Performance of classification criteria for peripheral spondyloarthritis and psoriatic arthritis in the Leiden early arthritis cohort. Annals of the Rheumatic Diseases, 2012, 71, 1366-1369.	0.5	46
409	Psoriatic Arthritis. Journal of the American Academy of Orthopaedic Surgeons, The, 2012, 20, 28-37.	1.1	39
410	Predictors of Early Minimal Disease Activity in Patients with Psoriatic Arthritis Treated with Tumor Necrosis Factor-α Blockers. Journal of Rheumatology, 2012, 39, 568-573.	1.0	48
412	GRAPPA Trainees Symposium 2011: A Report from the GRAPPA 2011 Annual Meeting. Journal of Rheumatology, 2012, 39, 2184-2188.	1.0	9
413	Differential human leucocyte allele association between psoriasis and psoriatic arthritis: a family-based association study. Annals of the Rheumatic Diseases, 2012, 71, 1361-1365.	0.5	37
414	Spondyloarthropathies in Autoimmune Diseases and Vice Versa. Autoimmune Diseases, 2012, 2012, 1-7.	2.7	11
415	Can Imaging Be Used for Inflammatory Arthritis Screening?. Seminars in Musculoskeletal Radiology, 2012, 16, 401-409.	0.4	13
416	Enthesitis in Psoriatic Disease. Dermatology, 2012, 225, 100-109.	0.9	39
417	Utility of the new rheumatoid arthritis 2010 ACR/EULAR classification criteria in routine clinical care. BMJ Open, 2012, 2, e001117.	0.8	35
418	High Prevalence of Psoriatic Arthritis in a Cohort of Patients with Psoriasis Seen in a Dermatology Practice. Journal of Cutaneous Medicine and Surgery, 2012, 16, 122-127.	0.6	37
420	Performance of hands and feet radiographs in differentiation of psoriatic arthritis from rheumatoid arthritis. International Journal of Rheumatic Diseases, 2012, 15, 462-467.	0.9	15
421	Epidemiology of Spondyloarthritis. Rheumatic Disease Clinics of North America, 2012, 38, 441-476.	0.8	177
422	Not simply a matter of psoriatic arthritis: epidemiology of rheumatic diseases in psoriatic patients. Archives of Dermatological Research, 2012, 304, 719-726.	1.1	24
423	Decreased heart rate variability in patients with psoriatic arthritis. Clinical Rheumatology, 2012, 31, 1377-1381.	1.0	12
424	Serial interferon-Î ³ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents. Clinical Rheumatology, 2012, 31, 1567-1575.	1.0	29
425	99mTc-labeled Rituximab for Imaging B Lymphocyte Infiltration in Inflammatory Autoimmune Disease Patients. Molecular Imaging and Biology, 2012, 14, 637-646.	1.3	52
426	Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine, 2012, 79, 591-596.	0.8	63

#	Article	IF	CITATIONS
427	Development of a preliminary US power Doppler composite score for monitoring treatment in PsA. Rheumatology, 2012, 51, 1261-1268.	0.9	75
428	Ustekinumab en la artritis psoriásica y la enfermedad de Crohn. Actas Dermo-sifiliográficas, 2012, 103, 65-72.	0.2	0
429	Platelet Reactivity and Disease Activity in Subjects with Psoriatic Arthritis. Journal of Rheumatology, 2012, 39, 334-336.	1.0	32
430	Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. Annals of the Rheumatic Diseases, 2012, 71, 553-556.	0.5	136
431	Mitochondrial mutagenesis correlates with the local inflammatory environment in arthritis. Annals of the Rheumatic Diseases, 2012, 71, 582-588.	0.5	70
432	Identification of the Clinical Features Distinguishing Psoriatic Arthritis and Fibromyalgia. Journal of Rheumatology, 2012, 39, 849-855.	1.0	94
433	Entheseal Power Doppler Ultrasonography: A Comparison of Psoriatic Arthritis and Fibromyalgia. Journal of rheumatology Supplement, The, 2012, 89, 29-31.	2.2	37
434	Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. Annals of the Rheumatic Diseases, 2012, 71, 50-55.	0.5	131
437	Advances in the treatment of inflammatory arthritis. Best Practice and Research in Clinical Rheumatology, 2012, 26, 251-261.	1.4	46
438	Improving musculoskeletal health: Global issues. Best Practice and Research in Clinical Rheumatology, 2012, 26, 237-249.	1.4	91
439	A comparative study of serum and synovial fluid lipoprotein levels in patients with various arthritides. Clinica Chimica Acta, 2012, 413, 303-307.	0.5	62
440	Developments in therapies for spondyloarthritis. Nature Reviews Rheumatology, 2012, 8, 280-287.	3.5	47
441	Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical healthâ€related quality of life. Arthritis Care and Research, 2012, 64, 1593-1601.	1.5	103
442	Is there subclinical enthesitis in early psoriatic arthritis? A clinical comparison with power doppler ultrasound. Arthritis Care and Research, 2012, 64, 1617-1621.	1.5	70
443	Sensitivity and specificity of the Classification of Psoriatic Arthritis criteria in early psoriatic arthritis. Arthritis and Rheumatism, 2012, 64, 3150-3155.	6.7	84
444	Integrated Approach to Comorbidity in Patients With Psoriasis. Actas Dermo-sifiliográficas, 2012, 103, 1-64.	0.2	8
445	Comorbidities significantly impact patients' preferences for psoriasis treatments. Journal of the American Academy of Dermatology, 2012, 67, 363-372.	0.6	48
446	IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade. Cytokine, 2012, 60, 38-42.	1.4	168

#	Article	IF	CITATIONS
449	Differences in the Patient's and the Physician's Perspective of Disease in Psoriatic Arthritis. Seminars in Arthritis and Rheumatism, 2012, 42, 32-41.	1.6	40
450	Can Magnetic Resonance Imaging of the Hand and Wrist Differentiate Between Rheumatoid Arthritis and Psoriatic Arthritis in the Early Stages of the Disease?. Seminars in Arthritis and Rheumatism, 2012, 42, 234-245.	1.6	71
451	Capillaroscopic pattern in inflammatory arthritis. Microvascular Research, 2012, 83, 318-322.	1.1	38
452	Early Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2012, 38, 373-386.	0.8	62
453	Classification, Diagnosis, and Referral of Patients with Axial Spondyloarthritis. Rheumatic Disease Clinics of North America, 2012, 38, 477-485.	0.8	21
454	Rheumatologie aus der Praxis. , 2012, , .		1
456	Analysis of granulysin-mediated cytotoxicity in peripheral blood of patients with psoriatic arthritis. Rheumatology International, 2012, 32, 2777-2784.	1.5	9
457	Changes in Proliferation Kinetics of T Cells: A New Predictive Cellular Biomarkers for Early Rheumatoid Arthritis?. Journal of Clinical Immunology, 2012, 32, 991-999.	2.0	7
458	Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study. Arthritis Research and Therapy, 2012, 14, R211.	1.6	30
459	Identification of low frequency TRAF3IP2 coding variants in psoriatic arthritis patients and functional characterization. Arthritis Research and Therapy, 2012, 14, R84.	1.6	16
460	Functional role of IL-22 in psoriatic arthritis. Arthritis Research and Therapy, 2012, 14, R65.	1.6	95
461	ls IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? a multicentre retrospective observational study. Arthritis Research and Therapy, 2012, 14, R53.	1.6	27
462	Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Research and Therapy, 2012, 14, R93.	1.6	60
463	Triggering of the dsRNA Sensors TLR3, MDA5, and RIG-I Induces CD55 Expression in Synovial Fibroblasts. PLoS ONE, 2012, 7, e35606.	1.1	29
464	Adipokines in Psoriatic Arthritis Patients: The Correlations with Osteoclast Precursors and Bone Erosions. PLoS ONE, 2012, 7, e46740.	1.1	80
465	Psoriatic arthritis in patients with psoriasis: evaluation of clinical and epidemiological features in 133 patients followed at the University Hospital of BrasÃlia. Anais Brasileiros De Dermatologia, 2012, 87, 539-544.	0.5	25
466	Psoriasis, a Systemic Disease Beyond the Skin, as Evidenced by Psoriatic Arthritis and Many Comorbities – Clinical Remission with a Leishmania Amastigotes Vaccine, a Serendipity Finding. , 2012, , .		0
467	Multiple arthritis: three in one. BMJ Case Reports, 2012, 2012, bcr1120115151-bcr1120115151.	0.2	1

CITATION RE	CITATION REPORT	
Article	IF	CITATIONS
Detecting Psoriasis Arthritis Early in the Disease Course – Why This is Important and How Dermatologists and Rheumatologists Can Successfully Cooperate?. , 0, , .		0
2 Rheumatoid arthritis. , 2012, , 7-40.		0
Biomarkers in the pathogenesis, diagnosis, and treatment of psoriasis. Psoriasis: Targets and Therapy, 0, , 55.	1.2	2
Prevalence of eye disease in Brazilian patients with psoriatic arthritis. Clinics, 2012, 67, 249-253.	0.6	32
lt is not always about gains: utilities and disutilities associated with treatment features in patients with moderate-to-severe psoriasis. Patient Preference and Adherence, 2012, 6, 187.	0.8	11
Severe cutaneous and arthritic psoriasis in patient with Aids: a good outcome with therapy using etanercept. Anais Brasileiros De Dermatologia, 2012, 87, 135-138.	0.5	0
Artrite psoriásica: entidade clÃnica distinta da psorÃase?. Revista Brasileira De Reumatologia, 2012, 52, 630-638.	0.8	13
New Insights into the Concept of Psoriatic Disease. Journal of rheumatology Supplement, The, 2012, 89, 4-6.	2.2	14
Longitudinal study of the bidirectional association between pain and depressive symptoms in patients with psoriatic arthritis. Arthritis Care and Research, 2012, 64, 758-765.	1.5	49
HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis and Rheumatism, 2012, 64, 1134-1144.	6.7	187
Developing a provisional definition of flare in patients with established gout. Arthritis and Rheumatism, 2012, 64, 1508-1517.	6.7	90
Predictors of functional impairment and pain in erosive osteoarthritis of the interphalangeal joints: Comparison with controlled inflammatory arthritis. Arthritis and Rheumatism, 2012, 64, 1430-1436.	6.7	42
Enrichment of circulating interleukinâ€17–secreting interleukinâ€23 receptor–positive γ/δT cells in patients with active ankylosing spondylitis. Arthritis and Rheumatism, 2012, 64, 1420-1429.	6.7	222
Genome-Wide Meta-Analysis of Psoriatic Arthritis Identifies Susceptibility Locus at REL. Journal of Investigative Dermatology, 2012, 132, 1133-1140.	0.3	99
Angiopoietin-2 promotes inflammatory activation of human macrophages and is essential for murine experimental arthritis. Annals of the Rheumatic Diseases, 2012, 71, 1402-1417.	0.5	41

483	How Can Psoriatic Arthritis Be Diagnosed Early?. Current Rheumatology Reports, 2012, 14, 358-363.	2.1	9
484	A case of psoriasis vulgaris with diffuse idiopathic skeletal hyperostosis involved with ossifications of posterior and anterior longitudinal ligament. Rheumatology International, 2012, 32, 1343-1345.	1.5	2
485	Clinical and demographic characteristics of patients with psoriatic arthritis in northern Israel. Rheumatology International 2012 32 595-600	1.5	26

#

468

470

472

474

476

478

480

482

#	Article	IF	CITATIONS
486	Early spondyloarthritis in multiracial society: differences between gender, race, and disease subgroups with regard to first symptom at presentation, main problem that the disease is causing to patients, and employment status. Rheumatology International, 2012, 32, 1597-1604.	1.5	15
488	Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clinical Rheumatology, 2012, 31, 711-715.	1.0	100
489	Axial psoriatic arthritis: an intriguing clinical entity or a subset of an intriguing disease?. Clinical Rheumatology, 2012, 31, 1027-1032.	1.0	21
490	Disease severity and therapy as predictors of cardiovascular risk in psoriasis: a populationâ€based cohort study. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 336-343.	1.3	27
491	The diagnosis of early psoriatic arthritis in an outpatient dermatological centre for psoriasis. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 627-633.	1.3	16
492	Prevalence, severity and clinical features of psoriasis in fingernails and toenails in adult patients: Italian experience. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1354-1359.	1.3	60
493	Vitamin D status in patients with chronic plaque psoriasis. British Journal of Dermatology, 2012, 166, 505-510.	1.4	120
494	Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine, 2012, 79, 32-37.	0.8	81
495	Psoriatic arthritis in Sub-Saharan Africa. Joint Bone Spine, 2012, 79, 17-19.	0.8	25
496	Spondyloarthropathies. Best Practice and Research in Clinical Rheumatology, 2012, 26, 135-145.	1.4	33
497			
	Psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2012, 26, 147-156.	1.4	44
498	Psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2012, 26, 147-156. Preparedness of Foundation Year 1 doctors in dermatology. Clinical Teacher, 2012, 9, 108-111.	1.4 0.4	44 8
498 499			
	Preparedness of Foundation Year 1 doctors in dermatology. Clinical Teacher, 2012, 9, 108-111. Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study.	0.4	8
499	Preparedness of Foundation Year 1 doctors in dermatology. Clinical Teacher, 2012, 9, 108-111. Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study. International Journal of Rheumatic Diseases, 2012, 15, 414-418.	0.4 0.9	8
499 501	Preparedness of Foundation Year 1 doctors in dermatology. Clinical Teacher, 2012, 9, 108-111. Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study. International Journal of Rheumatic Diseases, 2012, 15, 414-418. Differential effect of etanercept on cutaneous and joint lesions in psoriatic arthritis. Journal of Dermatology, 2012, 39, 284-285. The increased prevalence of nonâ€elcoholic fatty liver disease in psoriatic patients: A study from South	0.4 0.9 0.6	8 54 0
499 501 502	Preparedness of Foundation Year 1 doctors in dermatology. Clinical Teacher, 2012, 9, 108-111. Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study. International Journal of Rheumatic Diseases, 2012, 15, 414-418. Differential effect of etanercept on cutaneous and joint lesions in psoriatic arthritis. Journal of Dermatology, 2012, 39, 284-285. The increased prevalence of nonâ€elcoholic fatty liver disease in psoriatic patients: A study from South India. Australasian Journal of Dermatology, 2012, 53, 190-197. Is the nail psoriasis severity index reliable in the assessment of nail psoriasis by rheumatologists?	0.4 0.9 0.6 0.4	8 54 0 71

ARTICLE IF CITATIONS # Relationship between psoriatic arthritis and moderate–severe psoriasis: analysis of a series of 166 psoriatic arthritis patients selected from a hospital population. Clinical Rheumatology, 2012, 31, 507 1.0 9 139-143. Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic. 1.1 Archives of Dermatological Research, 2012, 304, 7-13. Matching physicians' treatment recommendations to patients' treatment preferences is associated 509 with improvement in treatment satisfaction. Journal of the European Academy of Dermatology and 1.3 47 Venereology, 2013, 27, 763-770. Predictors of Chikungunya rheumatism: a prognostic survey ancillary to the TELECHIK cohort study. Arthritis Research and Therapy, 2013, 15, R9. Brief Report: Magnetic Resonance Imaging Assessment of Axial Psoriatic Arthritis: Extent of Disease 511 6.7 59 Relates to HLA–B27. Arthritis and Rheumatism, 2013, 65, 2274-2278. Burden of Disease: Psoriasis and Psoriatic Arthritis. American Journal of Clinical Dermatology, 2013, 3.3 118 14, 377-388. Classification Criteria: Peripheral Spondyloarthropathy and Psoriatic Arthritis. Current 513 2.1 26 Rheumatology Reports, 2013, 15, 317. Psoriatic Arthritis: Phenotypic Variance and Nosology. Current Rheumatology Reports, 2013, 15, 316. 2.1 514 37 515 Psoriatic Arthritis: a Critical Review. Clinical Reviews in Allergy and Immunology, 2013, 44, 141-148. 2.9 54 Imaging in Psoriatic Arthritis. Clinical Reviews in Allergy and Immunology, 2013, 44, 157-165. Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab. 517 1.3 46 Immunologic Research, 2013, 56, 382-389. Deoxyribonuclease activity of polyclonal IgGs: a putative serological marker in patients with 1.3 spondyloarthritides. Immúnologić Research, 2013, 56, 457-464. Autonomic dysfunction in psoriatic arthritis. Clinical Rheumatology, 2013, 32, 1059-1064. 519 1.0 28 Osteoporosis in psoriatic arthritis: an assessment of densitometry and fragility fractures. Clinical 1.0 Rheumatology, 2013, 32, 1799-1804. Functional variants of <i><scp>ERAP1</scp></i> gene are associated with <scp>HLAâ€B27</scp> positive 521 1.0 16 spondyloarthritis. Tissue Antigens, 2013, 82, 192-196. Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease. Clinical Chemistry and Laboratory Medicine, 2013, 51, 317-325. A comparison of telephone and paper self-completed questionnaires of main patient-related outcome 523 measures in patients with ankylosing spondylitis and psoriatic arthritis. Rheumatology International, 1.58 2013, 33, 2731-2736. IL-23A, IL-23R, IL-17A and IL-17R polymorphisms in different psoriatic arthritis clinical manifestations in 524 1.5 the northern Italian population. Rheumatology International, 2013, 33, 1165-1176.

#	Article	IF	CITATIONS
525	Synovial fluid and serum levels of IL-17, IL-23, and CCL-20 in rheumatoid arthritis and psoriatic arthritis: a Tunisian cross-sectional study. Rheumatology International, 2013, 33, 265-266.	1.5	22
526	Therapeutic Strategies in Psoriasis Patients with Psoriatic Arthritis: Focus on New Agents. BioDrugs, 2013, 27, 359-373.	2.2	26
528	Recomendações sobre diagnóstico e tratamento da artrite psoriásica. Revista Brasileira De Reumatologia, 2013, 53, 227-241.	0.8	18
530	Mycobacterial Interferon-Î ³ Release Variations During Longterm Treatment with Tumor Necrosis Factor Blockers: Lack of Correlation with Clinical Outcome. Journal of Rheumatology, 2013, 40, 157-165.	1.0	30
531	Spondyloarthritis with Onset After Age 45. Current Rheumatology Reports, 2013, 15, 374.	2.1	34
532	Arthritis Mimicking Sports-Related Injuries. Clinics in Sports Medicine, 2013, 32, 577-597.	0.9	1
533	Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study. Virology Journal, 2013, 10, 298.	1.4	15
534	Phenotypic and clinical differences between Caucasian and South Asian patients with psoriatic arthritis living in North East London. Clinical Rheumatology, 2013, 32, 591-599.	1.0	11
535	Periodontal Disease in Patients with Psoriatic Arthritis. Inflammation, 2013, 36, 665-669.	1.7	28
536	Progranulin antibodies entertain a proinflammatory environment in a subgroup of patients with psoriatic arthritis. Arthritis Research and Therapy, 2013, 15, R211.	1.6	43
537	Evaluation of the novel ultrasound score for large joints in psoriatic arthritis and ankylosing spondylitis: six month experience in daily clinical practice. BMC Musculoskeletal Disorders, 2013, 14, 358.	0.8	23
538	Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Research and Therapy, 2013, 15, R136.	1.6	212
539	Achilles tendon biomechanics in psoriatic arthritis patients with ultrasound proven enthesitis. Scandinavian Journal of Rheumatology, 2013, 42, 299-302.	0.6	25
540	Psoriasis and hemorheology. Influence of the metabolic syndrome. Clinical Hemorheology and Microcirculation, 2013, 55, 331-339.	0.9	8
542	Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study. British Journal of Dermatology, 2013, 169, 666-672.	1.4	138
543	Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy. Scandinavian Journal of Rheumatology, 2013, 42, 41-44.	0.6	29
544	Investigation of 20 non-HLA (human leucocyte antigen) psoriasis susceptibility loci in Chinese patients with psoriatic arthritis and psoriasis vulgaris. British Journal of Dermatology, 2013, 168, 1060-1065.	1.4	39
545	Psoriatic arthritis: recent progress in pathophysiology and drug development. Arthritis Research and Therapy, 2013, 15, 224.	1.6	22

ARTICLE IF CITATIONS Psoriatic arthritis mutilans (PAM) in the Nordic countries: demographics and disease status. The 0.6 22 546 Nordic PAM study. Scandinavian Journal of Rheumatology, 2013, 42, 373-378. 547 Rheumatic Disease., 2013, , 1415-1440. Exploring ankylosing spondylitis-associated ERAP1, IL23R and IL12B gene polymorphisms in 548 0.9 36 subphenotypes of psoriatic arthritis. Rheumatology, 2013, 52, 261-266. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. 549 Journal of the European Academy of Dermatology and Venereology, 2013, 27, 1387-1404. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study. Annals of the Rheumatic Diseases, 2013, 72, 550 0.5 30 1675-1679. Obesity and the prediction of minimal disease activity: A prospective study in psoriatic arthritis. Arthritis Care and Research, 2013, 65, 141-147. 1.5 144 Ultrasonographic evaluation of lower limb enthesis in patients with early spondyloarthropathies. 554 0.5 18 Egyptian Rheumatologist, 2013, 35, 29-35. Artritis mutilante/resortiva. Estudio de 24 pacientes de una serie de 360 artritis psoriÃ;sicas. 0.2 556 ReumatologÃa ClÃnica, 2013, 9, 38-41. 557 Outcome assessment in psoriatic arthritis. Indian Journal of Rheumatology, 2013, 8, S24-S28. 0.2 0 Psoriatic arthritis: How to diagnosis it early?. Indian Journal of Rheumatology, 2013, 8, 117-121. 0.2 Recommendations for the management and treatment of psoriatic arthritis. Revista Brasileira De 560 0.7 6 Reumatologia, 2013, 53, 227-241. Association study in Romanians confirms IL23A gene haplotype block rs2066808/rs11171806 as 1.4 conferring risk to psoriatic arthritis. Cytokine, 2013, 63, 67-73. Gender difference in disease expression, radiographic damage and disability among patients with 562 0.5 88 psoriatic arthritis. Annals of the Rheumatic Diseases, 2013, 72, 578-582. Periodontal Condition of Patients With Autoimmune Diseases and the Effect of Antiâ€Tumor Necrosis 1.7 Factorâ€it Therapy. Journal of Periodontology, 2013, 84, 136-142. Mutilating/Resorptive Arthritis. A Study of 24 Patients in a Series of 360 Patients With Psoriatic 564 0.2 6 Arthritis. ReumatologÃa ClÃnica (English Edition), 2013, 9, 38-41. Psoriatic patients have an increased risk of polycystic ovary syndrome: results of a cross-sectional 23 analysis. Fertility and Sterility, 2013, 99, 936-942. Enthesitis in psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2013, 43, 325-334. 566 1.6 66 Influence of the STAT3 genetic variants in the susceptibility to psoriatic arthritis and Behcet's disease. 1.2 Human Immunology, 2013, 74, 230-233.

ARTICLE IF CITATIONS # Human leukocyte antigen alleles and susceptibility to psoriatic arthritis. Human Immunology, 2013, 74, 568 1.2 51 1333-1338. Are Spondyloarthropathies Adequately Referred From Primary Care to Specialized Care?. ReumatologÃa 0.2 ClÃnica (English Edition), 2013, 9, 90-93. ¿Se derivan adecuadamente las espondiloartropatÃas desde primaria a especializada?. ReumatologÃa 570 0.2 11 ClÃnica, 2013, 9, 90-93. Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases. British 571 1.4 Journal of Dérmatology, 2013, 168, 210-212. The Genetics of Psoriasis and Psoriatic Arthritis. Clinical Reviews in Allergy and Immunology, 2013, 44, 572 2.9 86 149-156. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST) Tj ETQq1 1 0,784314 rgBT /Ove 573 574 Topical treatments for chronic plaque psoriasis. The Cochrane Library, 2013, , CD005028. 1.5 90 The functional <scp>MICA</scp>â€129 polymorphism is associated with skin but not joint manifestations of psoriatic disease independently of <scp>ĤLA</scp>â€B and <scp>HLA</scp>â€C. Tissue Antigens, 2013, 82, 1.0 29 43-47 Psoriatic arthritis: current therapy and future directions. Expert Opinion on Pharmacotherapy, 2013, 576 0.9 9 14, 1755-1764. Notch signalling pathways mediate synovial angiogenesis in response to vascular endothelial growth factor and angiopoietin 2. Annals of the Rheumatic Diseases, 2013, 72, 1080-1088. Periarticular Bone Gain at Proximal Interphalangeal Joints and Changes in Bone Turnover Markers in Response to Tumor Necrosis Factor Inhibitors in Rheumatoid and Psoriatic Arthritis. Journal of 578 1.0 25 Rheumatology, 2013, 40, 653-662. Soluble Biomarkers Associated with Response to Treatment with Tumor Necrosis Factor Inhibitors in 579 1.0 Psoriatic Arthritis. Journal of Rheumatology, 2013, 40, 866-871. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance 580 0.5 248 of screening questionnaires. Annals of the Rheumatic Diseases, 2013, 72, 736-740. Ultrasound and Magnetic Resonance Imaging in the Evaluation of Psoriatic Dactylitis: Status and Perspectives. Journal of Rheumatology, 2013, 40, 1951-1957. 1.0 66 Incremental Effects of Comorbidity on Quality of Life in Patients with Psoriatic Arthritis. Journal of 582 1.0 78 Rheumatology, 2013, 40, 1349-1356. Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with 96 disease activity. Annals of the Rheumatic Diseases, 2013, 72, 1956-1961. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome 586 1.0 98 components in a cohort of 210 psoriatic arthritis patients. Clinical Rheumatology, 2014, 33, 833-839. Remission of Psoriatic Arthritis after Etanercept Discontinuation: Analysis of Patients' Clinical Characteristics Leading to Disease Relapse. International Journal of Immunopathology and Pharmacology, 2013, 26, 833-838.

#	Article	IF	CITATIONS
589	Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors. Annals of the Rheumatic Diseases, 2013, 72, 1176-1181.	0.5	59
590	Successful use of tocilizumab in a patient with psoriatic arthritis. Rheumatology, 2013, 52, 1728-1729.	0.9	33
592	Diagnosis and management of psoriatic arthritis. Indian Journal of Dermatology, Venereology and Leprology, 2013, 79, 18.	0.2	7
593	The Historical Concept of Interrelated Conditions Grouped Together as a Family of Distinct Diseases Is Not Outdated: Comment on the Article by Baeten et al. Arthritis and Rheumatism, 2013, 65, 2214-2215.	6.7	6
594	Validation in Spanish of a screening questionnaire for the detection of psoriatic arthritis in patients with psoriasis. Rheumatology, 2013, 52, 510-514.	0.9	18
595	Diffuse Idiopathic Skeletal Hyperostosis in Psoriatic Arthritis. Journal of Rheumatology, 2013, 40, 1367-1373.	1.0	31
596	Comment on: A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology, 2013, 52, 761-761.	0.9	2
597	A Hot Spot for Systemic Lupus Erythematosus, but Not for Psoriatic Arthritis, Identified by Spatial Analysis Suggests an Interaction Between Ethnicity and Place of Residence. Arthritis and Rheumatism, 2013, 65, 1579-1585.	6.7	9
598	Differential diagnosis of a patient with low back and toe pain. Journal of Manual and Manipulative Therapy, 2013, 21, 81-89.	0.7	7
599	Erosive discovertebral lesion (Andersson lesion) as the first sign of disease in axial psoriatic arthritis. Scandinavian Journal of Rheumatology, 2013, 42, 220-225.	0.6	14
601	Psoriasis and phenotype of patients with early inflammatory back pain. Annals of the Rheumatic Diseases, 2013, 72, 566-571.	0.5	27
602	Early psoriatic arthritis: facing the challenge. British Journal of Nursing, 2013, 22, 1014-1020.	0.3	1
603	Psoriatic Arthritis Mutilans: Case Series and Literature Review. Journal of Rheumatology, 2013, 40, 1233-1236.	1.0	11
604	The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. Annals of the Rheumatic Diseases, 2013, 72, 715-720.	0.5	70
605	The link between enthesitis and arthritis in psoriatic arthritis: a switch to a vascular phenotype at insertions may play a role in arthritis development. Annals of the Rheumatic Diseases, 2013, 72, 992-995.	0.5	73
606	Dactylitis in Psoriatic Arthritis: Prevalence and Response to Therapy in the Biologic Era. Journal of Rheumatology, 2013, 40, 1357-1359.	1.0	72
607	Golimumab in Patients Affected by Moderate to Severe Psoriatic Arthritis: An Open-Label Study in Thirty-Two Patients Previously Treated with Other Biologics. Dermatology, 2013, 227, 305-310.	0.9	8
609	Cross-sectional study assessing family members of psoriatic arthritis patients affected by the same disease: differences between Caucasian, South Asian and Afro-Caribbean populations living in the same geographic region. International Journal of Rheumatic Diseases, 2013, 16, 418-424.	0.9	9

#	Article	IF	CITATIONS
611	Higher Levels of Autoantibodies Targeting Mutated Citrullinated Vimentin in Patients with Psoriatic Arthritis Than in Patients with Psoriasis Vulgaris. Clinical and Developmental Immunology, 2013, 2013, 1-9.	3.3	28
612	Disease Activity and Bone Mineral Density of MCP Joints in Patients with Rheumatoid and Psoriatic Arthritis: Is There a Correlation?—A Study in Patients Treated with Methotrexate and an Anti-TNFα Agent. ISRN Rheumatology, 2013, 2013, 1-6.	1.9	5
613	High Frequency of Fibromyalgia in Patients with Psoriatic Arthritis: A Pilot Study. Arthritis, 2013, 2013, 1-4.	2.0	32
614	Capillaroscopy in Psoriatic and Rheumatoid Arthritis: A Useful Tool for Differential Diagnosis. Arthritis, 2013, 2013, 1-5.	2.0	47
615	Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. British Journal of Dermatology, 2013, 168, 749-755.	1.4	65
616	Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1793-1799.	0.5	57
617	Effects of adalimumab therapy on musculoskeletal manifestations and health-related quality of life in patients with active psoriatic arthritis. Modern Rheumatology, 2013, 23, 529-537.	0.9	4
618	Serological markers in psoriatic arthritis: promising tools. Experimental Biology and Medicine, 2013, 238, 1431-1436.	1.1	24
619	Real-time Sonoelastography of the Plantar Fascia: Comparison between Patients with Plantar Fasciitis and Healthy Control Subjects. Radiology, 2013, 267, 195-200.	3.6	74
620	Metabolic syndrome in psoriatic arthritis patients: A cross-sectional study. International Journal of Rheumatic Diseases, 2013, 16, 667-673.	0.9	22
621	Comparison of EuroQol-5D and Short Form-6D Utility Scores in Multiethnic Asian Patients with Psoriatic Arthritis: A Cross-sectional Study. Journal of Rheumatology, 2013, 40, 859-865.	1.0	18
622	Limitations in Screening Instruments for Psoriatic Arthritis: A Comparison of Instruments in Patients with Psoriasis. Journal of Rheumatology, 2013, 40, 287-293.	1.0	55
624	Imaging in rheumatology. Imaging, 2013, 22, 20120008.	0.0	0
625	Diagnosis of Lumbar Spinal Stenosis. Spine, 2013, 38, E469-E481.	1.0	101
626	Adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in therapeutic programmes – personal experience. Reumatologia, 2013, 1, 9-14.	0.5	2
627	Epidemiology, genetics and management of psoriatic arthritis 2013: focus on developments of who develops the disease, its clinical features, and emerging treatment options. Psoriasis: Targets and Therapy, 2013, , 11.	1.2	1
628	Differences in synovial fluid cytokine levels but not in synovial tissue cell infiltrate between anti-citrullinated peptide/protein antibody-positive and –negative rheumatoid arthritis patients. Arthritis Research and Therapy, 2013, 15, R182.	1.6	34
629	Clinical Differences between Men and Women with Psoriatic Arthritis: Relevance of the Analysis of Genes and Polymorphisms in the Major Histocompatibility Complex Region and of the Age at Onset of Psoriasis. Clinical and Developmental Immunology, 2013, 2013, 1-7.	3.3	52

#	Article	IF	Citations
630	Focus on the spondyloarthritides. Can earlier diagnosis change the course of the disease?. Italian Journal of Medicine, 0, , 277-283.	0.2	0
631	Spondyloarthrites. , 2013, , 137-187.		0
632	Are New Tools for Early Detection of Psoriatic Arthritis Ready for Widespread Clinical Use? A Review. Psoriasis Forum, 2013, 19a, 98-104.	0.1	0
633	Clinical Presentation of Psoriasis. , 2013, , .		0
634	Hip and Knee Arthroplasty in the Patient with Inflammatory Arthritis. , 0, , .		0
635	Certolizumab pegol – new option in the treatment of psoriatic arthritis. Reumatologia, 2014, 3, 181-188.	0.5	1
636	Validity of Diagnostic Codes and Prevalence of Physician-Diagnosed Psoriasis and Psoriatic Arthritis in Southern Sweden – A Population-Based Register Study. PLoS ONE, 2014, 9, e98024.	1.1	94
637	Disease Activity in Psoriatic Arthritis: Comparison of the Discriminative Capacity and Construct Validity of Six Composite Indices in a Real World. BioMed Research International, 2014, 2014, 1-12.	0.9	71
638	Psoriatic arthritis: Epidemiology, diagnosis, and treatment. World Journal of Orthopedics, 2014, 5, 537.	0.8	96
639	Decreased Number of Circulating Endothelial Progenitor Cells (CD133+/KDR+) in Patients with Psoriatic Arthritis. Acta Dermato-Venereologica, 2014, 96, 754-7.	0.6	6
640	An intractable case of suspected psoriatic arthritiscombined with Dupuytren's disease. Pakistan Journal of Medical Sciences, 2014, 31, 229-32.	0.3	0
641	The Frequency of anti-CCP antibodies in patients with rheumatoid arthritis and psoriatic arthritis and their relationship with clinical features and parameters of angiogenesis: A comparative study. European Journal of Rheumatology, 2014, 49, 67-71.	1.3	10
642	Influence of Cutaneous Involvement in Deciding how to Treat Psoriatic Arthritis. Psoriasis Forum, 2014, 20a, 91-95.	0.1	0
643	Certolizumab pegol in the treatment of spondyloarthritis. Reumatologia, 2014, 4, 263-268.	0.5	0
644	Development of Criteria to Distinguish Inflammatory from Noninflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2013 Annual Meeting. Journal of Rheumatology, 2014, 41, 1249-1251.	1.0	24
645	A review of disease activity measures for psoriatic arthritis: what is the best approach?. Expert Review of Clinical Immunology, 2014, 10, 1241-1254.	1.3	16
646	Impaired Left Ventricular Apical Rotation is Associated with Disease Activity of Psoriatic Arthritis. Journal of Rheumatology, 2014, 41, 706-713.	1.0	17
648	Hemostatic and Fibrinolytic Changes Are Related to Inflammatory Conditions in Patients with Psoriatic Arthritis — Effect of Different Treatments. Journal of Rheumatology, 2014, 41, 714-722.	1.0	15

#	Article		F	CITATIONS
649	Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity. Expert Opinion on Biological Therapy, 2014, 14, 1825-1836.	:	1.4	13
650	How Much Is Fatigue Explained by Standard Clinical Characteristics of Disease Activity in Patients With Inflammatory Arthritis? A Longitudinal Study. Arthritis Care and Research, 2014, 66, 1597-1603		1.5	11
651	Circulating adiponectin levels in Indian patients with psoriasis and its relation to metabolic syndrome. Indian Journal of Endocrinology and Metabolism, 2014, 18, 191.		0.2	7
652	Systemic Lupus Erythematosus, Treatment. , 2014, , 1184-1188.			0
653	Immunologic Biomarkers for Clinical and Therapeutic Management of Psoriasis. Mediators of Inflammation, 2014, 2014, 1-11.	:	1.4	20
654	Drug Retention Rates and Treatment Discontinuation among Anti-TNF- <i>α</i> Agents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice. Mediators of Inflammation, 2014, 2014, 1-7.		1.4	49
655	The Region Centromeric to HLA-C Is a Key Region for Understanding the Phenotypic Variability of Psoriatic Arthritis. ISRN Dermatology, 2014, 2014, 1-5.	:	1.9	4
656	Prevalence of Past and Reactivated Viral Infections and Efficacy of Cyclosporine A as Monotherapy or in Combination in Patients with Psoriatic Arthritis—Synergy Study: A Longitudinal Observational Study. BioMed Research International, 2014, 2014, 1-7.		0.9	22
657	Involvement of the Inconstant Bursa of the Fifth Metatarsophalangeal Joint in Psoriatic Arthritis: A Clinical and Ultrasonographic Study. BioMed Research International, 2014, 2014, 1-5.	1	0.9	6
658	Prevalence and clinical patterns of psoriatic arthritis in Indian patients with psoriasis. Indian Journal of Dermatology, Venereology and Leprology, 2014, 80, 15.		0.2	38
659	Current Concepts in Psoriatic Arthritis: Pathogenesis and Management. Acta Dermato-Venereologica, 2014, 94, 627-634.	,	0.6	58
660	GRAPPA 2013 Annual Meeting, Rheumatology Updates: Psoriatic Arthritis (PsA) Biomarker Project, Arthritis Mutilans, PsA-Peripheral Spondyloarthritis Epidemiology Project. Journal of Rheumatology, 2014, 41, 1244-1248.		1.0	5
661	How to investigate new-onset polyarthritis. Best Practice and Research in Clinical Rheumatology, 2014, 28, 844-859.	:	1.4	6
662	Occurrence of Psoriatic Arthritis during Interferon Beta 1a Treatment for Multiple Sclerosis. Case Reports in Rheumatology, 2014, 2014, 1-3.		0.2	10
663	Relationships between Adipose Tissue and Psoriasis, with or without Arthritis. Frontiers in Immunology, 2014, 5, 368.	:	2.2	63
665	Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Annals of the Rheumatic Diseases, 2014, 73, 233-23		0.5	70
666	<i>PDE3A-SLCO1C1</i> locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis. Pharmacogenomics, 2014, 15, 1763-1769.		0.6	9
667	Rheumatoid arthritis and outcomes in first and subsequent births based on data from a national birth registry. Acta Obstetricia Et Gynecologica Scandinavica, 2014, 93, 302-307.		1.3	57

#	Article	IF	CITATIONS
668	Reliability of Radiographic Scoring Methods in Axial Psoriatic Arthritis. Arthritis Care and Research, 2014, 66, 1417-1422.	1.5	25
669	Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network. Pharmacoepidemiology and Drug Safety, 2014, 23, 918-922.	0.9	48
670	Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis – Xenograft model. Journal of Autoimmunity, 2014, 55, 63-72.	3.0	58
671	Is There Subclinical Synovitis in Early Psoriatic Arthritis? A Clinical Comparison With Grayâ€Scale and Power Doppler Ultrasound. Arthritis Care and Research, 2014, 66, 432-439.	1.5	79
673	Psoriatic Arthritis: An Update. Actas Dermo-sifiliográficas, 2014, 105, 913-922.	0.2	3
674	Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 17-26.	1.3	72
675	Feasibility, Reliability, and Sensitivity to Change of Four Radiographic Scoring Methods in Patients With Psoriatic Arthritis. Arthritis Care and Research, 2014, 66, 311-317.	1.5	21
676	Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2014, 28, 711-728.	1.4	29
677	The concept of spondyloarthritis: Where are we now?. Best Practice and Research in Clinical Rheumatology, 2014, 28, 663-672.	1.4	82
678	Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy. British Journal of Dermatology, 2014, 171, 884-890.	1.4	25
679	Hyperuricemia in Patients with Chronic Plaque Psoriasis. Drug Development Research, 2014, 75, S70-2.	1.4	10
680	Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Annals of the Rheumatic Diseases, 2014, 73, 990-999.	0.5	576
681	Simple clinical indicators for early psoriatic arthritis detection. SpringerPlus, 2014, 3, 759.	1.2	42
682	Ultrasound composite scores for the assessment of inflammatory and structural pathologies in Psoriatic Arthritis (PsASon-Score). Arthritis Research and Therapy, 2014, 16, 476.	1.6	51
683	Large vessel vasculitis and spondyloarthritis: coincidence or associated diseases?. Scandinavian Journal of Rheumatology, 2014, 43, 246-248.	0.6	26
684	Ultrasound Nail Imaging on Patients With Psoriasis and Psoriatic Arthritis Compared With Rheumatoid Arthritis and Control Subjects. Journal of Clinical Rheumatology, 2014, 20, 21-24.	0.5	67
685	Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common coâ€morbidities in patients with moderateâ€toâ€severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1661-1669.	1.3	36
686	Inflammatory Bone Spur Formation in Psoriatic Arthritis Is Different From Bone Spur Formation in Hand Osteoarthritis. Arthritis and Rheumatology, 2014, 66, 2968-2975.	2.9	41

#	Article	IF	Citations
687	Systemic Lupus Erythematosus, Animal Models. , 2014, , 1134-1141.		0
688	S-Calprotectin (S100A8/S100A9): A Potential Marker of Inflammation in Patients with Psoriatic Arthritis. Journal of Immunology Research, 2014, 2014, 1-5.	0.9	50
689	Clinical and Contrast-Enhanced Ultrasound Echography Outcomes in Psoriatic Arthritis Patients after One Year of Continuous Therapy with Anti-TNF Drugs. ISRN Dermatology, 2014, 2014, 1-8.	1.9	8
690	Metatarsophalangeal joint pain in psoriatic arthritis: a cross-sectional study. Rheumatology, 2014, 53, 737-740.	0.9	24
691	Ustekinumab for the treatment of psoriatic arthritis. Expert Review of Clinical Immunology, 2014, 10, 189-202.	1.3	12
692	Ustekinumab for the treatment of psoriatic arthritis. Expert Review of Clinical Pharmacology, 2014, 7, 111-121.	1.3	2
693	Predictors of functional deterioration in Chinese patients with Psoriatic arthritis: a longitudinal study. BMC Musculoskeletal Disorders, 2014, 15, 284.	0.8	12
694	Psoriatic arthritis and sacroiliitis are associated with increased vascular inflammation by 18-fluorodeoxyglucose positron emission tomography computed tomography: baseline report from the Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative. Arthritis Research and Therapy, 2014, 16, R161.	1.6	37
695	Diagnosis and Management of Psoriatic Arthritis. Journal of the Dermatology Nurses' Association, 2014, 6, S44-S54.	0.1	0
696	Validation of the Thai version of the Health Assessment Questionnaire for patients with psoriatic arthritis. International Journal of Rheumatic Diseases, 2014, 17, 181-185.	0.9	5
698	Bone mineral density status and frequency of osteoporosis and clinical fractures in 155 patients with psoriatic arthritis followed in a university hospital. ReumatologÃa ClÃnica (English Edition), 2014, 10, 89-93.	0.2	1
699	Other seronegative spondyloarthropathies. Medicine, 2014, 42, 257-261.	0.2	4
700	Hyperuricemia in patients with chronic plaqueÂpsoriasis. Journal of the American Academy of Dermatology, 2014, 70, 127-130.	0.6	45
701	Bone mineral density status and frequency of osteoporosis and clinical fractures in 155 patients with psoriatic arthritis followed in a university hospital. ReumatologÃa ClÃnica, 2014, 10, 89-93.	0.2	33
702	Recommendations for the Coordinated Management of Psoriatic Arthritis by Rheumatologists and Dermatologists: A Delphi Study. Actas Dermo-sifiliográficas, 2014, 105, 216-232.	0.2	14
703	Experiencia de 4 años de funcionamiento de una unidad multidisciplinar de psoriasis y artritis psoriásica. Actas Dermo-sifiliográficas, 2014, 105, 371-377.	0.2	16
704	Effect of treatment on prolactin levels in patients with psoriasis vulgaris. Clinica Chimica Acta, 2014, 429, 212-214.	0.5	5
705	Impact of hypertension on vascular remodeling in patients with psoriatic arthritis. Journal of Human Hypertension, 2014, 28, 105-110.	1.0	11

#	Article	IF	Citations
706	Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors. Rheumatology, 2014, 53, 1477-1481.	0.9	28
707	Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis. Drugs, 2014, 74, 423-441.	4.9	209
708	Deletion of late cornified envelope genes, LCE3C_LCE3B-del, is not associated with psoriatic arthritis in Tunisian patients. Molecular Biology Reports, 2014, 41, 4141-4146.	1.0	5
709	High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a cross-sectional study. Rheumatology International, 2014, 34, 227-234.	1.5	63
710	Interleukinâ€17+CD8+ T Cells Are Enriched in the Joints of Patients With Psoriatic Arthritis and Correlate With Disease Activity and Joint Damage Progression. Arthritis and Rheumatology, 2014, 66, 1272-1281.	2.9	226
711	Multidisciplinary Psoriasis and Psoriactic Arthritis Unit: Report of 4 years' Experience. Actas Dermo-sifiliogrA¡ficas, 2014, 105, 371-377.	0.2	3
712	Increased Prevalence of Metabolic Syndrome in Patients with Psoriatic Arthritis. Metabolic Syndrome and Related Disorders, 2014, 12, 43-48.	0.5	27
713	Can traumatic injury trigger psoriatic arthritis? A review of the literature. Clinical Rheumatology, 2014, 33, 601-608.	1.0	45
714	Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Annals of the Rheumatic Diseases, 2014, 73, 349-356.	0.5	308
716	Anticyclic Citrullinated Peptide Antibodies in Rheumatoid and Nonrheumatoid Rheumatic Disorders: Experience with 1162 Patients. Journal of Rheumatology, 2014, 41, 2395-2402.	1.0	63
717	Utility of the PASE questionnaire, psoriatic arthritis (PsA) prevalence and PsA improvement with anti-TNF therapy: results from the PRISTINE trial. Journal of Dermatological Treatment, 2014, 25, 90-95.	1.1	9
718	Work Productivity Loss and Fatigue in Psoriatic Arthritis. Journal of Rheumatology, 2014, 41, 1670-1674.	1.0	54
719	Immunoglobulin G Subclass Analysis in Psoriatic Arthritis. Journal of Rheumatology, 2014, 41, 2421-2424.	1.0	2
720	Symptoms dermatologists should look for in daily practice to improve detection of psoriatic arthritis in psoriasis patients: an expert group consensus. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 27-32.	1.3	24
721	Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24â€Week Patientâ€Reported Outcome Results of a Phase III, Multicenter Study. Arthritis Care and Research, 2014, 66, 1085-1092.	1.5	64
722	Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment. Clinical and Experimental Immunology, 2014, 177, 234-243.	1.1	45
723	Progression de l'athérosclérose chez les patients ayant un rhumatisme psoriasique malgré un traitement par anti-TNF-alphaÂ: étude prospective observationnelle de 2Âans. Revue Du Rhumatisme (Edition Francaise), 2014, 81, 395-399.	0.0	0
724	Factores de riesgo para el desarrollo de artritis psoriásica. Piel, 2014, 29, 533-535.	0.0	0

		LPORT	
#	Article	IF	CITATIONS
725	Advances in the management of psoriatic arthritis. Nature Reviews Rheumatology, 2014, 10, 531-542.	3.5	65
726	Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review. Autoimmunity, 2014, 47, 287-306.	1.2	16
727	Is the Madrid Sonographic Enthesitis Index Useful for Differentiating Psoriatic Arthritis from Psoriasis Alone and Healthy Controls?. Journal of Rheumatology, 2014, 41, 466-472.	1.0	75
728	Distinct genetic profile in peripheral blood mononuclear cells of psoriatic arthritis patients treated with methotrexate and TNF-inhibitors. Clinical Rheumatology, 2014, 33, 1815-1821.	1.0	8
730	Depression and Anxiety in Psoriatic Disease: Prevalence and Associated Factors. Journal of Rheumatology, 2014, 41, 887-896.	1.0	184
731	Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease. Science, 2014, 346, 363-368.	6.0	86
732	Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Annals of the Rheumatic Diseases, 2014, 73, 48-55.	0.5	393
734	Ustekinumab: targeting the IL-17 pathway to improve outcomes in psoriatic arthritis. Expert Opinion on Biological Therapy, 2014, 14, 515-526.	1.4	27
735	TNF-α Gene Polymorphisms: Association with Disease Susceptibility and Response to Anti-TNF-α Treatment in Psoriatic Arthritis. Journal of Investigative Dermatology, 2014, 134, 2503-2509.	0.3	89
736	Prevalence of cardiovascular risk factors in patients with psoriatic arthritis. Clinical Rheumatology, 2014, 33, 1495-1500.	1.0	42
737	Intraocular pressure in chronic users of low-dose oral corticosteroids for connective tissue disease. Canadian Journal of Ophthalmology, 2014, 49, 363-366.	0.4	5
738	Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus. Journal of Dermatological Science, 2014, 75, 167-172.	1.0	73
740	Fine Mapping Major Histocompatibility Complex Associations in Psoriasis and Its Clinical Subtypes. American Journal of Human Genetics, 2014, 95, 162-172.	2.6	182
741	Is HLA-B27 Increased in Patients Diagnosed with Undifferentiated Arthritis? Results from the Leiden Early Arthritis Cohort. Journal of Rheumatology, 2014, 41, 1948-1951.	1.0	1
742	Identification of psoriatic arthritis mediators in synovial fluid by quantitative mass spectrometry. Clinical Proteomics, 2014, 11, 27.	1.1	49
743	Biomarkers in Psoriatic Arthritis: Recent Progress. Current Rheumatology Reports, 2014, 16, 453.	2.1	21
744	A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Annals of the Rheumatic Diseases, 2014, 73, 1012-1019.	0.5	314
745	Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Annals of the Rheumatic Diseases, 2014, 73, 1020-1026.	0.5	372

#	Article	IF	CITATIONS
746	Épidémiologie de la spondyloarthrite au xxie siÃ [°] cle. Revue Du Rhumatisme Monographies, 2014, 81, 225-229.	0.0	5
747	Are anti-CCP antibodies in psoriatic arthritis patients a biomarker of erosive disease?. Rheumatology International, 2014, 34, 1211-1216.	1.5	28
748	Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety. Rheumatology International, 2014, 34, 1345-1360.	1.5	42
749	Serum complement C3 correlates with insulin resistance in never treated psoriatic arthritis patients. Clinical Rheumatology, 2014, 33, 1759-1764.	1.0	27
750	Remission criteria and activity indices in psoriatic arthritis. Clinical Rheumatology, 2014, 33, 1323-1330.	1.0	42
751	Disparity between ultrasound and clinical findings in psoriatic arthritis. Annals of the Rheumatic Diseases, 2014, 73, 1529-1536.	0.5	95
752	Diagnosing and treating psoriatic arthritis: an update. British Journal of Dermatology, 2014, 170, 772-786.	1.4	28
753	Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials. Annals of the Rheumatic Diseases, 2014, 73, 414-419.	0.5	63
754	JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunologic Research, 2014, 58, 61-69.	1.3	65
755	New developments in our understanding of psoriatic arthritis and their impact on the diagnosis and clinical management of the disease. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 264-270.	1.3	20
756	The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Annals of the Rheumatic Diseases, 2014, 73, 1990-1996.	0.5	83
757	Achilles tendon ultrasonography may detect early features of psoriatic arthropathy in patients with cutaneous psoriasis. British Journal of Dermatology, 2014, 171, 1220-1222.	1.4	18
758	Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Annals of the Rheumatic Diseases, 2014, 73, 1157-1162.	0.5	186
759	Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Annals of the Rheumatic Diseases, 2014, 73, 407-413.	0.5	148
760	Autoantibodies against CD74 in spondyloarthritis. Annals of the Rheumatic Diseases, 2014, 73, 1211-1214.	0.5	77
761	Senescence marker killer cell lectin-like receptor G1 (KLRG1) contributes to TNF-α production by interaction with its soluble E-cadherin ligand in chronically inflamed joints. Annals of the Rheumatic Diseases, 2014, 73, 1223-1231.	0.5	33
762	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2014, 73, 6-16.	0.5	397
763	Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: A two-year prospective observational study. Joint Bone Spine, 2014, 81, 421-425.	0.8	51

#	Article	IF	CITATIONS
764	Elaboración mediante el método Delphi de recomendaciones para el manejo coordinado (reumatólogo/dermatólogo) de la artritis psoriásica. Actas Dermo-sifiliográficas, 2014, 105, 216-232.	0.2	24
765	A Report of 4 Years of Experience of a Multidisciplinary Unit of Psoriasis and Psoriatic Arthritis. ReumatologÃa ClÃnica (English Edition), 2014, 10, 141-146.	0.2	17
766	Répartition des rhumatismes du sujet âgéÂ: enquête auprès des rhumatologues de la région Auvergne. Revue Du Rhumatisme (Edition Francaise), 2014, 81, 69-73.	0.0	3
767	Actualización en artritis psoriásica. Actas Dermo-sifiliográficas, 2014, 105, 913-922.	0.2	8
768	Arthritis and Onychophagia: A Confounding Factor. ReumatologÃa ClÃnica (English Edition), 2014, 10, 260-261.	0.2	0
769	Psoriatic arthritis and nail changes: Exploring the relationship. Seminars in Arthritis and Rheumatism, 2014, 44, 162-169.	1.6	38
770	Influence of tumor necrosis factor \hat{I}_{\pm} inhibitors on testicular function and semen in spondyloarthritis patients. Fertility and Sterility, 2014, 101, 359-365.	0.5	61
771	The hand in systemic diseases other than rheumatoid arthritis. Chirurgie De La Main, 2014, 33, 155-173.	0.7	6
772	Artritis y onicofagia: un factor de confusión. ReumatologÃa ClÃnica, 2014, 10, 260-261.	0.2	2
773	Cardiovascular risk profile in patients with spondyloarthritis. Joint Bone Spine, 2014, 81, 57-63.	0.8	63
774	A crossâ€sectional study on the prevalence of metabolic syndrome in psoriasis compared to psoriatic arthritis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 507-511.	1.3	30
775	Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis. New England Journal of Medicine, 2014, 370, 2295-2306.	13.9	350
776	Prevalence of psoriatic arthritis in psoriasis patients according to newer classification criteria. Clinical Rheumatology, 2014, 33, 243-246.	1.0	17
777	Prevalence of psoriatic arthritis in psoriasis patients according to newer classification criteria. Clinical Rheumatology, 2014, 33, 1489-1493.	1.0	29
778	Imaging of Disorders Affecting the Bone and Skin. Radiographics, 2014, 34, 197-216.	1.4	25
779	Pattern of bone erosion and bone proliferation in psoriatic arthritis hands: a high-resolution computed tomography and radiography follow-up study during adalimumab therapy. Scandinavian Journal of Rheumatology, 2014, 43, 202-208.	0.6	14
780	No overall damage progression despite persistent inflammation in adalimumab-treated psoriatic arthritis patients: results from an investigator-initiated 48-week comparative magnetic resonance imaging, computed tomography and radiography trial. Rheumatology, 2014, 53, 746-756.	0.9	34
781	Experiencia de 4 años de funcionamiento de una unidad multidisciplinar de psoriasis y artritis psoriásica. ReumatologÃa ClÃnica, 2014, 10, 141-146.	0.2	38

	CHAHON	REPORT	
#	Article	IF	Citations
782	Le pied et la cheville des spondyloarthrites. Revue Du Rhumatisme Monographies, 2014, 81, 115-119.	0.0	4
786	Big Data and Clinicians: A Review on the State of the Science. JMIR Medical Informatics, 2014, 2, e1.	1.3	110
787	Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?. Arthritis Research and Therapy, 2014, 16, 426.	1.6	133
788	Aiming for remission in psoriatic arthritis. International Journal of Clinical Rheumatology, 2014, 9, 147-153.	0.3	1
789	Diagnosis and management of psoriatic arthropathy in primary care. British Journal of General Practice, 2014, 64, 424-425.	0.7	9
790	The EPIPSOFIRE project: A Preliminary Report. Drug Development Research, 2014, 75, S85-S87.	1.4	1
791	Mild Cognitive Impairment in Patients with Moderate to Severe Chronic Plaque Psoriasis. Dermatology, 2014, 228, 78-85.	0.9	51
792	Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Research and Therapy, 2015, 17, 115.	1.6	147
793	Vitamin D ₃ levels and bone mineral density in patients with psoriasis and/or psoriatic arthritis. Journal of Dermatology, 2015, 42, 679-684.	0.6	32
794	Adalimumab markedly improves enthesitis in patients with psoriatic arthritis: Evaluation with a magnetic resonance imaging scoring system. Journal of Dermatology, 2015, 42, 1153-1159.	0.6	10
795	Relationship of CD146 expression to secretion of interleukin (IL)-17, IL-22 and interferon-γ by CD4+ T cells in patients with inflammatory arthritis. Clinical and Experimental Immunology, 2015, 179, 378-391.	1.1	17
796	High-Frequency Ultrasound in the Evaluation of Psoriatic Arthritis: A Clinical Study. American Journal of the Medical Sciences, 2015, 350, 42-46.	0.4	21
797	Comorbidities in patients with psoriatic arthritis: a comparison with rheumatoid arthritis and psoriasis. International Journal of Rheumatic Diseases, 2015, 18, 873-879.	0.9	21
798	Development of Simple Clinical Criteria for the Definition of Inflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2014 Annual Meeting. Journal of Rheumatology, 2015, 42, 1041-1043.	1.0	2
799	Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD Open, 2015, 1, e000181.	1.8	62
800	Four cases of Japanese patients with psoriatic arthritis in whom effective treatments by antiâ€tumor necrosis factorâ€î± drugs were evaluated by magnetic resonance imaging together with improvement of skin lesions. Journal of Dermatology, 2015, 42, 49-55.	0.6	4
801	Radiographic development during three decades in a patient with psoriatic arthritis mutilans. Acta Radiologica Open, 2015, 4, 205846011558809.	0.3	3
802	Further Evidence Supporting a Parentâ€ofâ€Origin Effect in Psoriatic Disease. Arthritis Care and Research, 2015, 67, 1586-1590.	1.5	15

#	Article	IF	CITATIONS
803	Reliability and Validity of the Psoriasis Symptom Inventory in Patients With Psoriatic Arthritis. Arthritis Care and Research, 2015, 67, 1750-1756.	1.5	4
804	Quantitative and Qualitative Changes of Bone in Psoriasis and Psoriatic Arthritis Patients. Journal of Bone and Mineral Research, 2015, 30, 1775-1783.	3.1	58
805	AB0819â€Axial Psoriatic Arthritis with and Without Radiological Involvement: Are There Any Differences?: Table 1. Annals of the Rheumatic Diseases, 2015, 74, 1173.1-1173.	0.5	0
806	Metric Sex Determination of the Human Coxal Bone on a Virtual Sample using Decision Trees. Journal of Forensic Sciences, 2015, 60, 1395-1400.	0.9	10
807	Oral fumaric acid esters for psoriasis. The Cochrane Library, 2017, 2017, CD010497.	1.5	19
808	Frequency of undiagnosed psoriatic arthritis among psoriasis patients in Australian dermatology practice. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2184-2191.	1.3	24
809	Association of psoriasis and/or psoriatic arthritis with autoimmune diseases: the experience of two Italian integrated Dermatology/Rheumatology outpatient clinics. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2160-2168.	1.3	13
810	Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis – a systematic review. Psoriasis: Targets and Therapy, 2015, 5, 71.	1.2	5
811	A Prospective Study on Inflammatory Cytokines and Bone Metabolism Mediators in Patients Affected by Rheumatoid and Psoriatic Arthritis treated with Adalimumab. Journal of Arthritis, 2015, 04, .	0.3	1
812	Optimal management of dactylitis in patients with psoriatic arthritis. Open Access Rheumatology: Research and Reviews, 2015, 7, 55.	0.8	11
813	Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment. PLoS ONE, 2015, 10, e0129120.	1.1	51
814	Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients. PLoS ONE, 2015, 10, e0144335.	1.1	19
815	Incidence of active mycobacterial infections in Brazilian patients with chronic inflammatory arthritis and negative evaluation for latent tuberculosis infection at baseline - A longitudinal analysis after using TNFa blockers. Memorias Do Instituto Oswaldo Cruz, 2015, 110, 921-928.	0.8	13
816	Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis. Clinical, Cosmetic and Investigational Dermatology, 2015, 8, 563.	0.8	25
817	Clinical and radiographic involvement of cervical spine in patients with psoriatic arthritis. Indian Journal of Rheumatology, 2015, 10, 65-69.	0.2	1
818	A Clinician's Guide to Diagnosing and Managing Psoriatic Arthritis. Journal of Psoriasis and Psoriatic Arthritis, 2015, 1, 9-25.	0.3	0
819	Serum IL-6 and IL-23 Levels and Their Correlation with Angiogenic Cytokines and Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome. Mediators of Inflammation, 2015, 2015, 1-7.	1.4	38
820	Prevalence of acute and chronic viral seropositivity and characteristics of disease in patients with psoriatic arthritis treated with cyclosporine: a post hoc analysis from a sex point of view on the observational study of infectious events in psoriasis complicated by active psoriatic arthritis. Clinical. Cosmetic and Investigational Dermatology. 2016. 9. 1.	0.8	5

#	Article	IF	CITATIONS
821	Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MG. Brazilian Journal of Pharmaceutical Sciences, 2015, 51, 709-719.	1.2	4
822	Management of patients with psoriatic arthritis. Nurse Practitioner, 2015, 40, 40-46.	0.2	10
824	Cardiovascular risk markers in patients with psoriatic arthritis: A meta-analysis of literature studies. Annals of Medicine, 2015, 47, 346-353.	1.5	49
825	Factors Explaining the Discrepancy Between Physician and Patient Global Assessment of Joint and Skin Disease Activity in Psoriatic Arthritis Patients. Arthritis Care and Research, 2015, 67, 264-272.	1.5	63
826	Decreased Bacterial Diversity Characterizes the Altered Gut Microbiota in Patients With Psoriatic Arthritis, Resembling Dysbiosis in Inflammatory Bowel Disease. Arthritis and Rheumatology, 2015, 67, 128-139.	2.9	602
827	Clinical features and types of articular involvement in patients with psoriatic arthritis. Clinical Rheumatology, 2015, 34, 1091-1096.	1.0	14
828	Psoriatic Arthritis Under a Proteomic Spotlight: Application of Novel Technologies to Advance Diagnosis and Management. Current Rheumatology Reports, 2015, 17, 35.	2.1	17
829	Psoriatic Nail Changes Are Associated With Clinical Outcomes in Psoriatic Arthritis. Journal of Cutaneous Medicine and Surgery, 2015, 19, 367-376.	0.6	15
830	Psoriatic Arthritis Mutilans: Characteristics and Natural Radiographic History. Journal of Rheumatology, 2015, 42, 1169-1176.	1.0	22
831	A deletion atADAMTS9-MAGI1locus is associated with psoriatic arthritis risk. Annals of the Rheumatic Diseases, 2015, 74, 1875-1881.	0.5	18
832	The Prevalence and Characteristics of Psoriatic Arthritis in Patients With Psoriasis in a Tertiary Hospital. Archives of Rheumatology, 2015, 30, 23-27.	0.3	5
833	Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes. Expert Review of Clinical Immunology, 2015, 11, 935-946.	1.3	13
834	lt's not just the joints, it's the whole thing: qualitative analysis of patients' experience of flare in psoriatic arthritis. Rheumatology, 2015, 54, 1448-1453.	0.9	32
835	Making the next steps in psoriatic arthritis management: current status and future directions. Therapeutic Advances in Musculoskeletal Disease, 2015, 7, 173-186.	1.2	9
836	Pixel-based approach to assess contrast-enhanced ultrasound kinetics parameters for differential diagnosis of rheumatoid arthritis. Journal of Medical Imaging, 2015, 2, 034503.	0.8	15
837	Patient's Global Assessment as an Outcome Measure for Psoriatic Arthritis in Clinical Practice: A Surrogate for Measuring Low Disease Activity?. Journal of Rheumatology, 2015, 42, 2332-2338.	1.0	41
838	Cardiovascular effects of Etanercept in patients with psoriatic arthritis: evidence from the cardiovascular risk in rheumatic diseases database. Expert Opinion on Drug Safety, 2015, 14, 1905-1913.	1.0	11
839	Influence of Fcγ Receptor Polymorphisms on Response to Anti–Tumor Necrosis Factor Treatment in Psoriasis, IAMA Dermatology, 2015, 151, 1376.	2.0	6

 #
 ARTICLE
 IF
 CITATIONS

 840
 <i>>TNFAIP3
 i>> and <i>>TNIP1
 polymorphisms confer psoriasis risk in South Indian Tamils. British
 1.2
 14

 841
 Pro-inflammatory effects of interleukin-35 in rheumatoid arthritis. Cytokine, 2015, 73, 36-43.
 1.4
 44

 842
 Inflammatory Arthritis in Clinical Practice., 2015, .
 2

 A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis
 2

CITATION REPORT

#	Article	IF	CITATIONS
859	Association between Skin and Joint Involvement in Patients with Psoriatic Arthritis Treated with Adalimumab: Analysis of Data from a German Non-Interventional Study. Dermatology, 2015, 230, 213-221.	0.9	4
860	Nail psoriasis as a predictor of the development of psoriatic arthritis. Actas Dermo-sifiliográficas, 2015, 106, 452-457.	0.2	59
861	Effects of mud-bath therapy in psoriatic arthritis patients treated with TNF inhibitors. Clinical evaluation and assessment of synovial inflammation by contrast-enhanced ultrasound (CEUS). Joint Bone Spine, 2015, 82, 104-108.	0.8	38
862	Prevalence and Clinical Characteristics of Psoriatic Arthritis in Japan. Journal of Rheumatology, 2015, 42, 1439-1442.	1.0	63
863	Summary of Sensitivity and Specificity for Psoriatic Arthritis in a South African Cohort according to Classification Criteria. Journal of Rheumatology, 2015, 42, 960-962.	1.0	3
864	Psoriatic Arthritis Mutilans: Clinical and Radiographic Criteria. A Systematic Review. Journal of Rheumatology, 2015, 42, 1432-1438.	1.0	22
866	Treatment Satisfaction of Patients with Psoriasis. Acta Dermato-Venereologica, 2015, 95, 572-578.	0.6	48
867	Nested Case–Control Study of Selected Systemic Autoimmune Diseases in World Trade Center Rescue/Recovery Workers. Arthritis and Rheumatology, 2015, 67, 1369-1376.	2.9	57
868	Nail psoriasis as a predictor of the development of psoriatic arthritis. Actas Dermo-sifiliográficas, 2015, 106, 452-457.	0.2	1
869	Psoriasis and polycystic ovary syndrome: a new link in different phenotypes. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 191, 101-105.	0.5	6
871	Counting Costs under Severe Financial Constraints: A Cost-of-Illness Analysis of Spondyloarthropathies in a Tertiary Hospital in Greece. Journal of Rheumatology, 2015, 42, 963-967.	1.0	5
872	Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity. Rheumatology International, 2015, 35, 1385-1392.	1.5	14
874	Vascular perfusion kinetics by contrast-enhanced ultrasound are related to synovial microvascularity in the joints of psoriatic arthritis. Clinical Rheumatology, 2015, 34, 1903-1912.	1.0	36
875	Poorer functionality is related to better quality of life response following the use of biological drugs: 6-month outcomes in a prospective cohort from the Public Health System (<i>Sistema Único de) Tj ETQq1 15, 403-412.</i>	1.0.7843	14.rgBT /O
876	Psoriatic arthritis: an evolving matter. RMD Open, 2015, 1, e000006-e000006.	1.8	0
877	Enthesitis as a component of dactylitis in psoriatic juvenile idiopathic arthritis: histology of an established clinical entity. Pediatric Rheumatology, 2015, 13, 7.	0.9	24
878	Cumulative inflammatory burden is independently associated with increased arterial stiffness in patients with psoriatic arthritis: a prospective study. Arthritis Research and Therapy, 2015, 17, 75.	1.6	40
879	Prevalence and clinical features of psoriatic arthritis in psoriasis patients in Spain. Limitations of PASE as a screening tool. European Journal of Dermatology, 2015, 25, 57-63.	0.3	20

#	Article	IF	CITATIONS
880	Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Annals of the Rheumatic Diseases, 2015, 74, 813-817.	0.5	138
881	Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. Rheumatology, 2015, 54, 792-797.	0.9	67
882	Musculoskeletal Ultrasonography in Rheumatic Diseases. , 2015, , .		5
883	What makes psoriatic and rheumatoid arthritis so different?. RMD Open, 2015, 1, e000025-e000025.	1.8	75
884	Prevalence of Psoriatic Arthritis in a Large Cohort of Brazilian Patients with Psoriasis. Journal of Rheumatology, 2015, 42, 829-834.	1.0	39
885	Biomarkers for rheumatoid and psoriatic arthritis. Clinical Immunology, 2015, 161, 2-10.	1.4	45
886	Targeting extra-articular manifestations in PsA. Current Opinion in Rheumatology, 2015, 27, 111-117.	2.0	31
888	Spondyloarthritis in African Blacks. Journal of Rheumatology, 2015, 42, 139-139.	1.0	6
889	Validation of the Toronto Psoriatic Arthritis Screen Version 2 (ToPAS 2). Journal of Rheumatology, 2015, 42, 841-846.	1.0	50
890	Enthesitis in patients with psoriatic arthritis, axial spondyloarthritis and healthy subjects assessed by â€~head-to-toe' whole-body MRI and clinical examination. Annals of the Rheumatic Diseases, 2015, 74, 823-829.	0.5	106
892	Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. New England Journal of Medicine, 2015, 373, 1329-1339.	13.9	629
893	Early Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2015, 41, 615-622.	0.8	20
894	Lengthening the time intervals between doses of biological agents in psoriatic arthritis patients: A single-center retrospective study. International Journal of Immunopathology and Pharmacology, 2015, 28, 479-487.	1.0	13
895	Single-joint Assessment for the Evaluation of Intraarticular Treatment: Responsiveness and Discrimination of the Composite Change Index. Journal of Rheumatology, 2015, 42, 1672-1676.	1.0	3
896	High-resolution MRI assessment of dactylitis in psoriatic arthritis shows flexor tendon pulley and sheath-related enthesitis. Annals of the Rheumatic Diseases, 2015, 74, 185-189.	0.5	95
897	The Role of Tumor Necrosis Factor-Â Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2015, 93, 73-78.	2.2	12
898	Effect of certolizumab pegol over 96â€weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. RMD Open, 2015, 1, e000119.	1.8	40
899	Prevalence of Inflammatory Back Pain and Axial Spondyloarthritis Among University Employees in Izmir, Turkey. Journal of Rheumatology, 2015, 42, 1647-1651.	1.0	7

#	Article	IF	CITATIONS
900	Differential Antigen-presenting B Cell Phenotypes from Synovial Microenvironment of Patients with Rheumatoid and Psoriatic Arthritis. Journal of Rheumatology, 2015, 42, 1825-1834.	1.0	15
901	Auto-reactions, autoimmunity and psoriatic arthritis. Autoimmunity Reviews, 2015, 14, 1142-1146.	2.5	47
902	Imaging in Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2015, 41, 593-613.	0.8	32
903	Association between single nucleotide polymorphisms IL17RA rs4819554 and IL17E rs79877597 and Psoriasis in a Spanish cohort Journal of Dermatological Science, 2015, 80, 111-115.	1.0	39
904	Clinical Features and Diagnostic Considerations in Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2015, 41, 569-579.	0.8	94
905	Comparison between the intermalleolar distance measured on the couch and on the floor in axial spondyloarthritis. Rheumatology International, 2015, 35, 2021-2027.	1.5	0
906	Ultrasound in psoriatic arthritis. Can it facilitate a best routine practice in the diagnosis and management of psoriatic arthritis?. Clinical Rheumatology, 2015, 34, 1847-1855.	1.0	18
907	Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clinical Rheumatology, 2015, 34, 1571-1580.	1.0	36
908	Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24â€weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study. Annals of the Rheumatic Diseases, 2015, 74, 44-51.	0.5	30
909	A novel evidence-based detection of undiagnosed spondyloarthritis in patients presenting with acute anterior uveitis: the DUET (Dublin Uveitis Evaluation Tool). Annals of the Rheumatic Diseases, 2015, 74, 1990-1995.	0.5	108
910	The Epidemiology of Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2015, 41, 545-568.	0.8	354
911	Novel Treatment Concepts in Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2015, 41, 739-754.	0.8	6
912	The Swedish Early Psoriatic Arthritis Registry 5-year Followup: Substantial Radiographic Progression Mainly in Men with High Disease Activity and Development of Dactylitis. Journal of Rheumatology, 2015, 42, 2110-2117.	1.0	57
913	Nonrheumatoid Inflammatory Arthroses of the Hand and Wrist. Journal of Hand Surgery, 2015, 40, 2477-2487.	0.7	9
914	Verna Wright Lecture: Psoriatic Arthritis: The Need for Early Intervention. Journal of rheumatology Supplement, The, 2015, 93, 10-13.	2.2	8
915	Relationship of Psoriatic Arthritis to Other Spondyloarthritides. Journal of rheumatology Supplement, The, 2015, 93, 33-35.	2.2	3
916	An Integrative Approach to Biomarker Development in Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2015, 93, 43-47.	2.2	1
918	Distribution of interleukin-10 family cytokines in serum and synovial fluid of patients with inflammatory arthritis reveals different contribution to systemic and joint inflammation. Clinical and Experimental Immunology, 2015, 179, 300-308.	1.1	32

#	Article	IF	CITATIONS
919	Minimal Disease Activity and Anti–Tumor Necrosis Factor Therapy in Psoriatic Arthritis. Arthritis Care and Research, 2015, 67, 842-847.	1.5	45
920	Clinical remission of psoriatic arthritis in patients receiving continuous biological therapies for 1Âyear: the experience of an outpatient dermatological clinic for psoriasis. Clinical and Experimental Dermatology, 2015, 40, 136-141.	0.6	16
921	Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1924-1930.	0.5	58
922	Prevalence and incidence rates of psoriatic arthritis in central Norway: data from the Nord-TrÃ,ndelag Health Study (HUNT). Annals of the Rheumatic Diseases, 2015, 74, 60-64.	0.5	42
923	Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants. Annals of the Rheumatic Diseases, 2015, 74, 1603-1611.	0.5	35
924	Classification and Diagnosis of Axial Spondyloarthritis — What Is the Clinically Relevant Difference?. Journal of Rheumatology, 2015, 42, 31-38.	1.0	37
925	Increased circulating endothelial cells and microparticles in patients with psoriasis. Clinical Hemorheology and Microcirculation, 2015, 60, 283-290.	0.9	18
926	Pain threshold and intensity in rheumatic patients: correlations with the Hamilton Depression Rating scale. Clinical Rheumatology, 2015, 34, 555-561.	1.0	30
927	Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1830-1835.	0.5	70
928	Free fatty acids: potential proinflammatory mediators in rheumatic diseases. Annals of the Rheumatic Diseases, 2015, 74, 303-310.	0.5	94
929	Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunologic Research, 2015, 61, 147-153.	1.3	70
930	Serum Soluble Bone Turnover Biomarkers in Psoriatic Arthritis and Psoriatic Spondyloarthropathy. Journal of Rheumatology, 2015, 42, 21-30.	1.0	51
931	Psoriatic Arthritis for the Dermatologist. Dermatologic Clinics, 2015, 33, 127-148.	1.0	13
932	Psoriatic arthritis: current therapy and future approaches. Rheumatology, 2015, 54, 20-28.	0.9	56
933	Treatment response, drug survival and safety of anti-tumour necrosis factor α therapy in 193 patients with psoriatic arthritis: A twelve-year "real life―experience. Joint Bone Spine, 2015, 82, 31-37.	0.8	24
934	Efficacy of methotrexate and tumor necrosis factor inhibitors in Japanese patients with active psoriatic arthritis. Modern Rheumatology, 2015, 25, 431-434.	0.9	6
935	C-reactive protein gene and Toll-like receptor 4 gene polymorphisms can relate to the development of psoriatic arthritis. Clinical Rheumatology, 2015, 34, 301-306.	1.0	12
936	Tailored approach to early psoriatic arthritis patients: clinical and ultrasonographic predictors for structural joint damage. Clinical Rheumatology, 2015, 34, 307-313.	1.0	66

		CITATION R	EPORT	
#	Article		IF	CITATIONS
937	Extra-articular manifestations in psoriatic arthritis patients. Clinical Rheumatology, 201	.5, 34, 745-753.	1.0	61
938	Responsiveness to therapy change of a global ultrasound assessment in spondyloarthr Clinical Rheumatology, 2015, 34, 125-132.	itis patients.	1.0	10
939	Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in dete features of the psoriatic arthritis phenotype. Annals of the Rheumatic Diseases, 2016,	rmining specific 75, 155-162.	0.5	100
940	Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis the public health system $\hat{a} \in $ the case of Poland. Reumatologia, 2016, 54, 278-284.	patients in	0.5	9
941	Incidence, clinical manifestations and clipping of nail psoriasis in the dermatology cent Hospital Universitário Evangélico de Curitiba. Anais Brasileiros De Dermatologia, 20	er of the 16, 91, 300-305.	0.5	14
942	The relationship between body mass index, waist circumference and psoriatic arthritis population. Postepy Dermatologii I Alergologii, 2016, 3, 219-223.	in the Turkish	0.4	1
943	Recent advances in understanding and managing psoriatic arthritis. F1000Research, 20	016, 5, 2670.	0.8	29
944	Psoriasis and Psoriatic Arthritis: Flip Sides of the Coin?. Acta Dermato-Venereologica, 2	016, 96, 436-441.	0.6	18
945	Reliability and Validity of the Turkish Adaptation of VITACORA-19 in Patients with Psori Archives of Rheumatology, 2016, 31, 321-328.	atic Arthritis.	0.3	1
946	Diagnostyka obrazowa Å,uszczycowego zapalenia stawów. Część I: etiopatogen rentgenodiagnostyka. , 2016, 16, 65-77.	eza, klasyfikacje i		36
947	Psoriatic arthritis: An assessment of clinical, biochemical and radiological features in a south African cohort. South African Medical Journal, 2016, 106, 630.	single-centre	0.2	2
948	Extra-Articular Symptoms in Constellation with Selected Serum Cytokines and Disease Spondyloarthritis. Mediators of Inflammation, 2016, 2016, 1-7.	Activity in	1.4	22
949	The Diagnosis and Treatment of Nail Disorders. Deutsches Ärzteblatt Int 113, 509-18.	ernational, 2016,	0.6	45
950	Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by in psoriatic Arthritis (IDEA). Reumatismo, 2016, 68, 126-136.	Italian DElphi	0.4	15
951	The Psoriatic Arthritis Impact of Disease 12-item questionnaire: equivalence, reliability, feasibility of the touch-screen administration versus the paper-and-pencil version. There Clinical Risk Management, 2016, 12, 631.	validity, and apeutics and	0.9	26
952	Diagnosis and treatment of anterior uveitis: optometric management. Clinical Optome	try, 2016, 8, 23.	0.4	33
953	Severe psoriatic dactylitis: when psoriasis involves beyond the skin. Reumatismo, 2016	, 68, 112-113.	0.4	1
954	Increased Prevalence of Human Polyomavirus JC Viruria in Chronic Inflammatory Rheun Patients in Treatment with Anti-TNF α: A 18 Month Follow-Up Study. Frontiers in Micro 672.	natic Diseases bbiology, 2016, 7,	1.5	4

#	Article	IF	CITATIONS
955	Serum Interleukin-18, Fetuin-A, Soluble Intercellular Adhesion Molecule-1, and Endothelin-1 in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome. International Journal of Molecular Sciences, 2016, 17, 1255.	1.8	33
956	S100A8/A9, a potent serum and molecular imaging biomarker for synovial inflammation and joint destruction in seronegative experimental arthritis. Arthritis Research and Therapy, 2016, 18, 247.	1.6	20
957	Psoriatic arthritis is associated with bone loss of the metacarpals. Arthritis Research and Therapy, 2016, 18, 248.	1.6	13
958	Anti-Ephrin Type-B Receptor 2 (EphB2) and Anti-Three Prime Histone mRNA EXonuclease 1 (THEX1) Autoantibodies in Scleroderma and Lupus. PLoS ONE, 2016, 11, e0160283.	1.1	1
959	Complement C3 Is the Strongest Predictor of Whole-Body Insulin Sensitivity in Psoriatic Arthritis. PLoS ONE, 2016, 11, e0163464.	1.1	13
960	Selected issues in diagnostic imaging of spondyloarthritides: psoriatic arthritis and juvenile spondyloarthritis. Reumatologia, 2016, 6, 310-317.	0.5	4
961	Psoriasis Trends and Practice Gaps. Dermatologic Clinics, 2016, 34, 235-242.	1.0	8
962	Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis. International Journal of Dermatology, 2016, 55, 296-302.	0.5	45
963	Nonâ€alcoholic fatty liver disease fibrosis score in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 282-287.	1.3	50
964	Impaired <i>Porphyromonas gingivalis</i> –Induced Tumor Necrosis Factor Production by Dendritic Cells Typifies Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2016, 68, 795-804.	2.9	10
965	Prevalence of Psoriatic Arthritis in Primary Care Patients With Psoriasis. Arthritis and Rheumatology, 2016, 68, 924-931.	2.9	17
966	Clinical and Imaging Signs of Spondyloarthritis in Firstâ€Degree Relatives of HLA–B27–Positive Ankylosing Spondylitis Patients: The Preâ€ S pondyloarthritis (Preâ€ S pA) Cohort Study. Arthritis and Rheumatology, 2016, 68, 2444-2455.	2.9	18
967	Brief Report: Management of Chronic Postâ€Chikungunya Rheumatic Disease: The Martinican Experience. Arthritis and Rheumatology, 2016, 68, 2817-2824.	2.9	61
968	Editorial: Sacroiliac Joint Magnetic Resonance Imaging in the Diagnosis of Axial Spondyloarthritis: "A Tiny Bit of White on Two Consecutive Slices―May Be Objective, but Not Specific. Arthritis and Rheumatology, 2016, 68, 775-778.	2.9	27
969	Screening of Patients with Psoriasis for Psoriatic Arthritis in the Slovak Republic. Acta Medica Martiniana, 2016, 16, 32-42.	0.4	4
970	Psoriatic Arthritis with Annular Pustular Psoriasis. Internal Medicine, 2016, 55, 519-521.	0.3	0
971	Nagelbefall kann bei Patienten mit Psoriasis auf eine Enthesiopathie hinweisen. JDDG - Journal of the German Society of Dermatology, 2016, 14, 1102-1108.	0.4	4
972	Juvenile idiopathic arthritis in adulthood: fulfilment of classification criteria for adult rheumatic diseases, long-term outcomes and predictors of inactive disease, functional status and damage. RMD Open, 2016, 2, e000304.	1.8	47

#	Article	IF	CITATIONS
973	Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity. Annals of the Rheumatic Diseases, 2016, 75, 2108-2113.	0.5	40
974	Ultrasonographic evaluation of femoral cartilage thickness in patients with psoriatic arthritis. Journal of Back and Musculoskeletal Rehabilitation, 2016, 29, 703-708.	0.4	4
975	Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis. Rheumatology, 2017, 56, kew433.	0.9	20
976	Differential gene and protein expression of chemokines and cytokines in synovial fluid of patients with arthritis. Arthritis Research and Therapy, 2016, 18, 296.	1.6	40
977	Atherosclerosis in Psoriatic Arthritis: A Multiparametric Analysis Using Imaging Technique and Laboratory Markers of Inflammation and Vascular Function. International Journal of Angiology, 2016, 25, 222-228.	0.2	20
978	Performance of screening tools for psoriatic arthritis: a cross-sectional study in primary care. Rheumatology, 2017, 56, kew410.	0.9	15
979	Orthopaedic interventions in patients with psoriatic arthritis: a descriptive report from the SPAR cohort. RMD Open, 2016, 2, e000293.	1.8	10
980	7.7 THE EFFECT OF MARINE N-3 POLYUNSATURATED FATTY ACIDS ON CARDIAC AUTONOMIC AND HEMODYNAMIC FUNCTION IN PATIENTS WITH PSORIATIC ARTHRITIS: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Artery Research, 2016, 16, 64.	0.3	0
981	Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis. Arthritis Research and Therapy, 2016, 18, 297.	1.6	53
982	Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors. Journal of Rheumatology, 2016, 43, 918-923.	1.0	52
983	Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Seminars in Arthritis and Rheumatism, 2016, 46, 95-101.	1.6	77
984	Distress, misperceptions, poor coping and suicidal ideation in psoriatic arthritis: a qualitative study:. Rheumatology, 2016, 55, 1047-1052.	0.9	13
985	Relationship between self-efficacy, beliefs, and physical activity in inflammatory arthritis. Hong Kong Physiotherapy Journal, 2016, 34, 33-40.	0.3	12
986	Reduced CLEC9A expression in synovial tissue of psoriatic arthritis patients after adalimumab therapy. Rheumatology, 2016, 55, 1575-1584.	0.9	5
987	Association of IL1l² (-511 A/C) and IL6 (-174 G > C) polymorphisms with higher disease activity and clinical pattern of psoriatic arthritis. Clinical Rheumatology, 2016, 35, 1789-1794.	1.0	11
989	Proteomic biomarkers for psoriasis and psoriasis arthritis. Journal of Proteomics, 2016, 140, 55-61.	1.2	35
990	308C/A and 238C/A polymorphisms in the TNF-α gene may not contribute to the risk of arthritis among Turkish psoriatic patients. Egyptian Rheumatologist, 2016, 38, 313-317.	0.5	9
991	Psoriatic arthritis and psoriasis: differential diagnosis. Clinical Rheumatology, 2016, 35, 1893-1901.	1.0	64

#	Article	IF	CITATIONS
992	High-resolution ¹⁸ F-FDG PET/CT for assessing disease activity in rheumatoid and psoriatic arthritis: findings of a prospective pilot study. British Journal of Radiology, 2016, 89, 20160138.	1.0	49
993	The Association of HLA-class I Genes and the Extent of Atherosclerotic Plaques in Patients with Psoriatic Disease. Journal of Rheumatology, 2016, 43, 1844-1851.	1.0	11
994	Endothelial progenitor cell biology in psoriatic arthritis patients in the absence of traditional cardiovascular risk. Indian Journal of Rheumatology, 2016, 11, 14-20.	0.2	1
995	An ultrasonographic study of enthesis in early psoriatic arthritis patients naive to traditional and biologic DMARDs treatment. Rheumatology International, 2016, 36, 1579-1583.	1.5	58
996	Adult Inflammatory Arthritides: What the Radiologist Should Know. Radiographics, 2016, 36, 1849-1870.	1.4	20
997	Combination therapy with etanercept in psoriasis: Retrospective analysis of efficacy and safety outcomes from real-life practice. Journal of International Medical Research, 2016, 44, 100-105.	0.4	9
998	Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity. International Journal of Rheumatic Diseases, 2016, 19, 672-677.	0.9	38
999	Sensitivity of the GEPARD Patient Questionnaire to Identify Psoriatic Arthritis in Patients with Psoriasis in Daily Practice: The GEPARD-Life Study. Dermatology, 2016, 232, 597-605.	0.9	15
1000	Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis. Rheumatology, 2016, 55, 1791-1795.	0.9	31
1001	Immunophenotyping of T cells in the peripheral circulation in psoriasis. British Journal of Biomedical Science, 2016, 73, 174-179.	1.2	34
1002	Brief Report: CXCL10 Is a Possible Biomarker for the Development of Psoriatic Arthritis Among Patients With Psoriasis. Arthritis and Rheumatology, 2016, 68, 2911-2916.	2.9	68
1003	Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis. Journal of Rheumatology, 2016, 43, 1718-1723.	1.0	16
1004	Psoriatic arthritis. British Journal of Hospital Medicine (London, England: 2005), 2016, 77, C102-C108.	0.2	6
1005	Anti cytokine therapy in chronic inflammatory arthritis. Cytokine, 2016, 86, 92-99.	1.4	47
1006	Implications of the diversity of class I HLA associations in psoriatic arthritis. Clinical Immunology, 2016, 172, 29-33.	1.4	19
1007	Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis. Journal of Dermatology, 2016, 43, 305-310.	0.6	127
1008	Impact of training on concordance among rheumatologists and dermatologists in the assessment of patients with psoriasis and psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2016, 46, 305-311.	1.6	12
1009	PASE and EARP questionnaires for the identification of enthesitis, synovitis, and tenosynovitis in patients with psoriasis. Clinical Rheumatology, 2016, 35, 2463-2468.	1.0	6

#	Article	IF	CITATIONS
1010	Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study. Postgraduate Medicine, 2016, 128, 693-696.	0.9	14
1011	A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial. Journal of Rheumatology, 2016, 43, 1724-1734.	1.0	175
1012	Malignancy incidence in patients with psoriatic arthritis: a comparison cohort-based incidence study. Clinical Rheumatology, 2016, 35, 2603-2607.	1.0	25
1013	Interleukin (IL)-9/IL-9R axis drives γδT cells activation in psoriatic arthritis patients. Clinical and Experimental Immunology, 2016, 186, 277-283.	1.1	43
1014	Rheumatoid Arthritis and Spondyloarthritis. , 2016, , 181-215.		0
1016	Influence of Extracellular RNAs, Released by Rheumatoid Arthritis Synovial Fibroblasts, on Their Adhesive and Invasive Properties. Journal of Immunology, 2016, 197, 2589-2597.	0.4	25
1017	Psoriasis. Nature Reviews Disease Primers, 2016, 2, 16082.	18.1	585
1018	Nail involvement can predict enthesopathy in patients with psoriasis. JDDG - Journal of the German Society of Dermatology, 2016, 14, 1102-1107.	0.4	31
1019	Elevated serum levels of free interleukin-18 in adult-onset Still's disease. Rheumatology, 2016, 55, 2237-2247.	0.9	135
1020	Incidence of Malignancies in a Cohort of Psoriatic Arthritis Patients Taking Traditional Disease Modifying Antirheumatic Drug and Tumor Necrosis Factor Inhibitor Therapy: An Observational Study. Journal of Rheumatology, 2016, 43, 2149-2154.	1.0	35
1021	Developing the Thai Siriraj Psoriatic Arthritis Screening Tool and validating the Thai Psoriasis Epidemiology Screening Tool and the Early Arthritis for Psoriatic Patients questionnaire. Rheumatology International, 2016, 36, 1459-1468.	1.5	10
1022	The prolactin receptor is expressed in rheumatoid arthritis and psoriatic arthritis synovial tissue and contributes to macrophage activation. Rheumatology, 2016, 55, 2248-2259.	0.9	29
1024	Juvenile Spondyloarthropathies. Current Rheumatology Reports, 2016, 18, 55.	2.1	28
1025	Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central–eastern Europe. Journal of Comparative Effectiveness Research, 2016, 5, 475-485.	0.6	5
1026	Association between small dense LDL and sub-clinical atherosclerosis in patients with psoriatic arthritis. Clinical Rheumatology, 2016, 35, 2023-2029.	1.0	22
1027	Secukinumab: a promising therapeutic option in spondyloarthritis. Clinical Rheumatology, 2016, 35, 2151-2161.	1.0	2
1028	Plantar forefoot pressures in psoriatic arthritis-related dactylitis: an exploratory study. Clinical Rheumatology, 2016, 35, 2333-2338.	1.0	19
1029	Serum thymosin $\hat{I}\pm1$ levels in patients with chronic inflammatory autoimmune diseases. Clinical and Experimental Immunology, 2016, 186, 39-45.	1.1	18

#	Article	IF	CITATIONS
1030	Imaging in the diagnosis and management of peripheral psoriatic arthritis—The clinical utility of magnetic resonance imaging and ultrasonography. Best Practice and Research in Clinical Rheumatology, 2016, 30, 624-637.	1.4	29
1031	New targets in psoriatic arthritis. Rheumatology, 2016, 55, ii30-ii37.	0.9	14
1032	Expression of immunoglobulin-like transcript 4 as an inhibitory receptor in patients with psoriatic arthritis. Journal of International Medical Research, 2016, 44, 22-27.	0.4	0
1033	MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis. Nature Communications, 2016, 7, 12970.	5.8	97
1034	Evaluation of a Novel Semi-Automated Ultrasound System for the Detection of Synovitis: A Prospective Study involving 45 Patients with Rheumatoid Arthritis. Ultrasound International Open, 2016, 02, E117-E123.	0.3	3
1035	Phosphodiesterase 4 inhibitors for psoriatic arthritis. The Cochrane Library, 2016, , .	1.5	1
1036	Adaptation of Chinese and English versions of the Psoriatic Arthritis Quality of Life (PsAQoL) scale for use in Singapore. BMC Musculoskeletal Disorders, 2016, 17, 432.	0.8	13
1037	The effect of marine n-3 polyunsaturated fatty acids on cardiac autonomic and hemodynamic function in patients with psoriatic arthritis: a randomised, double-blind, placebo-controlled trial. Lipids in Health and Disease, 2016, 15, 216.	1.2	19
1038	Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: protocol for a prospective, exploratory cohort study. BMJ Open, 2016, 6, e010650.	0.8	11
1039	Presidential Round Table: A Report from the GRAPPA Annual Meeting. Journal of Rheumatology, 2016, 43, 986-989.	1.0	2
1040	Developing clinically relevant biomarkers in inflammatory arthritis: A multiplatform approach for serum candidate protein discovery. Proteomics - Clinical Applications, 2016, 10, 691-698.	0.8	21
1041	Interleukinâ€9 Overexpression and Th9 Polarization Characterize the Inflamed Gut, the Synovial Tissue, and the Peripheral Blood of Patients With Psoriatic Arthritis. Arthritis and Rheumatology, 2016, 68, 1922-1931.	2.9	80
1042	Shortâ€Term Total Hip Arthroplasty Outcomes in Patients With Psoriatic Arthritis or Psoriatic Skin Disease Compared to Patients With Osteoarthritis. Arthritis and Rheumatology, 2016, 68, 410-417.	2.9	11
1043	Japanese version of the early psoriatic arthritis screening questionnaire (<scp>EARP</scp>). Journal of Dermatology, 2016, 43, 385-388.	0.6	10
1044	Clinical and Demographic Characteristics of Erosion-free and Erosion-present Status in Psoriatic Arthritis in a Cohort Study. Journal of Rheumatology, 2016, 43, 1057-1062.	1.0	7
1045	A Family History of Psoriasis in a First-degree Relative in Children with JIA: to Include or Exclude?. Journal of Rheumatology, 2016, 43, 944-947.	1.0	9
1046	The Effect of the Presence of Fibromyalgia on Common Clinical Disease Activity Indices in Patients with Psoriatic Arthritis: A Cross-sectional Study. Journal of Rheumatology, 2016, 43, 1749-1754.	1.0	85
1047	The association of clinical parameters and ultrasound verified inflammation with patients' and physicians' global assessments in psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2016, 46, 183-189.	1.6	14

#	Article	IF	CITATIONS
1048	Fatigue in psoriatic arthritis–Âa cross-sectional study of 246Âpatients from 13Âcountries. Joint Bone Spine, 2016, 83, 439-443.	0.8	47
1049	Disease-modifying antirheumatic drugs improve cardiovascular autonomic neuropathy in psoriatic arthritis. Therapeutic Advances in Musculoskeletal Disease, 2016, 8, 42-48.	1.2	3
1050	Colony-stimulating factor (CSF) 1 receptor blockade reduces inflammation in human and murine models of rheumatoid arthritis. Arthritis Research and Therapy, 2016, 18, 75.	1.6	85
1051	Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey. Arthritis Research and Therapy, 2016, 18, 78.	1.6	52
1052	Psoriatic nail involvement and its relationship with distal interphalangeal joint disease. Clinical Rheumatology, 2016, 35, 2031-2037.	1.0	32
1053	Improvements in diagnostic tools for early detection of psoriatic arthritis. Expert Review of Clinical Immunology, 2016, 12, 1209-1215.	1.3	26
1054	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis and Rheumatology, 2016, 68, 1060-1071.	2.9	726
1055	The Efficacy and Safety of Clazakizumab, an Anti–Interleukinâ€6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis. Arthritis and Rheumatology, 2016, 68, 2163-2173.	2.9	134
1056	Safety of tumor necrosis factor inhibitor therapy in patients with a prior malignancy. International Journal of Rheumatic Diseases, 2016, 19, 961-967.	0.9	2
1057	Comparison of screening questionnaires to identify psoriatic arthritis in a primary-care population: a cross-sectional study. British Journal of Dermatology, 2016, 175, 542-548.	1.4	25
1058	Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synoviocyte activation by suppressing HDAC5 expression. Annals of the Rheumatic Diseases, 2016, 75, 430-438.	0.5	68
1059	Ultrasound assessment of enthesis thickening in psoriatic arthritis patients treated with adalimumab compared to methotrexate. Clinical Rheumatology, 2016, 35, 363-370.	1.0	11
1060	Analysis of periarticular bone changes in patients with cutaneous psoriasis without associated psoriatic arthritis. Annals of the Rheumatic Diseases, 2016, 75, 660-666.	0.5	62
1061	Juvenile Psoriatic Arthritis. , 2016, , 256-267.e5.		4
1062	Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients. Autoimmunity Reviews, 2016, 15, 184-190.	2.5	39
1063	The HLA-C*06 allele as a possible genetic predisposing factor to psoriasis in South Indian Tamils. Archives of Dermatological Research, 2016, 308, 193-199.	1.1	17
1064	Emerging drugs for psoriatic arthritis. Expert Opinion on Emerging Drugs, 2016, 21, 69-79.	1.0	36
1065	The Incidence and Predictors of Infection in Psoriasis and Psoriatic Arthritis: Results from Longitudinal Observational Cohorts. Journal of Rheumatology, 2016, 43, 362-366.	1.0	30

#	Article	IF	CITATIONS
1066	Diagnosis and evaluation of psoriasis and psoriatic arthritis. , 2016, , 27-42.		0
1067	Radiographic Assessment of Psoriatic Arthritis (PsA). , 2016, , 173-187.		0
1068	GRAPPA Historical Perspective. , 2016, , 7-14.		0
1069	Classification Criteria for Psoriasis and Psoriatic Arthritis. , 2016, , 17-26.		0
1070	Longterm Efficacy of an Antipneumococcal Polysaccharide Vaccine among Patients with Autoimmune Inflammatory Rheumatic Diseases. Journal of Rheumatology, 2016, 43, 267-272.	1.0	25
1071	Psoriatic arthritis: complexities, comorbidities and implications for the clinic. Expert Review of Clinical Immunology, 2016, 12, 405-416.	1.3	33
1072	IL-9, a local growth factor for synovial T cells in inflammatory arthritis. Cytokine, 2016, 79, 45-51.	1.4	52
1073	Age at disease onset may help to further characterize the disease phenotype in psoriatic arthritis. Joint Bone Spine, 2016, 83, 533-537.	0.8	23
1074	Novel Composite Radiographic Score for Longitudinal Observational Studies of Psoriatic Arthritis: A Proof-of-concept Study. Journal of Rheumatology, 2016, 43, 367-370.	1.0	5
1075	Comorbidities Associated with Psoriatic Arthritis Compared with Non-psoriatic Spondyloarthritis: A Cross-sectional Study. Journal of Rheumatology, 2016, 43, 376-382.	1.0	50
1076	Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs. Journal of Rheumatology, 2016, 43, 350-355.	1.0	66
1077	Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis. Expert Review of Clinical Immunology, 2016, 12, 315-331.	1.3	30
1078	L'échographie des ongles dans le rhumatisme psoriasiqueÂ: étude pilote sur la faisabilité, la reproductibilité et la validité de mesure. Revue Du Rhumatisme (Edition Francaise), 2016, 83, 37-43.	0.0	4
1079	Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden. Journal of Rheumatology, 2016, 43, 81-87.	1.0	33
1080	Post–September 11, 2001, Incidence of Systemic Autoimmune Diseases in World Trade Center–Exposed Firefighters and Emergency Medical Service Workers. Mayo Clinic Proceedings, 2016, 91, 23-32.	1.4	33
1081	Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, doubleâ€blind, phase 3 study. Journal of Dermatology, 2016, 43, 869-880.	0.6	79
1082	Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings. Journal of Rheumatology, 2016, 43, 911-917.	1.0	19
1083	Assessing disease activity in psoriasis and psoriatic arthritis: impact on management and therapy. Expert Review of Clinical Immunology, 2016, 12, 573-582.	1.3	11

		CITATION R	EPORT	
# 1084	ARTICLE Subclinical joint inflammation in patients with psoriasis without concomitant psoriatic art cross-sectional and longitudinal analysis. Annals of the Rheumatic Diseases, 2016, 75, 206		IF 0.5	Citations 86
1085	Cartilage collagen type II seromarker patterns in axial spondyloarthritis and psoriatic arthr associations with disease activity, smoking and HLA-B27. Rheumatology International, 20	itis: 16, 36, 541-549.	1.5	9
1086	Autoantibodies in inflammatory arthritis. Autoimmunity Reviews, 2016, 15, 673-683.		2.5	95
1088	Psoriatic Arthritis and Psoriasis. , 2016, , .			3
1089	Maintien des traitements anti-TNF dans le rhumatisme psoriasiqueÂ: étude rétrospec monocentrique. Revue Du Rhumatisme (Edition Francaise), 2016, 83, 32-36.	tive	0.0	0
1090	Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to cor in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare International Journal of Immunopathology and Pharmacology, 2016, 29, 252-266.		1.0	32
1091	Patient global assessment in psoriatic arthritis – what does it mean? An analysis of 223, the Psoriatic arthritis impact of disease (PsAID) study. Joint Bone Spine, 2016, 83, 335-34		0.8	35
1092	Reliability, validity and feasibility of nail ultrasonography in psoriatic arthritis. Joint Bone S 83, 539-544.	bine, 2016,	0.8	18
1093	Effect of Chronic Periodontitis on Oxidative Status in Patients With Psoriasis and Psoriatic Journal of Periodontology, 2016, 87, 557-565.	: Arthritis.	1.7	20
1094	Psoriasis and sleep disorders: A systematic review. Sleep Medicine Reviews, 2016, 29, 63-7	75.	3.8	110
1095	Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. Anna Rheumatic Diseases, 2016, 75, 1680-1686.	als of the	0.5	85
1096	Investigation of association of the IL-12B and IL-23R genetic variations with psoriatic risk i Indian Tamil cohort. Human Immunology, 2016, 77, 54-62.	n a South	1.2	15
1097	Clinical experience in 115 patients with arthritis and/or enthesitis who met the classificati for psoriatic arthritis (CASPAR) within the last two years—Possible association with mali disorders. Modern Rheumatology, 2016, 26, 625-629.		0.9	3
1098	A patient-initiated DMARD self-monitoring service for people with rheumatoid or psoriatic on methotrexate: a randomised controlled trial. Annals of the Rheumatic Diseases, 2016,	arthritis 75, 1343-1349.	0.5	17
1099	Study of endothelial dysfunction in patients of psoriatic arthritis by flow mediated and nitroglycerine mediated dilatation of brachial artery. International Journal of Rheumatic Di 2016, 19, 300-304.	seases,	0.9	13
1100	Discovery and confirmation of a protein biomarker panel with potential to predict respons biological therapy in psoriatic arthritis. Annals of the Rheumatic Diseases, 2016, 75, 234-2		0.5	50
1101	Splicing factor proline/glutamine-rich is a novel autoantigen of dermatomyositis and associanti-melanoma differentiation-associated gene 5 antibody. Journal of Autoimmunity, 2017		3.0	18
1102	The Juvenile Psoriatic Arthritis Cohort in the CARRA Registry: Clinical Characteristics, Class and Outcomes. Journal of Rheumatology, 2017, 44, 342-351.	ification,	1.0	54

#	Article	IF	CITATIONS
1103	The Risk of Developing Diabetes Mellitus in Patients with Psoriatic Arthritis: A Cohort Study. Journal of Rheumatology, 2017, 44, 286-291.	1.0	39
1104	Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population. Journal of Rheumatology, 2017, 44, 431-436.	1.0	18
1105	Sensitivity and Specificity of Radiographic Scoring Instruments for Detecting Change in Axial Psoriatic Arthritis. Arthritis Care and Research, 2017, 69, 1700-1705.	1.5	14
1106	Impact of treatment with TNF antagonists on total cholesterol in patients with ankylosing spondylitis and psoriatic arthritis. Clinical Rheumatology, 2017, 36, 1167-1172.	1.0	7
1107	Cardiovascular Involvement in Psoriatic Arthritis. Handbook of Systemic Autoimmune Diseases, 2017, , 409-426.	0.1	3
1108	Treatment preferences for biologicals in psoriasis: experienced patients appreciate sustainability. JDDG - Journal of the German Society of Dermatology, 2017, 15, 189-200.	0.4	7
1109	Psoriasis in systemic lupus erythematosus: a single-center experience. Clinical Rheumatology, 2017, 36, 879-884.	1.0	26
1110	Artritis psoriásica. Medicine, 2017, 12, 1508-1519.	0.0	0
1111	Protocolo diagnÃ ³ stico de la dactilitis. Medicine, 2017, 12, 1546-1549.	0.0	0
1112	The Association Between Obesity and Clinical Features of Psoriatic Arthritis: A Case-control Study. Journal of Rheumatology, 2017, 44, 437-443.	1.0	39
1113	Psoriatic Arthritis. New England Journal of Medicine, 2017, 376, 957-970.	13.9	931
1114	Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Annals of the Rheumatic Diseases, 2017, 76, 79-87.	0.5	454
1115	Psoriatic arthritis: state of the art review. Clinical Medicine, 2017, 17, 65-70.	0.8	198
1116	Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). Annals of the Rheumatic Diseases, 2017, 76, 203-207.	0.5	78
1117	Psoriasis Associated. , 2017, , 221-229.		0
1118	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Annals of the Rheumatic Diseases, 2017, 76, 673-680.	0.5	194
1119	Apremilast in the treatment of psoriatic arthritis: a perspective review. Therapeutic Advances in Musculoskeletal Disease, 2017, 9, 45-53.	1.2	23
1120	Clinical Examination, Ultrasound and MRI Imaging of The Painful Elbow in Psoriatic Arthritis and Rheumatoid Arthritis: Which is Better, Ultrasound or MR, for Imaging Enthesitis?. Rheumatology and Therapy, 2017, 4, 71-84.	1.1	22

#	Article	IF	CITATIONS
1121	Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease. Annals of the Rheumatic Diseases, 2017, 76, 1237-1244.	0.5	43
1122	Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?. Annals of the Rheumatic Diseases, 2017, 76, 1228-1236.	0.5	70
1123	Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2017, 47, 108-114.	1.6	37
1124	Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature. Lung Cancer, 2017, 108, 217-221.	0.9	35
1126	Case-control Study on Dactylitis, Enthesitis, and Anterior Uveitis in Spondyloarthritis Associated with Inflammatory Bowel Diseases: Role of Coexistent Psoriasis. Journal of Rheumatology, 2017, 44, 1341-1346.	1.0	15
1127	New Interleukins in Psoriasis and Psoriatic Arthritis Patients: The Possible Roles of Interleukin-33 to Interleukin-38 in Disease Activities and Bone Erosions. Dermatology, 2017, 233, 37-46.	0.9	74
1128	Ultrasound entheseal abnormalities at the distal interphalangeal joints and clinical nail involvement in patients with psoriasis and psoriatic arthritis, supporting the nail-enthesitis theory. Seminars in Arthritis and Rheumatism, 2017, 47, 338-342.	1.6	43
1129	Utility of Power Doppler Ultrasound–detected Synovitis for the Prediction of Short-term Flare in Psoriatic Patients with Arthritis in Clinical Remission. Journal of Rheumatology, 2017, 44, 1018-1023.	1.0	19
1130	Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1550-1558.	0.5	184
1132	Extracellular vesicles regulate the human osteoclastogenesis: divergent roles in discrete inflammatory arthropathies. Cellular and Molecular Life Sciences, 2017, 74, 3599-3611.	2.4	44
1133	IL-10 producing Bregs are impaired in psoriatic arthritis and psoriasis and inversely correlate with IL-17- and IFNÎ ³ -producing T cells. Clinical Immunology, 2017, 184, 33-41.	1.4	52
1134	Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping. Clinical Rheumatology, 2017, 36, 2035-2043.	1.0	8
1136	Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis. European Journal of Clinical Pharmacology, 2017, 73, 965-971.	0.8	31
1137	Demographic, clinical and radiological characteristics of seronegative spondyloarthritis Egyptian patients: A rheumatology clinic experience in Mansoura. Egyptian Rheumatologist, 2017, 39, 109-114.	0.5	17
1138	The 12-item Psoriatic Arthritis Impact of Disease Questionnaire: Construct Validity, Reliability, and Interpretability in a Clinical Setting. Journal of Rheumatology, 2017, 44, 279-285.	1.0	66
1139	Sleep Disturbance in Psoriatic Disease: Prevalence and Associated Factors. Journal of Rheumatology, 2017, 44, 1369-1374.	1.0	39
1140	Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate. Clinical Rheumatology, 2017, 36, 1797-1802.	1.0	8
1141	Ultrasound Imaging of Nails in Psoriasis and Psoriatic Arthritis. Current Treatment Options in Rheumatology, 2017, 3, 129-140.	0.6	3

#	Article	IF	CITATIONS
1142	Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet, The, 2017, 389, 2317-2327.	6.3	316
1143	Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort. Journal of Rheumatology, 2017, 44, 1159-1164.	1.0	42
1144	Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study. Clinical Rheumatology, 2017, 36, 1589-1593.	1.0	12
1145	Anti-TNF- \hat{I}_{\pm} effects on anemia in rheumatoid and psoriatic arthritis. International Journal of Immunopathology and Pharmacology, 2017, 30, 302-307.	1.0	18
1148	The performance of psoriatic arthritis classification criteria in <scp>T</scp> urkish patients with psoriatic arthritis. International Journal of Rheumatic Diseases, 2017, 20, 985-989.	0.9	6
1150	Traducción y validación de la versión en español del cuestionario ToPAS (Toronto Psoriatic Arthritis) Tj ETQq1 dermatológica en Colombia. Revista Colombiana De ReumatologÃa, 2017, 24, 79-83.	1 0.7843 0.0	14 rgBT /O
1151	Disease activity in and quality of life of patients with psoriatic arthritis mutilans: the Nordic PAM Study. Scandinavian Journal of Rheumatology, 2017, 46, 454-460.	0.6	5
1152	Serum peptides as putative modulators of inflammation in psoriasis. Journal of Dermatological Science, 2017, 87, 36-49.	1.0	12
1153	Ankle pathologies in patients with inflammatory rheumatic diseases: a clinical and ultrasonographic study. International Journal of Rheumatic Diseases, 2017, 20, 675-684.	0.9	12
1154	Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Annals of the Rheumatic Diseases, 2017, 76, 701-707.	0.5	152
1155	T helper-2 cytokine/regulatory T-cell gene polymorphisms and their relation with risk of psoriasis in a South Indian Tamil cohort. Human Immunology, 2017, 78, 209-215.	1.2	20
1156	Clinical Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort: Incidence, Prevalence, Characteristics, and Outcome. Arthritis Care and Research, 2017, 69, 1685-1691.	1.5	108
1157	Quantitative imaging by pixel-based contrast-enhanced ultrasound reveals a linear relationship between synovial vascular perfusion and the recruitment of pathogenic IL-17A-F+IL-23+ CD161+ CD4+ T helper cells in psoriatic arthritis joints. Clinical Rheumatology, 2017, 36, 391-399.	1.0	21
1158	Complete Regression of Psoriatic Arthritis After Belatacept Conversion in a Highly HLA-Sensitized Kidney Transplant Patient. American Journal of Transplantation, 2017, 17, 1409-1413.	2.6	2
1159	Frequency of Arthritis-Like MRI Findings in the Forefeet of Healthy Volunteers Versus Patients With Symptomatic Rheumatoid Arthritis or Psoriatic Arthritis. American Journal of Roentgenology, 2017, 208, W45-W53.	1.0	9
1160	Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. New England Journal of Medicine, 2017, 377, 1537-1550.	13.9	434
1161	Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. New England Journal of Medicine, 2017, 377, 1525-1536.	13.9	405
1162	Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. Annals of the Rheumatic Diseases, 2017, 76, 1774-1779.	0.5	51

	CITA	ATION REPORT	
#	Article	IF	Citations
1163	A review on golimumab in the treatment of psoriatic arthritis. Immunotherapy, 2017, 9, 871-889.	1.0	9
1165	The spectrum of psoriatic arthritis in a South African cohort. Clinical Rheumatology, 2017, 36, 2501-2507.	1.0	4
1166	Achilles enthesitis defined by ultrasound is not associated with clinical enthesitis in patients with psoriatic arthritis. RMD Open, 2017, 3, e000486.	1.8	32
1167	Small molecule therapy for managing moderate to severe psoriatic arthritis. Expert Opinion on Pharmacotherapy, 2017, 18, 1557-1567.	0.9	39
1168	Methotrexate for psoriatic arthritis. The Cochrane Library, 2017, , .	1.5	8
1169	Retrospective Study of Patients on Etanercept Therapy for Rheumatic Diseases in Patients With Chronic Hepatitis C Virus. Journal of Clinical Rheumatology, 2017, 23, 252-257.	0.5	8
1170	Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients. Journal of Dermatology, 2017, 44, 1349-1352.	0.6	49
1171	The psychosocial burden of psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2017, 47, 351-360). 1.6	124
1172	Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritides. Clinical Reviews in Allergy and Immunology, 2017, 53, 371-393.	2.9	52
1173	Translation and validation of the Spanish version of the ToPAS (Toronto Psoriatic Arthritis) Tj ETQq1 1 C Colombia. Revista Colombiana De ReumatologÃa (English Edition), 2017, 24, 79-83.	0.784314 rgBT /Over 0.1	lock 10 Tf 5 0
1174	A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors. Clinical Rheumatology, 2017, 36, 2253-2260.	1.0	31
1175	Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis. Arthritis and Rheumatology, 2017, 69, 2151-2161.	2.9	90
1176	Vascular endothelial growth factor (VEGF) gene polymorphisms (rs699947, rs833061, and rs2010963) and psoriatic risk in South Indian Tamils. Human Immunology, 2017, 78, 657-663.	1.2	15
1177	Characteristics of Turkish patients with elderly onset psoriatic arthritis. Medicine (United States), 2017, 96, e7833.	0.4	16
1178	Therapeutic depletion of myeloid lineage leukocytes by adsorptive apheresis for psoriatic arthritis: Efficacy of a nonâ€drug intervention for patients refractory to pharmacologics. Journal of Dermatology, 2017, 44, 1353-1359.	0.6	21
1179	BehandlungsprÄferenzen fļr Biologika bei Psoriasis: erfahrene Patienten legen Wert auf Nachhaltigkeit. JDDG - Journal of the German Society of Dermatology, 2017, 15, 189-201.	0.4	12
1180	Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis. Nature Communications, 2017, 8, 1510.	5.8	118
1182	Rheumatoid arthritis and psoriatic arthritis synovial fluids stimulate prolactin production by macrophages. Journal of Leukocyte Biology, 2017, 102, 897-904.	1.5	16

#	Article	IF	CITATIONS
1183	In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls. Clinical Rheumatology, 2017, 36, 2377-2381.	1.0	38
1184	Meaningful patient engagement in inflammatory arthritis: development of the Patient Motivation Questionnaire. Clinical Rheumatology, 2017, , 1.	1.0	7
1185	Prevalence of immune-related systemic adverse events inÂpatients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. European Journal of Cancer, 2017, 82, 34-44.	1.3	146
1186	Psoriasis and associated variables in classification and outcome of juvenile idiopathic arthritis - an eight-year follow-up study. Pediatric Rheumatology, 2017, 15, 13.	0.9	15
1187	Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis. Arthritis Research and Therapy, 2017, 19, 63.	1.6	17
1188	Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. Arthritis Research and Therapy, 2017, 19, 72.	1.6	64
1189	The performance of different classification criteria sets for spondyloarthritis in the worldwide ASAS-COMOSPA study. Arthritis Research and Therapy, 2017, 19, 96.	1.6	16
1191	Cardiovascular disease in immune-mediated inflammatory diseases. Medicine (United States), 2017, 96, e7308.	0.4	32
1192	The Effect of Anterior Uveitis and Previously Undiagnosed Spondyloarthritis: Results from the DUET Cohort. Journal of Rheumatology, 2017, 44, 1347-1354.	1.0	20
1193	The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patients. Rheumatology, 2017, 56, 279-286.	0.9	29
1194	Effect of ethnicity on disease activity and physical function in psoriatic arthritis in a multiethnic Asian population. Clinical Rheumatology, 2017, 36, 125-131.	1.0	19
1195	Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. Clinical Rheumatology, 2017, 36, 251-260.	1.0	22
1196	Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies. Journal of Autoimmunity, 2017, 76, 21-37.	3.0	94
1197	Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52â€week, openâ€label, phase 3 study (<scp>UNCOVER</scp> â€J). Journal of Dermatology, 2017, 44, 355-362.	0.6	157
1198	Synovial IL-21/TNF-producing CD4+ T cells induce joint destruction in rheumatoid arthritis by inducing matrix metalloproteinase production by fibroblast-like synoviocytes. Journal of Leukocyte Biology, 2017, 101, 775-783.	1.5	33
1199	Evaluation of IL-34 in psoriasis and psoriatic arthritis patients: Correlation with disease activity and severity. Egyptian Rheumatologist, 2017, 39, 25-31.	0.5	15
1200	Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice. Clinical Rheumatology, 2017, 36, 439-443.	1.0	20
1201	The Development of Psoriatic Arthritis in Patients With Psoriasis Is Preceded by a Period of Nonspecific Musculoskeletal Symptoms: A Prospective Cohort Study. Arthritis and Rheumatology, 2017, 69, 622-629.	2.9	93

	Сітатіс	on Report	
#	Article	IF	CITATIONS
1202	Comparison of four validated psoriatic arthritis screening tools in diagnosing psoriatic arthritis in patients with psoriasis (COMPAQ Study). British Journal of Dermatology, 2017, 176, 765-770.	1.4	47
1203	Development and pilotâ€ŧesting of a new tool to screen psoriasis patients for the presence of psoriatic arthritis: the Simple Psoriatic Arthritis Screening (Si <scp>PAS</scp>) questionnaire. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e167-e169.	1.3	8
1204	Screening for psoriatic arthritis using the Psoriasis Epidemiology Screening Tool questionnaire: examining the optimal cut-off. British Journal of Dermatology, 2017, 176, 1357-1359.	1.4	6
1205	Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. Autoimmunity Reviews, 2017, 16, 10-15.	2.5	95
1206	Secukinumab for Longâ€Term Treatment of Psoriatic Arthritis: A Twoâ€Year Followup From a Phase III, Randomized, Doubleâ€Blind Placeboâ€Controlled Study. Arthritis Care and Research, 2017, 69, 347-355.	1.5	72
1207	Early Disease Activity or Clinical Response as Predictors of Longâ€Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis. Arthritis Care and Research, 2017, 69, 1030-1039.	1.5	14
1208	Gender specific differences in patients with psoriatic arthritis. Modern Rheumatology, 2017, 27, 345-349.	0.9	44
1209	Psoriasis and Psoriatic Arthritis-Related Uveitis: Different Ophthalmological Manifestations and Ocular Inflammation Features. Seminars in Ophthalmology, 2017, 32, 715-720.	0.8	40
1210	Investigation of the genetic overlap between rheumatoid arthritis and psoriatic arthritis in a Greek population. Scandinavian Journal of Rheumatology, 2017, 46, 180-186.	0.6	14
1211	Cardiovascular risk profiles in a hospital-based population of patients with psoriatic arthritis and ankylosing spondylitis: a cross-sectional study. Rheumatology International, 2017, 37, 113-120.	1.5	14
1212	State of the art of ultrasound in the assessment of psoriasis and psoriatic arthritis. Expert Review of Clinical Immunology, 2017, 13, 439-447.	1.3	22
1213	Fatigue and psychosocial variables in autoimmune rheumatic disease and chronic fatigue syndrome: A cross-sectional comparison. Journal of Psychosomatic Research, 2017, 92, 1-8.	1.2	23
1214	Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthritis Following Lyme Disease. Arthritis and Rheumatology, 2017, 69, 194-202.	2.9	43
1215	Multidisciplinary care for psoriatic disease. Rheumatology, 2017, 56, kew485.	0.9	8
1216	Singapore <scp>C</scp> hapter of <scp>R</scp> heumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying antiâ€rheumatic agents for the treatment of psoriatic arthritis. International Journal of Rheumatic Diseases, 2017, 20, 1527-1540.	0.9	1
1217	Th17 Inhibitors in Active Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. Dermatology, 2017, 233, 366-377.	0.9	20
1219	Serum bone-turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a prospective cross-sectional comparative study. Arthritis Research and Therapy, 2017, 19, 210.	1.6	40
1220	lxekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naĀīve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1. RMD Open, 2017, 3, e000567.	1.8	24

		CITATION REPORT		
#	Article		IF	Citations
1221	SAT0460â€Association between inflammasome-related polymorphisms and psoriation	c arthritis. , 2017, , .		0
1222	Role and Function of A2A and A3 Adenosine Receptors in Patients with Ankylosing Spo Psoriatic Arthritis and Rheumatoid Arthritis. International Journal of Molecular Sciences 697.	ondylitis, s, 2017, 18,	1.8	46
1223	Results from Polish Spondyloarthritis Initiative registry (PolSPI) – methodology and of first year of observation. Reumatologia, 2017, 2, 59-64.	lata from – the	0.5	0
1224	Changes in body composition and bone mineral density n postmenopausal women wit arthritis. Reumatologia, 2017, 55, 215-221.	h psoriatic	0.5	28
1225	Imaging in Rheumatic Diseases. , 2017, , 858-907.e8.			0
1226	Stromal cell markers are differentially expressed in the synovial tissue of patients with arthritis. PLoS ONE, 2017, 12, e0182751.	early	1.1	43
1227	Fever as an initial manifestation of spondyloarthritis: A retrospective study. PLoS ONE, e0184323.	2017, 12,	1.1	5
1228	The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, recontrolled trial of GOLimumab and methotrexate versus methotrexate in early diagnost arthritis using clinical and whole body MRI outcomes. BMC Musculoskeletal Disorders,	sed psoriatic	0.8	9
1229	Rationale and Design of the Brigham Cohort for psoriasis and psoriatic arthritis registry BMC Dermatology, 2017, 17, 11.	y (COPPAR).	2.1	8
1230	Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthr Research and Therapy, 2017, 19, 158.	itis. Arthritis	1.6	26
1231	The association between sonographic enthesitis and radiographic damage in psoriatic Arthritis Research and Therapy, 2017, 19, 189.	arthritis.	1.6	57
1232	Residual disease activity and treatment adjustments in psoriatic arthritis in current clir Arthritis Research and Therapy, 2017, 19, 226.	iical practice.	1.6	8
1233	Ultrasonographic Enthesopathy and Disease Activity in Psoriatic Arthritis. Open Access Journal of Medical Sciences, 2017, 5, 651-656.	Macedonian	0.1	9
1234	Methicillin Resistant Staphylococcus Aureus Sacroiliac Joint Septic Arthritis in an Adult Treated with Daptomycin. Journal of Bone and Joint Infection, 2017, 2, 143-148.	Patient	0.6	0
1235	Evaluation of fatigue and its correlation with quality of life index, anxiety symptoms, d activity of disease in patients with psoriatic arthritis. Clinical, Cosmetic and Investigati Dermatology, 2017, Volume 10, 155-163.		0.8	26
1236	Biologic Markers in Clinical Trials and Clinical Care. , 2017, , 509-519.			0
1237	Could Psoriatic Arthritis Be Easily Diagnosed from Current Suspicious Physical Findings Dermatology Clinic?. Annals of Dermatology, 2017, 29, 48.	; in the	0.3	15
1238	Spondyloarthritides. , 2017, , 189-211.			0

#	Article	IF	CITATIONS
1239	Umbilical Plaque in Psoriatic Arthritis. Internal Medicine, 2017, 56, 235-236.	0.3	0
1240	Prevalence and type II diabetes-associated factors in psoriatic arthritis. Clinical Rheumatology, 2018, 37, 1059-1064.	1.0	16
1241	Increased Prevalence of Metabolic Syndrome and Adipocytokine Levels in a Psoriatic Arthritis Cohort. Journal of Clinical Rheumatology, 2018, 24, 302-307.	0.5	30
1242	Minimal Disease Activity and Patient-Acceptable Symptom State in Psoriatic Arthritis. Journal of Clinical Rheumatology, 2018, 24, 381-384.	0.5	12
1243	MRI of psoriatic nail disease pre- and post-TNF inhibitor therapy shows persistent subclinical inflammation after 6 months despite good clinical response. RMD Open, 2018, 4, e000599.	1.8	7
1244	Safety of treatment options for spondyloarthritis: a narrative review. Expert Opinion on Drug Safety, 2018, 17, 475-486.	1.0	20
1245	Early and sustained efficacy with apremilast monotherapy in biological-naÃ ⁻ ve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Annals of the Rheumatic Diseases, 2018, 77, 690-698.	0.5	76
1246	â€~Deep Koebner' phenomenon of the flexor tendon-associated accessory pulleys as a novel factor in tenosynovitis and dactylitis in psoriatic arthritis. Annals of the Rheumatic Diseases, 2018, 77, 922-925.	0.5	73
1247	Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. Rheumatology, 2018, 57, 1253-1263.	0.9	72
1249	Correlation of Highâ€Ðensity Lipoprotein–Associated Paraoxonase 1 Activity With Systemic Inflammation, Disease Activity, and Cardiovascular Risk Factors in Psoriatic Disease. Arthritis and Rheumatology, 2018, 70, 1240-1250.	2.9	19
1250	Role of Methotrexate in the Management of Psoriatic Arthritis. Drugs, 2018, 78, 611-619.	4.9	20
1251	The role of ultrasound-defined tenosynovitis and synovitis in the prediction of rheumatoid arthritis development. Rheumatology, 2018, 57, 1243-1252.	0.9	42
1252	Early Psoriatic Arthritis Versus Early Seronegative Rheumatoid Arthritis: Role of Dermoscopy Combined with Ultrasonography for Differential Diagnosis. Journal of Rheumatology, 2018, 45, 648-654.	1.0	33
1253	Pain threshold and temporomandibular function in systemic sclerosis: comparison with psoriatic arthritis. Clinical Rheumatology, 2018, 37, 1861-1867.	1.0	27
1254	Interaction between microbiome and host genetics in psoriatic arthritis. Autoimmunity Reviews, 2018, 17, 276-283.	2.5	38
1255	Psoriatic arthritis screening by the dermatologist: development and first validation of the â€~ <scp>PURE</scp> â€4 scale'. Journal of the European Academy of Dermatology and Venereology, 2018, 32 1950-1953.	2, 1.3	26
1256	The Association Between <scp>HLA</scp> Genetic Susceptibility Markers and Sonographic Enthesitis in Psoriatic Arthritis. Arthritis and Rheumatology, 2018, 70, 756-762.	2.9	14
1257	Impact of cardiovascular risk factors on the achievement of therapeutic goals in psoriatic arthritis: is there any association?. Clinical Rheumatology, 2018, 37, 661-666.	1.0	8

#	Article	IF	Citations
1258	Psoriatic Arthritis in Nigeria. Journal of Clinical Rheumatology, 2018, 24, 183-187.	0.5	0
1259	Modification of a sonographic enthesitis score to differentiate between psoriatic arthritis and young healthy volunteers. Scandinavian Journal of Rheumatology, 2018, 47, 291-294.	0.6	24
1260	Augmented Th17 Differentiation Leads to Cutaneous and Synovioâ€Entheseal Inflammation in a Novel Model of Psoriatic Arthritis. Arthritis and Rheumatology, 2018, 70, 855-867.	2.9	29
1261	Inflammatory back pain and associated disease conditions among patients with chronic low back pain in Bangladesh. International Journal of Rheumatic Diseases, 2018, 21, 937-942.	0.9	1
1262	What does evidence-based medicine tell us about treatments for different subtypes of psoriatic arthritis? A systematic literature review on randomized controlled trials. Rheumatology Advances in Practice, 2018, 2, rkx019.	0.3	7
1263	Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 2018, 48, 28-34.	1.6	128
1264	Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1). Journal of Rheumatology, 2018, 45, 367-377.	1.0	102
1265	Musculoskeletal ultrasonography of the Achilles tendon and plantar fascia in spondyloarthritis patients. Egyptian Rheumatologist, 2018, 40, 249-253.	0.5	4
1267	A Case Series on Patients on Tofacitinib in Combination With a Biologic. Journal of Clinical Rheumatology, 2018, 24, 349-351.	0.5	19
1268	Novel approach to characterising individuals with low back-related leg pain: cluster identification with latent class analysis and 12-month follow-up. Pain, 2018, 159, 728-738.	2.0	9
1269	Circulating microRNAs as potential biomarkers of disease activity and structural damage in ankylosing spondylitis patients. Human Molecular Genetics, 2018, 27, 875-890.	1.4	58
1270	Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. European Journal of Cancer, 2018, 91, 21-29.	1.3	222
1271	Effectiveness and safety of ustekinumab in naÃ ⁻ ve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study. Clinical Rheumatology, 2018, 37, 397-405.	1.0	36
1272	Enthesitis: A hallmark of psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2018, 48, 35-43.	1.6	126
1273	Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study. Clinical Rheumatology, 2018, 37, 579-586.	1.0	43
1274	Three-dimensional ultrashort echo time cones (3D UTE-Cones) magnetic resonance imaging of entheses and tendons. Magnetic Resonance Imaging, 2018, 49, 4-9.	1.0	33
1275	Apremilast for the treatment of active psoriatic arthritis: a single-centre real-life experience. Rheumatology, 2018, 57, 578-580.	0.9	17
1276	Low Doses of Etanercept Can Be Effective to Maintain Remission in Psoriatic Arthritis Patients. Journal of Clinical Rheumatology, 2018, 24, 127-131.	0.5	7

			Circum
#	ARTICLE	IF	CITATIONS
1277	PGAĀ—BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol. Journal of Rheumatology, 2018, 45, 922-928.	1.0	6
1278	Subclinical enthesopathy of extensor digitorum tendon is highly prevalent and associated with clinical and ultrasound alterations of the adjacent fingernails in patients with psoriatic disease. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1728-1736.	1.3	21
1279	Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial. BMJ Open, 2018, 8, e019231.	0.8	51
1280	Dactylitis: A hallmark of psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2018, 48, 263-273.	1.6	88
1281	Cardiovascular risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis. Seminars in Arthritis and Rheumatism, 2018, 48, 367-373.	1.6	32
1282	New Myositis Classification Criteria—What We Have Learned Since Bohan and Peter. Current Rheumatology Reports, 2018, 20, 18.	2.1	65
1283	Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212687.	0.5	193
1284	The effect of interactive digital interventions on physical activity in people with inflammatory arthritis: a systematic review. Rheumatology International, 2018, 38, 1623-1634.	1.5	22
1285	4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open, 2018, 4, e000582.	1.8	34
1286	Psoriatic arthritis and seronegative spondyloarthropathies. Medicine, 2018, 46, 237-242.	0.2	2
1287	Psoriasis-Arthritis Units: Three Years On. Actas Dermo-sifiliográficas, 2018, 109, 101-103.	0.2	0
1288	Subclinical impairment of myocardial and endothelial functionality in very early psoriatic and rheumatoid arthritis patients: Association with vitamin D and inflammation. Atherosclerosis, 2018, 271, 214-222.	0.4	30
1289	Monoclonal gammopathy in rheumatic diseases. Clinical Rheumatology, 2018, 37, 1751-1762.	1.0	22
1290	Beneficial effect of n-3 polyunsaturated fatty acids on inflammation and analgesic use in psoriatic arthritis: a randomized, double blind, placebo-controlled trial. Scandinavian Journal of Rheumatology, 2018, 47, 27-36.	0.6	32
1291	The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia. Rheumatology, 2018, 57, 32-40.	0.9	93
1292	Residual disease activity in psoriatic arthritis: discordance between the rheumatologist's opinion and minimal disease activity measurement. Rheumatology, 2018, 57, 283-290.	0.9	34
1293	Differentiating Psoriatic Arthritis From Psoriasis Without Psoriatic Arthritis Using Novel Serum Biomarkers. Arthritis Care and Research, 2018, 70, 454-461.	1.5	46
1294	The current status and unmet needs in the management of psoriatic arthritis: Viewpoint from physicians in Taiwan. Journal of the Formosan Medical Association, 2018, 117, 404-412.	0.8	6

#	Article	IF	CITATIONS
1295	Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs. Clinical Reviews in Allergy and Immunology, 2018, 55, 271-294.	2.9	52
1296	Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian study. International Journal of Rheumatic Diseases, 2018, 21, 510-516.	0.9	3
1297	La talalgia en la artropatÃa psoriÃ;sica. AnÃ;lisis de una serie de 291 pacientes. ReumatologÃa ClÃnica, 2018, 14, 290-293.	0.2	1
1298	Psoriasis and migraine. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 57-61.	1.3	18
1299	PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis. Journal of Dermatological Treatment, 2018, 29, 481-486.	1.1	15
1300	Incidence of rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica in an inland area of central Italy: results of the CAMPO-RHE study. Postgraduate Medicine, 2018, 130, 137-141.	0.9	13
1301	Anti-carbamylated protein antibodies in psoriatic arthritis patients: Relation to disease activity, severity and ultrasonographic scores. Egyptian Rheumatologist, 2018, 40, 17-21.	0.5	12
1302	Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Metaâ€Epidemiologic Study. Arthritis Care and Research, 2018, 70, 1206-1217.	1.5	4
1303	Expression of MIF and TNFA in psoriatic arthritis: relationship with Th1/Th2/Th17 cytokine profiles and clinical variables. Clinical and Experimental Medicine, 2018, 18, 229-235.	1.9	13
1304	Unidades psoriasis-artritis: 3 años después. Actas Dermo-sifiliogrÃ;ficas, 2018, 109, 101-103.	0.2	1
1305	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. Joint Bone Spine, 2018, 85, 455-459.	0.8	14
1306	Higher Coronary Plaque Burden in Psoriatic Arthritis Is Independent of Metabolic Syndrome and Associated With Underlying Disease Severity. Arthritis and Rheumatology, 2018, 70, 396-407.	2.9	42
1307	Consensus on the management of patients with psoriatic arthritis in a dermatology setting. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 515-528.	1.3	15
1308	Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey. Dermatologic Therapy, 2018, 31, e12565.	0.8	4
1309	Characteristic and Outcome of Psoriatic Arthritis Patients with Hyperuricemia. Journal of Rheumatology, 2018, 45, 213-217.	1.0	26
1310	Relatedness of Antibodies to Peptides Containing Homocitrulline or Citrulline in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2018, 45, 302-309.	1.0	9
1311	Psoriatic Arthritis Quality of Life questionnaire: translation, cultural adaptation and validation into Portuguese language. Rheumatology International, 2018, 38, 249-254.	1.5	6
1312	Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tightâ€Control Clinical Trial and an Observational Cohort. Arthritis Care and Research, 2018, 70, 1198-1205.	1.5	29

#	Article	IF	CITATIONS
1313	Validation of the Toronto Psoriatic Arthritis Screen II (TOPAS II) questionnaire in a Turkish population. Rheumatology International, 2018, 38, 255-259.	1.5	9
1314	Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice. Annals of the Rheumatic Diseases, 2018, 77, 343-347.	0.5	38
1315	Underestimation of Risk of Carotid Subclinical Atherosclerosis by Cardiovascular Risk Scores in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2018, 45, 218-226.	1.0	23
1316	Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis. Patient, 2018, 11, 329-340.	1.1	7
1317	Current concepts and unmet needs in psoriatic arthritis. Clinical Rheumatology, 2018, 37, 297-305.	1.0	26
1318	Role of TNF-Alpha and IL10 genes in the development and clinical manifestations of psoriatic arthritis. Revista Colombiana De ReumatologÃa (English Edition), 2018, 25, 9-15.	0.1	0
1319	Long-term effectiveness of tumour necrosis factor-α inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study. Rheumatology Advances in Practice, 2018, 2, rky042.	0.3	7
1321	Peripheral spondyloarthritis: Concept, diagnosis and treatment. Best Practice and Research in Clinical Rheumatology, 2018, 32, 357-368.	1.4	21
1322	Delayed Diagnosis of Psoriatic Arthritis Mutilans due to Arthritis Prior to Skin Lesion. Case Reports in Rheumatology, 2018, 2018, 1-3.	0.2	1
1323	Dermatological Disorders. , 2018, , 409-479.		1
1324	Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial. Arthritis Research and Therapy, 2018, 20, 269.	1.6	9
1325	An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 453-471.	1.4	16
1326	The effects of cultural background on patient-perceived impact of psoriatic arthritis - a qualitative study conducted in Brazil and France. Advances in Rheumatology, 2018, 58, 33.	0.8	5
1327	ASSOCIATION OF ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY IN A SAMPLE OF ADULT PATIENTS WITH PSORIASIS AND PSORIATIC ARTHROPATHY. Asian Journal of Pharmaceutical and Clinical Research, 2018, 11, 385.	0.3	0
1328	The Impact of Fibromyalgia in Spondyloarthritis: From Classification Criteria to Outcome Measures. Frontiers in Medicine, 2018, 5, 290.	1.2	20
1329	The Patient-Reported Outcomes Thermometer–5-Item Scale (5T-PROs): Validation of a New Tool for the Quick Assessment of Overall Health Status in Painful Rheumatic Diseases. Pain Research and Management, 2018, 2018, 1-16.	0.7	10
1330	Coexistence of Kaposi's sarcoma and psoriasis: is there a hidden relationship?. European Journal of Dermatology, 2018, 28, 320-325.	0.3	6
1331	Inflammatory markers predict insulin sensitivity in active rheumatoid arthritis but not in psoriatic arthritis. Reumatismo, 2018, 70, 232-240.	0.4	3

#	Article	IF	CITATIONS
1332	Effect of Methotrexate in the Treatment of Distal Interphalangeal Joint Extensor Tendon Enthesopathy in Patients with Nail Psoriasis. Journal of Clinical Medicine, 2018, 7, 546.	1.0	12
1333	Anti-SIRT1 autoantibody is elevated in ankylosing spondylitis: a potential disease biomarker. BMC Immunology, 2018, 19, 38.	0.9	12
1335	Sleep disorders in patients with psoriatic arthritis and psoriasis. Reumatologia, 2018, 56, 301-306.	0.5	37
1336	DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs. RMD Open, 2018, 4, e000765.	1.8	14
1337	Evaluation of the occurrence of sexual dysfunction and general quality of life in female patients with psoriasis. Anais Brasileiros De Dermatologia, 2018, 93, 801-806.	0.5	12
1338	Performances of five risk algorithms in predicting cardiovascular events in patients with Psoriatic Arthritis: An Italian bicentric study. PLoS ONE, 2018, 13, e0205506.	1.1	28
1339	Osteoporosis in psoriatic arthritis: a cross-sectional study of an outpatient clinic population. RMD Open, 2018, 4, e000631.	1.8	20
1340	Greater magnitude of entheseal microdamage and repair in psoriatic arthritis compared with ankylosing spondylitis on ultrasound. Rheumatology, 2018, 58, 299-303.	0.9	9
1341	Identification of a Single Nucleotide Polymorphism in NFKBIA with Different Effects on Psoriatic Arthritis and Cutaneous Psoriasis in China. Acta Dermato-Venereologica, 2018, 99, 84-88.	0.6	6
1342	Assessment of nail unit structures by ultrasound in patients with psoriatic arthritis and their correlations with disease activity indices: a case–control study. Rheumatology International, 2018, 38, 2087-2093.	1.5	15
1343	Ustekinumab in psoriatic arthritis and related phenotypes. Therapeutic Advances in Chronic Disease, 2018, 9, 191-198.	1.1	10
1344	Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA. Frontiers in Immunology, 2018, 9, 1936.	2.2	71
1345	Evaluation of circulating invariant T cells before and after IL-17 inhibitor treatment in a patient with psoriatic arthritis. Clinical Immunology, 2018, 197, 107-109.	1.4	1
1346	Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients. Nature Communications, 2018, 9, 4178.	5.8	95
1347	Semantic and psychometric validation of the Brazilian Portuguese version (PASE-P) of the Psoriatic Arthritis Screening and Evaluation questionnaire. PLoS ONE, 2018, 13, e0205486.	1.1	6
1348	Pediatric Psoriatic Arthritis. Journal of Psoriasis and Psoriatic Arthritis, 2018, 3, 131-136.	0.3	22
1349	The thickening of flexor tendons pulleys: a useful ultrasonographical sign in the diagnosis of psoriatic arthritis. Journal of Ultrasound, 2018, 21, 309-314.	0.7	12
1350	Effectiveness and safety of anti-TNF in psoriatic arthritis patients in Brazil: a post-incorporation analysis. Journal of Comparative Effectiveness Research, 2018, 7, 989-1000.	0.6	10

#	Article	IF	CITATIONS
1351	Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part I: Mild psoriasis. Przeglad Dermatologiczny, 2018, 105, 225-243.	0.0	7
1352	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet, The, 2018, 392, 2367-2377.	6.3	159

Heel Pain in Psoriatic Arthropathy: Analysis of a Series of 291 Patients. ReumatologÃa ClÃnica (English) Tj ETQq0 0 0 rgBT /Overlock 10

1354	Ultrasound Assessment of Changes in Nails in Psoriasis and Psoriatic Arthritis. BioMed Research International, 2018, 2018, 1-7.	0.9	23
1355	Simultaneous quantification of bone erosions and enthesiophytes in the joints of patients with psoriasis or psoriatic arthritis - effects of age and disease duration. Arthritis Research and Therapy, 2018, 20, 203.	1.6	35
1356	The Value of an Automated Ultrasound System in the Detection of Synovitis. Ultrasound International Open, 2018, 04, E61-E68.	0.3	2
1357	Gender does not make a difference in "composite psoriatic disease activity index (CPDAI)―in patients with psoriatic arthritis. Rheumatology International, 2018, 38, 2069-2076.	1.5	11
1358	Classification and Outcome Measures for Psoriatic Arthritis. Frontiers in Medicine, 2018, 5, 246.	1.2	20
1359	Methodology of a new inflammatory arthritis registry: TReasure. Turkish Journal of Medical Sciences, 2018, 48, 856-861.	0.4	7
1360	Validation and cultural adaptation of the qualisex questionnaire in patients with axial spondyloarthritis in Argentina. Rheumatology International, 2018, 38, 2103-2109.	1.5	9
1361	Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. RMD Open, 2018, 4, e000667.	1.8	15
1362	Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritis. Quality of Life Research, 2018, 27, 2443-2451.	1.5	17
1363	Mannan-induced Nos2 in macrophages enhances IL-17–driven psoriatic arthritis by innate lymphocytes. Science Advances, 2018, 4, eaas9864.	4.7	33
1364	Clinical and immunological effects of adsorptive myeloid lineage leukocyte apheresis in patients with immune disorders. Journal of Dermatology, 2018, 45, 943-950.	0.6	16
1365	Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases. Scientific Reports, 2018, 8, 7881.	1.6	8
1366	Clinical management of psoriatic arthritis. Lancet, The, 2018, 391, 2285-2294.	6.3	96
1367	Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet, The, 2018, 391, 2213-2224.	6.3	159
1368	Phase <scp>II</scp> Study of <scp>ABT</scp> â€122, a Tumor Necrosis Factor– and Interleukinâ€17A–Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate. Arthritis and Rheumatology, 2018, 70, 1778-1789.	2.9	77

#	Article	IF	CITATIONS
1369	Entheseal involvement in patients with systemic lupus erythematosus: an ultrasound study. Rheumatology, 2018, 57, 1822-1829.	0.9	26
1370	Development and Evaluation of Diagnostic Criteria for Vogt-Koyanagi-Harada Disease. JAMA Ophthalmology, 2018, 136, 1025.	1.4	83
1371	Standardization of red flags for referral to rheumatologists and ophthalmologists in patients with rheumatic diseases and ocular involvement: a consensus statement. Rheumatology International, 2018, 38, 1727-1734.	1.5	7
1372	Psoriasis and Psoriatic Arthritis. , 2018, , 239-250.		0
1373	Psoriatic Arthritis and Nail Psoriasis in a Patient with Concomitant Atopic Dermatitis. Case Reports in Dermatological Medicine, 2018, 2018, 1-3.	0.1	1
1374	Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Journal of Rheumatology, 2018, 45, 1389-1396.	1.0	100
1375	Interleukin inhibitors for psoriatic arthritis. The Cochrane Library, 0, , .	1.5	0
1376	Overdiagnosis and overtreatment in rheumatology: a little caution is in order. Annals of the Rheumatic Diseases, 2018, 77, 1394-1396.	0.5	62
1378	Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives. Psoriasis: Targets and Therapy, 2018, Volume 8, 31-39.	1.2	12
1379	lxekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naÃ ⁻ ve patients with active psoriatic arthritis (SPIRIT-P1). Rheumatology, 2018, 57, 1777-1788.	0.9	27
1380	Clinical diagnostic model for sciatica developed in primary care patients with low back-related leg pain. PLoS ONE, 2018, 13, e0191852.	1.1	29
1381	Nail Unit Psoriasis. , 2018, , 99-126.		0
1382	Synovial Predictors of Differentiation to Definite Arthritis in Patients With Seronegative Undifferentiated Peripheral Inflammatory Arthritis: microRNA Signature, Histological, and Ultrasound Features. Frontiers in Medicine, 2018, 5, 186.	1.2	24
1383	Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2. Rheumatology, 2018, 57, 2001-2011.	0.9	34
1384	Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis. Rheumatology, 2018, 57, 1972-1981.	0.9	30
1385	A comparative analysis of articular bone in large cohort of patients with chronic inflammatory diseases of the joints, the gut and the skin. Bone, 2018, 116, 87-93.	1.4	28
1386	Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. Arthritis Research and Therapy, 2018, 20, 160.	1.6	16
1387	Immune-Mediated Inflammation Promotes Subclinical Atherosclerosis in Recent-Onset Psoriatic Arthritis Patients without Conventional Cardiovascular Risk Factors. Frontiers in Immunology, 2018, 9, 139.	2.2	23

#	Article	IF	CITATIONS
1388	Distinct In Vitro T-Helper 17 Differentiation Capacity of Peripheral Naive T Cells in Rheumatoid and Psoriatic Arthritis. Frontiers in Immunology, 2018, 9, 606.	2.2	12
1389	Comparison of Serological Biomarkers in Rheumatoid Arthritis and Their Combination to Improve Diagnostic Performance. Frontiers in Immunology, 2018, 9, 1113.	2.2	22
1390	Tetraspanin CD82 affects migration, attachment and invasion of rheumatoid arthritis synovial fibroblasts. Annals of the Rheumatic Diseases, 2018, 77, 1619-1626.	0.5	26
1391	Influence of Disease Manifestations on Health-related Quality of Life in Early Psoriatic Arthritis. Journal of Rheumatology, 2018, 45, 1526-1531.	1.0	34
1392	Smoking cessation intervention for reducing disease activity in chronic autoimmune inflammatory joint diseases. The Cochrane Library, 0, , .	1.5	0
1393	Monitoring of Disease and Treatment of Patients With Rheumatic Disease. Handbook of Systemic Autoimmune Diseases, 2018, , 97-125.	0.1	2
1394	Position statement for the management of comorbidities in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2058-2073.	1.3	61
1395	IL-17 in the immunopathogenesis of spondyloarthritis. Nature Reviews Rheumatology, 2018, 14, 453-466.	3.5	102
1396	Oligoarticular Psoriatic Arthritis: Addressing Clinical Challenges in an Intriguing Phenotype. Rheumatology and Therapy, 2018, 5, 311-316.	1.1	5
1397	MiR-146a G/C rs2910164 variation in South African Indian and Caucasian patients with psoriatic arthritis. BMC Medical Genetics, 2018, 19, 48.	2.1	10
1398	Age and fecal microbial strain-specific differences in patients with spondyloarthritis. Arthritis Research and Therapy, 2018, 20, 14.	1.6	58
1399	Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study. Arthritis Research and Therapy, 2018, 20, 73.	1.6	30
1400	Patterns of peripheral joint involvement in psoriatic arthritis—Symmetric, ray and/or row?. Seminars in Arthritis and Rheumatism, 2018, 48, 430-435.	1.6	13
1401	Spondyloarthritis in the Democratic Republic of the Congo: a prospective hospital-based study. BMJ Open, 2018, 8, e020329.	0.8	9
1402	Enthesitis and Dactylitis in Psoriatic Disease: A Guide for Dermatologists. American Journal of Clinical Dermatology, 2018, 19, 839-852.	3.3	39
1403	Computational analysis of micro RNAs compatibility in pharmacogenomic based regulatory networks of psoriatic arthritis: An initiation towards identifying a potential miRNA to treat psoriatic arthritis. Biocatalysis and Agricultural Biotechnology, 2018, 16, 545-547.	1.5	2
1404	Role of CXCL13 and CCL20 in the recruitment of B cells to inflammatory foci in chronic arthritis. Arthritis Research and Therapy, 2018, 20, 114.	1.6	43
1405	The History of Psoriatic Arthritis (PsA): From Moll and Wright to Pathway-Specific Therapy. Current Rheumatology Reports, 2018, 20, 58.	2.1	3

	Сітатіс	CITATION REPORT	
#	Article	IF	CITATIONS
1406	Long-term etanercept survival in patients with psoriatic arthritis: a multicenter retrospective analysis in daily clinical practice in Spain. Rheumatology International, 2018, 38, 2037-2043.	1.5	4
1407	IL-9 receptor: Regulatory role on FLS and pannus formation. Cytokine, 2018, 111, 58-62.	1.4	12
1408	Distinguishing rheumatoid arthritis from psoriatic arthritis. RMD Open, 2018, 4, e000656.	1.8	90
1409	Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD Open, 2018, 4, e000723.	1.8	56
1410	Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity. BMC Rheumatology, 2018, 2, 24.	0.6	24
1411	The evaluation of the static and dynamic balance disorders in patients with psoriatic arthritis. Rheumatology International, 2018, 38, 2063-2068.	1.5	3
1412	Early response to apremilast treatment in psoriatic arthritis: a real-life ultrasonographic follow-up study. Rheumatology, 2018, 57, 1490-1491.	0.9	7
1413	Psoriasis and Psoriatic Spectrum Disease: A Primer for the Primary Care Physician. American Journal of Medicine, 2018, 131, 1146-1154.	0.6	9
1414	Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. Journal of Rheumatology, 2018, 45, 1256-1262.	1.0	10
1415	Talalgias. EMC - Aparato Locomotor, 2018, 51, 1-7.	0.1	1
1416	Pain Mechanisms and Ultrasonic Inflammatory Activity as Prognostic Factors in Patients With Psoriatic Arthritis: A Prospective Cohort Study. Arthritis Care and Research, 2019, 71, 798-810.	1.5	35
1417	Clinical practice guidance for juvenile idiopathic arthritis (JIA) 2018. Modern Rheumatology, 2019, 29, 41-59.	0.9	25
1418	Effect of Achieving Minimal Disease Activity on the Progression of Subclinical Atherosclerosis and Arterial Stiffness: A Prospective Cohort Study in Psoriatic Arthritis. Arthritis and Rheumatology, 2019, 71, 271-280.	2.9	24
1419	Spondyloarthritis. , 2019, , 769-787.		5
1420	Biologics for the primary care physician: Review and treatment of psoriasis. Disease-a-Month, 2019, 65, 51-90.	0.4	62
1421	The association between occupational-related mechanical stress and radiographic damage in psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2019, 48, 638-643.	1.6	18
1422	"A body in transformationâ€â€"An empirical phenomenological study about fearâ€avoidance beliefs towards physical activity among persons experiencing moderateâ€toâ€severe rheumatic pain. Journal of Clinical Nursing, 2019, 28, 321-329.	1.4	6
1423	Effectiveness of methotrexate in moderate to severe psoriasis patients: real-world registry data from the Swiss Dermatology Network for Targeted Therapies (SDNTT). Archives of Dermatological Research, 2019, 311, 753-760.	1.1	11

#	ARTICLE Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in	IF	CITATIONS
1424	patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial). BMJ Open, 2019, 9, e028517.	0.8	19
1425	Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients. Rheumatology and Therapy, 2019, 6, 521-528.	1.1	18
1426	Musculoskeletal ultrasound in monitoring response to apremilast in psoriatic arthritis patients: results from a longitudinal study. Clinical Rheumatology, 2019, 38, 3145-3151.	1.0	11
1427	Spondyloarthritis. , 2019, , 87-91.		0
1428	The incidence of extraâ€articular manifestations in southern Chinese patients with inflammatory joint diseases. International Journal of Rheumatic Diseases, 2019, 22, 1686-1694.	0.9	6
1429	Dietary habits in Japanese patients with psoriasis and psoriatic arthritis: Low intake of meat in psoriasis and high intake of vitamin A in psoriatic arthritis. Journal of Dermatology, 2019, 46, 759-769.	0.6	17
1430	Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients. Clinical Rheumatology, 2019, 38, 2843-2850.	1.0	39
1431	Late-Onset and Elderly Psoriatic Arthritis: Clinical Aspects and Management. Drugs and Aging, 2019, 36, 909-925.	1.3	15
1432	Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients. Arthritis Research and Therapy, 2019, 21, 162.	1.6	32
1433	Methotrexate Restores CD73 Expression on Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis Patients and May Contribute to Its Anti-Inflammatory Effect through Ado Production. Journal of Clinical Medicine, 2019, 8, 1859.	1.0	4
1434	The prevalence and impact of comorbid fibromyalgia in inflammatory arthritis. Best Practice and Research in Clinical Rheumatology, 2019, 33, 101423.	1.4	82
1435	Methotrexate for psoriatic arthritis. The Cochrane Library, 2019, 2019, CD012722.	1.5	22
1436	Smoking cessation intervention for reducing disease activity in chronic autoimmune inflammatory joint diseases. The Cochrane Library, 2019, 2019, CD012958.	1.5	13
1437	Spanish Registry of Recent-onset Psoriatic Arthritis (REAPSER study): Aims and methodology. ReumatologÃa ClÃnica (English Edition), 2019, 15, 252-257.	0.2	3
1438	Outer rotation curve of the Galaxy with VERA. IV. Astrometry of IRAS 01123+6430 and the possibility of cloud–cloud collision. Publication of the Astronomical Society of Japan, 2019, 71, .	1.0	1
1439	Crossâ€sectional multicenter observational study of psoriatic arthritis in Japanese patients: Relationship between skin and joint symptoms and results of treatment with tumor necrosis factorâ€î± inhibitors. Journal of Dermatology, 2019, 46, 193-198.	0.6	11
1440	Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis. Journal of Patient-Reported Outcomes, 2019, 3, 30.	0.9	24
1441	Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis. Medicine (United States), 2019, 98, e13955.	0.4	18

#	Article	IF	CITATIONS
1442	Dysregulated miR-125a promotes angiogenesis through enhanced glycolysis. EBioMedicine, 2019, 47, 402-413.	2.7	36
1444	Nailfold capillaroscopic changes in Egyptian patients with psoriatic arthritis in comparison to rheumatoid arthritis. Egyptian Rheumatologist, 2019, 41, 303-307.	0.5	6
1445	Vaspin, neutrophil gelatinase-associated lipocalin and apolipoprotein levels in patients with psoriatic arthritis. Bratislava Medical Journal, 2019, 120, 65-69.	0.4	13
1446	Safety and Efficacy of Methotrexate for Chinese Adults With Psoriasis With and Without Psoriatic Arthritis. JAMA Dermatology, 2019, 155, 327.	2.0	19
1447	MiR-146a-5p Expression in Peripheral CD14+ Monocytes from Patients with Psoriatic Arthritis Induces Osteoclast Activation, Bone Resorption, and Correlates with Clinical Response. Journal of Clinical Medicine, 2019, 8, 110.	1.0	29
1448	Disease activity and functional status associated with healthâ€related quality of life and patientâ€acceptable symptom state in patients with psoriatic arthritis in Thailand: A crossâ€sectional study. International Journal of Rheumatic Diseases, 2019, 22, 700-707.	0.9	6
1449	Pain and affective distress in arthritis: relationship to immunity and inflammation. Expert Review of Clinical Immunology, 2019, 15, 541-552.	1.3	64
1450	Incidence of infection other than tuberculosis in patients with autoimmune rheumatic diseases treated with bDMARDs: a real-time clinical experience from India. Rheumatology International, 2019, 39, 497-507.	1.5	5
1451	Peritenon Extensor Tendon Inflammation in Psoriatic Arthritis Is an Enthesitis-related Lesion. Journal of Rheumatology, 2019, 46, 1295-1298.	1.0	10
1452	Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis. Journal of Rheumatology, 2019, 46, 710-715.	1.0	19
1453	Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis. Advances in Therapy, 2019, 36, 691-707.	1.3	11
1454	Evaluating current definitions of low disease activity in psoriatic arthritis using ultrasound. Rheumatology, 2019, 58, 2212-2220.	0.9	12
1455	PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231984705.	1.1	4
1456	Ultrasonography of enthesis in psoriatic arthritis: a descriptive and reliability analysis of elemental lesions and power Doppler subtypes. Scandinavian Journal of Rheumatology, 2019, 48, 454-459.	0.6	11
1457	Correlation of enthesitis indices with disease activity and function in axial and peripheral spondyloarthritis: a cross-sectional study comparing MASES, SPARCC and LEI. Advances in Rheumatology, 2019, 59, 23.	0.8	21
1458	Relationship between structural damage with loss of strength and functional disability in psoriatic arthritis patients. Clinical Biomechanics, 2019, 68, 169-174.	0.5	9
1459	Disease burden and treatment challenges of psoriatic arthritis in Africa and the Middle East. Rheumatology International, 2019, 39, 1321-1329.	1.5	18
1460	Pro-inflammatory adipokine profile in psoriatic arthritis: results from a cross-sectional study comparing PsA subset with evident cutaneous involvement and subset "sine psoriasis― Clinical Rheumatology, 2019, 38, 2547-2552.	1.0	21

#	Article	IF	CITATIONS
1462	Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients With Psoriatic Disease. Arthritis and Rheumatology, 2019, 71, 1651-1659.	2.9	22
1463	Elucidating the endogenous synovial fluid proteome and peptidome of inflammatory arthritis using label-free mass spectrometry. Clinical Proteomics, 2019, 16, 23.	1.1	15
1464	Initial assessment of the early arthritis for psoriatic patients diagnostic questionnaire in dermatology clinics in Australia, Korea and China. International Journal of Rheumatic Diseases, 2019, 22, 1512-1520.	0.9	9
1465	Development of a multiplex assay based on chimeric citrullinated peptides as proof of concept for diagnosis of rheumatoid arthritis. PLoS ONE, 2019, 14, e0215927.	1.1	5
1466	Screening for psoriatic arthritis: targeting phenotypes may improve case detection. Joint Bone Spine, 2019, 86, 803-805.	0.8	1
1467	Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase <scp>III</scp> and Longâ€Term Extension Studies. Arthritis Care and Research, 2019, 71, 1387-1395.	1.5	38
1468	"Hepatic toxicity by methotrexate with weekly single doses associated with folic acid in rheumatoid and psoriatic arthritis. What is its real frequency?― Annals of Hepatology, 2019, 18, 765-769.	0.6	19
1469	Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis. Arthritis Research and Therapy, 2019, 21, 116.	1.6	23
1470	Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study. Dermatology Reports, 2019, 11, 7965.	0.4	19
1471	Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis. Arthritis Research and Therapy, 2019, 21, 118.	1.6	55
1472	Psoriatic Arthritis: What is Happening at the Joint?. Rheumatology and Therapy, 2019, 6, 305-315.	1.1	40
1474	Hyaluronan concentration and molecular mass in psoriatic arthritis: biomarkers of disease severity, resistance to treatment, and outcome. Scandinavian Journal of Rheumatology, 2019, 48, 284-293.	0.6	10
1475	<scp>TT</scp> genotype of rs10036748 in <i> <scp>TNIP</scp> 1 </i> shows better response to methotrexate in a Chinese population: a prospective cohort study. British Journal of Dermatology, 2019, 181, 778-785.	1.4	15
1476	Distal interphalangeal joint extensor tendon enthesopathy in patients with nail psoriasis. Scientific Reports, 2019, 9, 3628.	1.6	14
1477	Pregnancy Outcomes in Couples with Males Exposed to Longterm Anti–tumor Necrosis Factor– <i>α</i> Inhibitor Therapies: A Prospective Study. Journal of Rheumatology, 2019, 46, 1084-1088.	1.0	6
1478	Psoriatic Nail Dystrophy Is Associated with Erosive Disease in the Distal Interphalangeal Joints in Psoriatic Arthritis: A Retrospective Cohort Study. Journal of Rheumatology, 2019, 46, 1097-1102.	1.0	15
1479	Association of Physical Activity and Medication with Enthesitis on Ultrasound in Psoriatic Arthritis. Journal of Rheumatology, 2019, 46, 1290-1294.	1.0	17
1480	Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. Journal of Rheumatology, 2019, 46, 1089-1096.	1.0	37

#	Article	IF	CITATIONS
1481	Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis. Annals of the Rheumatic Diseases, 2019, 78, 796-801.	0.5	34
1482	Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis: A Case Report. Journal of Clinical Medicine, 2019, 8, 398.	1.0	7
1483	Ultrasound and clinical features of hip involvement in patients with gout. Joint Bone Spine, 2019, 86, 633-636.	0.8	10
1484	Dosing of intra-articular triamcinolone hexacetonide for knee synovitis in chronic polyarthritis: a randomized controlled study. Scandinavian Journal of Rheumatology, 2019, 48, 279-283.	0.6	8
1485	Hautentzündungen mit Arthritis, Synovitis und Enthesitis. Teil 1: Psoriasisarthritis, SAPHOâ€ S yndrom, Morbus Still, Morbus Behçet. JDDG - Journal of the German Society of Dermatology, 2019, 17, 43-66.	0.4	3
1486	Medication persistence for psoriatic arthritis in a Brazilian real-world setting. Future Science OA, 2019, 5, FSO369.	0.9	13
1487	Ultrasonographic and Clinical Assessment of Peripheral Enthesitis in Patients with Psoriatic Arthritis, Psoriasis, and Fibromyalgia Syndrome: The ULISSE Study. Journal of Rheumatology, 2019, 46, 904-911.	1.0	58
1488	Factors associated with patientâ€physician discordance in a prospective cohort of patients with psoriatic arthritis: An Asian perspective. International Journal of Rheumatic Diseases, 2019, 22, 1209-1215.	0.9	6
1489	Cogan's Syndrome and Spondyloarthritis: Case Report. ReumatologÃa ClÃnica (English Edition), 2019, 15, e170-e171.	0.2	0
1490	Hypertension is associated with increased age at the onset of psoriasis and a higher body mass index in psoriatic disease. Clinical Rheumatology, 2019, 38, 2063-2068.	1.0	10
1491	Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?. Clinical Drug Investigation, 2019, 39, 565-575.	1.1	8
1492	Amplifying the concept of psoriatic arthritis: The role of autoimmunity in systemic psoriatic disease. Autoimmunity Reviews, 2019, 18, 565-575.	2.5	49
1493	Clinical Characteristics of Patients with Spondyloarthritis in Japan in Comparison with Other Regions of the World. Journal of Rheumatology, 2019, 46, 896-903.	1.0	14
1494	Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial. Journal of Rheumatology, 2019, 46, 595-602.	1.0	6
1495	Radiographic scoring methods in rheumatoid arthritis and psoriatic arthritis. Radiologia Medica, 2019, 124, 1071-1086.	4.7	23
1496	Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nature Reviews Rheumatology, 2019, 15, 153-166.	3.5	208
1497	Treating to Target(s) With Interleukin-17 Inhibitors. Journal of Cutaneous Medicine and Surgery, 2019, 23, 3S-34S.	0.6	6
1498	Skin inflammation associated with arthritis, synovitis and enthesitis. Part 1: psoriatic arthritis, SAPHO syndrome, Still's disease, Behçet's disease. JDDG - Journal of the German Society of Dermatology, 2019, 17, 43-64.	0.4	6

#	Article	IF	CITATIONS
1499	Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate. Annals of the Rheumatic Diseases, 2019, 78, 610-616.	0.5	33
1500	Epigenome-wide analysis of sperm cells identifies IL22 as a possible germ line risk locus for psoriatic arthritis. PLoS ONE, 2019, 14, e0212043.	1.1	23
1501	Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase <scp>III</scp> Trial. Arthritis and Rheumatology, 2019, 71, 1112-1124.	2.9	164
1502	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. Journal of the American Academy of Dermatology, 2019, 80, 1073-1113.	0.6	281
1503	Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open, 2019, 5, e000806.	1.8	44
1504	Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. RMD Open, 2019, 5, e000808.	1.8	46
1505	Subclinical synovitis and enthesitis in psoriasis patients and controls by ultrasonography in Saudi Arabia; incidence of psoriatic arthritis during twoÂyears. Clinical Rheumatology, 2019, 38, 1627-1635.	1.0	49
1506	Band acro-osteolysis in a middle-aged woman. BMJ Case Reports, 2019, 12, e229054.	0.2	2
1507	Candida Infections in Clinical Trials of Ixekizumab (Taltz), an Interleukin-17A Monoclonal Antibody, in Patients With Psoriasis or Psoriatic Arthritis. Journal of the Dermatology Nurses' Association, 2019, 11, 250-263.	0.1	4
1508	Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study. Frontiers in Pharmacology, 2019, 10, 1497.	1.6	12
1509	Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia. RMD Open, 2019, 5, e001067.	1.8	56
1510	Assessment of Enthesitis in Psoriatic Arthritis. Journal of Rheumatology, 2019, 46, 869-870.	1.0	10
1511	The Performance of Psoriatic Arthritis Screening Questionnaires in Patients with Psoriasis. Journal of Rheumatology, 2019, 46, 1643-1645.	1.0	3
1512	Usefullnes of atherogenic indices and Ca-LDL level to predict subclinical atherosclerosis in patients with psoriatic arthritis?. Advances in Rheumatology, 2019, 59, 49.	0.8	14
1513	Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar. Reumatologia, 2019, 57, 257-263.	0.5	12
1514	Obesity in psoriatic arthritis. Medicine (United States), 2019, 98, e16400.	0.4	44
1515	The incidence of spondyloarthritis in Slovenia. Medicine (United States), 2019, 98, e16177.	0.4	3
1516	The Reliability of Laboratory Testing in Diagnosing Psoriatic Arthritis: A Case Report. Journal of the American Podiatric Medical Association, 2019, 109, 467-470.	0.2	1

#	Article	IF	CITATIONS
1517	Anti-cyclic citrullinated peptide antibody predicts the development of rheumatoid arthritis in patients with undifferentiated arthritis. Chinese Medical Journal, 2019, 132, 2899-2904.	0.9	7
1519	Interventions on Modifiable Risk Factors for the Development of Psoriatic Arthritis. Current Treatment Options in Rheumatology, 2019, 5, 313-325.	0.6	4
1521	Altered expression of microRNA-23a in psoriatic arthritis modulates synovial fibroblast pro-inflammatory mechanisms via phosphodiesterase 4B. Journal of Autoimmunity, 2019, 96, 86-93.	3.0	28
1522	Psoriatic Arthritis Disease Activity During and After Pregnancy: A Prospective Multicenter Study. Arthritis Care and Research, 2019, 71, 1092-1100.	1.5	24
1524	Late onset psoriatic arthritis in a longitudinal cohort: Disease presentation, activity over time and prognosis. Seminars in Arthritis and Rheumatism, 2019, 48, 834-839.	1.6	8
1525	Methotrexate achieves major cDAPSA response, and improvement in dactylitis and functional status in psoriatic arthritis. Rheumatology, 2019, 58, 869-873.	0.9	13
1526	A Review for Physician Assistants and Nurse Practitioners on the Considerations for Diagnosing and Treating Psoriatic Arthritis. Rheumatology and Therapy, 2019, 6, 5-21.	1.1	7
1527	Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. Annals of the Rheumatic Diseases, 2019, 78, 355-364.	0.5	44
1528	Pathophysiology, assessment and treatment of psoriatic dactylitis. Nature Reviews Rheumatology, 2019, 15, 113-122.	3.5	45
1529	Symptomatic psoriatic dactylitis is associated with ultrasound determined extra-synovial inflammatory features and shorter disease duration. Clinical Rheumatology, 2019, 38, 903-911.	1.0	21
1530	Polyarticular evolution and lateâ€onset psoriasis may be associated with cardiovascular disease in psoriatic arthritis. International Journal of Rheumatic Diseases, 2019, 22, 269-274.	0.9	9
1531	Hip Involvement in Patients With Calcium Pyrophosphate Deposition Disease: Potential and Limits of Musculoskeletal Ultrasound. Arthritis Care and Research, 2019, 71, 1671-1677.	1.5	17
1532	Metabolic syndrome and psoriatic arthritis among patients with psoriasis vulgaris: Quality of life and prevalence. Journal of Dermatology, 2019, 46, 3-10.	0.6	25
1533	A qualitative study of quality of life domains and subdomains relevant to patients with spondyloarthritis. International Journal of Rheumatic Diseases, 2019, 22, 242-251.	0.9	5
1534	Evaluation of restless legs syndrome and sleep disorders in patients with psoriatic arthritis. Zeitschrift Fur Rheumatologie, 2019, 78, 987-995.	0.5	17
1535	Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?. Rheumatology International, 2019, 39, 73-81.	1.5	16
1536	Regression of Peripheral Subclinical Enthesopathy in Therapyâ€Naive Patients Treated With Ustekinumab forÂModerateâ€toâ€Severe Chronic Plaque Psoriasis: A Fiftyâ€Two–Week, Prospective, Openâ€Label Feasibility Study. Arthritis and Rheumatology, 2019, 71, 626-631.	2.9	64
1537	Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic diseaseâ€modifying antirheumatic drug prescribing. International Journal of Rheumatic Diseases, 2019, 22, 262-268.	0.9	1

#	Article	IF	CITATIONS
1538	Analysis of association between cytokine gene polymorphisms and psoriatic disease in Russians of East Siberia. Meta Gene, 2019, 19, 60-64.	0.3	3
1539	Perspectives of patients and health professionals on the experience of living with psoriatic arthritis-related foot problems: a qualitative investigation. Clinical Rheumatology, 2019, 38, 1605-1613.	1.0	18
1540	Polymorphisms associated with antiâ€TNF drugs response in patients with psoriasis and psoriatic arthritis. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e175-e177.	1.3	13
1541	Spanish Validation of the GEPARD Questionnaire for the Detection of Psoriatic Arthritis in Argentinian Patients with Psoriasis. Dermatology, 2019, 235, 101-106.	0.9	1
1542	Registro Español de Artritis Psoriásica de Reciente Comienzo (estudio REAPSER). Objetivos y metodologÃa. ReumatologÃa ClÃnica, 2019, 15, 252-257.	0.2	7
1543	Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. Arthritis Research and Therapy, 2019, 21, 17.	1.6	92
1544	HLA-B46 is associated with severe sacroiliitis in Japanese patients with psoriatic arthritis. Modern Rheumatology, 2019, 29, 1017-1022.	0.9	7
1545	Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review. Rheumatology International, 2019, 39, 161-166.	1.5	16
1546	Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32â€week results from the randomized placeboâ€controlled <scp>TRANSFIGURE</scp> trial. British Journal of Dermatology, 2019, 181, 954-966.	1.4	84
1547	Development of a Preliminary Ultrasonographic Enthesitis Score in Psoriatic Arthritis — GRAPPA Ultrasound Working Group. Journal of Rheumatology, 2019, 46, 384-390.	1.0	50
1548	The persistence of golimumab compared to other tumour necrosis factor.α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs—BioRx.si. Clinical Rheumatology, 2019, 38, 297-305.	1.0	14
1549	Ultrasound Assessment of Psoriatic Onychopathy: A Cross-sectional Study Comparing Psoriatic Onychopathy with Onychomycosis. Acta Dermato-Venereologica, 2019, 99, 164-169.	0.6	12
1550	To what extend is nail ultrasound discriminative between psoriasis, psoriatic arthritis and healthy subjects?. Rheumatology International, 2019, 39, 697-705.	1.5	20
1551	Preliminary validation of the Simplified Psoriatic Arthritis Radiographic Score (SPARS). Skeletal Radiology, 2019, 48, 1033-1041.	1.2	9
1552	The ties that bind: skin, gut and spondyloarthritis. Current Opinion in Rheumatology, 2019, 31, 62-69.	2.0	36
1553	Comparison Between INSPIRE and Domjan method for measuring lumbar lateral flexion in patients of psoriatic arthritis (PsA) and correlation with radiographic damage. Clinical Rheumatology, 2019, 38, 1063-1066.	1.0	3
1554	Treating psoriatic arthritis to target: discordance between physicians and patients' assessment, non-adherence, and restricted access to drugs precluded therapy escalation in a real-world cohort. Clinical Rheumatology, 2019, 38, 961-968.	1.0	4
1555	Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. Journal of the American Academy of Dermatology, 2019, 80, 251-265.e19.	0.6	362

#	Article	IF	CITATIONS
1556	Interactions between rheumatoid arthritis synovial fibroblast migration and endothelial cells. Immunology and Cell Biology, 2019, 97, 178-189.	1.0	20
1557	Different ethnic background is associated with distinct clinical profiles in the spondyloarthritides in the North and South of Brazil. Clinical Rheumatology, 2019, 38, 195-203.	1.0	9
1558	Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology, 2019, 58, 336-344.	0.9	92
1559	SÃndrome de Cogan y espondiloartritis. Reporte de caso. ReumatologÃa ClÃnica, 2019, 15, e170-e171.	0.2	1
1561	IMSYC immunologic synovitis score: A new score for synovial membrane characterization in in in in in in in inflammatory and non-inflammatory arthritis. Joint Bone Spine, 2019, 86, 77-81.	0.8	18
1562	Association of anti-cyclic citrullinated peptide antibody with clinical features in patients with psoriatic arthritis. Modern Rheumatology, 2020, 30, 365-372.	0.9	10
1563	Ultrasonographic Evidence of Predominance of Acute Extracapsular and Chronic Intrasynovial Patterns in 100 Cases of Psoriatic Hand Dactylitis. Journal of Rheumatology, 2020, 47, 227-233.	1.0	18
1564	Impact of Having Family History of Psoriasis or Psoriatic Arthritis on Psoriatic Disease. Arthritis Care and Research, 2020, 72, 63-68.	1.5	35
1565	Role of Carotid Ultrasound and Systematic Coronary Risk Evaluation Charts for the Cardiovascular Risk Stratification of Patients with Psoriatic Arthritis. Journal of Rheumatology, 2020, 47, 682-689.	1.0	7
1566	Evaluation of red blood cell distribution width in patients with psoriatic arthritis. Egyptian Rheumatologist, 2020, 42, 309-312.	0.5	2
1567	Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis. Journal of Dermatological Treatment, 2020, 31, 692-697.	1.1	5
1568	Psoriatic arthritis for dermatologists. Journal of Dermatological Treatment, 2020, 31, 662-679.	1.1	52
1569	Peripheral Manifestations in Spondyloarthritis and their Effect: An Ancillary Analysis of the ASAS-COMOSPA Study. Journal of Rheumatology, 2020, 47, 211-217.	1.0	24
1570	Development of a Modified Psoriatic Arthritis Disease Activity Score Using the Medical Outcomes Study Short Form 12 as a Measure of Quality of Life. Arthritis Care and Research, 2020, 72, 577-582.	1.5	6
1571	Destructive psoriatic arthritis of the temporomandibular joint: a clinical case, an overview of the pathophysiology and its differential diagnoses. Cranio - Journal of Craniomandibular Practice, 2020, 38, 201-207.	0.6	6
1572	Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Rheumatology, 2020, 59, 1325-1334.	0.9	40
1573	Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease. Journal of Rheumatology, 2020, 47, 1496-1505.	1.0	14
1574	Prevalence of high-sensitivity cardiac troponin T in real-life cohorts of psoriatic arthritis and general population: a cross-sectional study. Rheumatology International, 2020, 40, 437-444.	1.5	3

#	Article	IF	CITATIONS
1575	Mediterranean diet and Psoriatic Arthritis activity: a multicenter cross-sectional study. Rheumatology International, 2020, 40, 951-958.	1.5	34
1576	Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial. Arthritis Care and Research, 2020, 72, 1579-1588.	1.5	11
1577	Promotion of macrophage activation by Tie2 in the context of the inflamed synovia of rheumatoid arthritis and psoriatic arthritis patients. Rheumatology, 2020, 59, 426-438.	0.9	19
1578	Anti-cyclic citrullinated peptide antibody in psoriatic arthritis: aÂmeta-analysis of its frequency and association with clinical features. Zeitschrift Fur Rheumatologie, 2020, 79, 397-403.	0.5	4
1579	Predominant ultrasonographic extracapsular changes in symptomatic psoriatic dactylitis: results from a multicenter cross-sectional study comparing symptomatic and asymptomatic hand dactylitis. Clinical Rheumatology, 2020, 39, 1157-1165.	1.0	19
1580	Non-specific rheumatic manifestations in patients with Hashimoto's thyroiditis: a pilot cross-sectional study. Journal of Endocrinological Investigation, 2020, 43, 87-94.	1.8	10
1581	Evaluation of the Economic Burden of Psoriatic Arthritis and the Relationship Between Functional Status and Healthcare Costs. Journal of Rheumatology, 2020, 47, 701-707.	1.0	14
1582	Cross-cultural validation and psychometric properties of the Brazilian Portuguese version of the Psoriasis Epidemiology Screening Tool (PEST-bp). Archives of Dermatological Research, 2020, 312, 197-206.	1.1	5
1583	Between National Polarization and Local Ideology: The Impact of Partisan Competition on State Medicaid Expansion Decisions. Publius, 2020, 50, 237-255.	1.0	6
1584	Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis. Rheumatology, 2020, 59, 1599-1606.	0.9	24
1585	Polyfunctional, Proinflammatory, Tissueâ€Resident Memory Phenotype and Function of Synovial Interleukinâ€17A+ <scp>CD</scp> 8+ T Cells in Psoriatic Arthritis. Arthritis and Rheumatology, 2020, 72, 435-447.	2.9	77
1586	A panâ€inflammatory microRNAâ€cluster is associated with orbital nonâ€Hodgkin lymphoma and idiopathic orbital inflammation. European Journal of Immunology, 2020, 50, 86-96.	1.6	7
1587	Serum IFI16 and anti-IFI16 antibodies in psoriatic arthritis. Clinical and Experimental Immunology, 2019, 199, 88-96.	1.1	14
1588	Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. Expert Review of Clinical Immunology, 2020, 16, 119-128.	1.3	12
1589	Fluorodeoxyglucose PET/CT of Arthritis in Rheumatic Diseases: A Pictorial Review. Radiographics, 2020, 40, 223-240.	1.4	38
1590	The impact of the presence of fibromyalgia on fatigue in patients with psoriatic arthritis: comparison with controls. Advances in Rheumatology, 2020, 60, 1.	0.8	16
1591	A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naÃ ⁻ ve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Annals of the Rheumatic Diseases, 2020, 79, 123-131.	0.5	206
1592	Emerging role of monocytes and their intracellular calcium pattern in spondyloarthritis. Clinica Chimica Acta, 2020, 500, 180-188.	0.5	7

#	Article	IF	CITATIONS
1594	Analysis by Age Group of Disease Outcomes in Patients with Psoriatic Arthritis: A Cross-Sectional Multicentre Study. Drugs and Aging, 2020, 37, 99-104.	1.3	3
1595	Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5â€year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatology, 2020, 2, 18-25.	0.9	39
1596	Enthesitis and its relationship with disease activity, functional status, and quality of life in psoriatic arthritis: a multi-center study. Rheumatology International, 2020, 40, 283-294.	1.5	28
1597	Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab. Vaccine, 2020, 38, 847-851.	1.7	26
1598	Paradoxical Pustular Psoriasis in a Patient With Psoriatic Arthritis on Secukinumab Treatment. Journal of Clinical Rheumatology, 2020, 26, e208-e209.	0.5	6
1599	Systematic literature review of non-topical treatments for early, untreated (systemic therapy naÃ⁻ve) psoriatic disease: a GRAPPA initiative. Rheumatology Advances in Practice, 2020, 4, rkaa032.	0.3	3
1600	BSR Spondyloarthritis Course, 27 February 2020. Spondyloarthritis: pathogenesis, diagnosis and management. Rheumatology Advances in Practice, 2020, 4, rkaa043.	0.3	0
1601	Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1. Przeglad Dermatologiczny, 2020, 107, 92-108.	0.0	12
1602	Correlation of metabolic syndrome with serum omentinâ€1 and visfatin levels and disease severity in psoriasis and psoriatic arthritis. Dermatologic Therapy, 2020, 33, e14378.	0.8	5
1603	The role of EMMPRIN/CD147 in regulating angiogenesis in patients with psoriatic arthritis. Arthritis Research and Therapy, 2020, 22, 240.	1.6	9
1604	Imagerie du rhumatisme psoriasique. Revue Du Rhumatisme Monographies, 2020, 87, 261-266.	0.0	0
1605	Defining Pre-Clinical Psoriatic Arthritis in an Integrated Dermato-Rheumatology Environment. Journal of Clinical Medicine, 2020, 9, 3262.	1.0	17
1606	Two-stage exchange Arthroplasty is a viable treatment for Periprosthetic joint infection in inflammatory diseases. BMC Musculoskeletal Disorders, 2020, 21, 681.	0.8	2
1607	Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up. Arthritis Research and Therapy, 2020, 22, 254.	1.6	23
1608	Imaging in the diagnosis and management of peripheral psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2020, 34, 101594.	1.4	15
1609	Nail affection as a central part of the entheseal organ in psoriasis patients for early detection of psoriatic arthritis. Egyptian Rheumatologist, 2020, 42, 319-324.	0.5	3
1610	Interleukinâ€17A biomarker as a predictor for detection of early axial spondyloarthritis changes in patients with psoriasis. International Journal of Rheumatic Diseases, 2020, 23, 1664-1669.	0.9	4
1611	Validation and clinical interpretability of PsAID - psoriatic arthritis impact of disease. Advances in Rheumatology, 2020, 60, 49.	0.8	12

#	Article	IF	CITATIONS
1613	Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis. Nature Reviews Rheumatology, 2020, 16, 415-433.	3.5	106
1614	Association between clinical specialty setting and disease management in patients with psoriatic arthritis: results from LOOP , a crossâ€sectional, multiâ€country, observational study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2035-2043.	1.3	13
1617	Validation of the Simple Psoriatic Arthritis Screening (SiPAS) questionnaire in a Turkish psoriatic population. International Journal of Rheumatic Diseases, 2020, 23, 1159-1164.	0.9	1
1618	Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study. RMD Open, 2020, 6, e001217.	1.8	19
1619	Prevalence of sacroiliitis and acute and structural changes on MRI in patients with psoriatic arthritis. Scientific Reports, 2020, 10, 11580.	1.6	21
1620	Axial Articular Manifestations in Primary Sjögren Syndrome: Association With Spondyloarthritis. Journal of Rheumatology, 2020, 48, jrheum.200189.	1.0	4
1621	Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: results from a national register-based cohort study. Rheumatology, 2021, 60, 2725-2734.	0.9	19
1622	Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function. ACR Open Rheumatology, 2020, 2, 734-740.	0.9	9
1623	Higher prevalence of psoriatic arthritis in the adult population in Spain? A population-based cross-sectional study. PLoS ONE, 2020, 15, e0234556.	1.1	19
1624	DAPSA, carotid plaque and cardiovascular events in psoriatic arthritis: a longitudinal study. Annals of the Rheumatic Diseases, 2020, 79, 1320-1326.	0.5	18
1625	Autoantibodies against specific nuclear antigens are present in psoriatic disease and are diminished by secukinumab. Clinica Chimica Acta, 2020, 510, 400-407.	0.5	9
1626	Prevalence and variables associated with fatigue in psoriatic arthritis: a cross-sectional study. Rheumatology International, 2020, 40, 1825-1834.	1.5	4
1627	Efectividad de certolizumab pegol en psoriasis en una cohorte de pacientes con artritis psoriásica. Actas Dermo-sifiliográficas, 2020, 111, 704-705.	0.2	2
1628	The influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients. Postepy Dermatologii I Alergologii, 2020, 37, 995-1000.	0.4	5
1629	Living with arthritis: a "training camp―for coping with stressful events? A survey on resilience of arthritis patients following the COVID-19 pandemic. Clinical Rheumatology, 2020, 39, 3163-3170.	1.0	16
1631	The impact of coexisting fibromyalgia syndrome on disease activity in patients with psoriatic arthritis and rheumatoid arthritis: A cross-sectional study. Modern Rheumatology, 2021, 31, 827-833.	0.9	6
1632	It Is High Time That We Define Axial Psoriatic Arthritis. Journal of Rheumatology, 2020, 47, 1301-1302.	1.0	4
1633	Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN. Current Rheumatology Reports, 2020, 22, 78.	2.1	10

#	Article	IF	CITATIONS
1634	High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study. Modern Rheumatology, 2022, 32, 87-95.	0.9	2
1635	Impact of disease activity on physical activity in psoriatic arthritis patients Arthritis Care and Research, 2020, 73, 1834-1844.	1.5	5
1636	The Number of Traditional Cardiovascular Risk Factors Is Independently Correlated with Disease Activity in Patients with Psoriatic Arthritis. Medicina (Lithuania), 2020, 56, 415.	0.8	7
1637	Measurement of minimal disease activity in psoriatic arthritis using PROMISâ€Physical Function or the Health Assessment Questionnaireâ€Disability Index. Arthritis Care and Research, 2020, , .	1.5	2
1639	Psoriatic arthritis with skin lesions localized to the scalp: A case report. Journal of General and Family Medicine, 2020, 21, 264-267.	0.3	1
1640	Development and initial validation of a questionnaire to assess facilitators and barriers to physical activity for patients with rheumatoid arthritis, axial spondyloarthritis and/or psoriatic arthritis. Rheumatology International, 2020, 40, 2085-2095.	1.5	11
1641	A novel biomarker of MMP-cleaved prolargin is elevated in patients with psoriatic arthritis. Scientific Reports, 2020, 10, 13541.	1.6	10
1642	Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study). Postepy Dermatologii I Alergologii, 2020, 37, 428-434.	0.4	11
1643	Do Obesity and Overweight Influence Disease Activity Measures in Axial Spondyloarthritis? A Systematic Review and Metaâ€Analysis. Arthritis Care and Research, 2021, 73, 1815-1825.	1.5	20
1644	Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study. Rheumatology and Therapy, 2020, 7, 825-836.	1.1	18
1645	Fourteen small molecule and biological agents for psoriatic arthritis. Medicine (United States), 2020, 99, e21447.	0.4	4
1646	Interleukin-18, interleukin-20, and matrix metalloproteinases (MMP-1, MMP-3) as markers of psoriatic arthritis disease severity and their correlations with biomarkers of inflammation and turnover of joint cartilage. Postepy Dermatologii I Alergologii, 2020, 37, 1001-1008.	0.4	7
1647	Prevalence of musculoskeletal conditions and related disabilities in Bangladeshi adults: a cross-sectional national survey. BMC Rheumatology, 2020, 4, 69.	0.6	10
1648	Complement component 3 as biomarker of disease activity and cardiometabolic risk factor in rheumatoid arthritis and spondyloarthritis. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232096506.	1.1	12
1649	Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular risk. Rheumatology, 2021, 60, 2816-2825.	0.9	15
1650	Introduction of a Simplified Psoriatic Arthritis Magnetic Resonance Imaging Score (sPsAMRIS): A Potential Tool for Treatment Monitoring in Peripheral Psoriatic Arthritis. Diagnostics, 2020, 10, 1093.	1.3	1
1651	Effectiveness of Certolizumab Pegol in the Treatment of Psoriasis in a Cohort of Patients With Psoriatic Arthritis. Actas Dermo-sifiliográficas, 2020, 111, 704-705.	0.2	0
1652	Dermatologists' Role in the Early Diagnosis of Psoriatic Arthritis: Expert Recommendations. Actas Dermo-sifiliográficas, 2020, 111, 835-846.	0.2	5

#	Article	IF	CITATIONS
1653	Prevalence and Factors Associated With Osteoporosis and Bone Mineral Density Testing in Psoriatic Arthritis. Arthritis Care and Research, 2022, 74, 1006-1012.	1.5	5
1654	Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis. Scientific Reports, 2020, 10, 21703.	1.6	5
1655	Comparison of the Heel Enthesitis MRI Scoring System (HEMRIS) with clinical enthesitis and local metabolic activity on PET-CT. RMD Open, 2020, 6, e001424.	1.8	8
1656	Interobserver reliability of Masei index validation by a multicenter collaborative group of rheumatologists. Rheumatology International, 2020, , 1.	1.5	2
1658	Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study. Advances in Therapy, 2020, 37, 2865-2883.	1.3	23
1659	Medication persistence on biological therapies prescribed for the treatment of chronic inflammatory arthropathies: a real-world data study. European Journal of Hospital Pharmacy, 2021, 28, e47-e50.	0.5	4
1660	Interleukin 17A and IL-17F Expression and Functional Responses in Rheumatoid Arthritis and Peripheral Spondyloarthritis. Journal of Rheumatology, 2020, 47, 1606-1613.	1.0	12
1661	Effectiveness of steroid injection for hand psoriatic dactylitis: results from a multicentre prospective observational study. Clinical Rheumatology, 2020, 39, 3383-3392.	1.0	10
1662	Novel and reliable DACTylitis glObal Sonographic (DACTOS) score in psoriatic arthritis. Annals of the Rheumatic Diseases, 2020, 79, 1037-1043.	0.5	17
1663	Radiographic scoring systems for psoriatic arthritis are insufficient for psoriatic arthritis mutilans: results from the Nordic PAM Study. Acta Radiologica Open, 2020, 9, 205846012092079.	0.3	3
1664	Imaging Techniques: Options for the Diagnosis and Monitoring of Treatment of Enthesitis in Psoriatic Arthritis. Journal of Rheumatology, 2020, 47, 973-982.	1.0	22
1665	Psoriatic arthritis and <scp>COVID</scp> â€19 pandemic: Consequences in medical treatment?. Dermatologic Therapy, 2020, 33, e13743.	0.8	11
1666	One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. Expert Opinion on Biological Therapy, 2020, 20, 813-821.	1.4	40
1667	Psoriatic arthritis – classification, diagnostic and clinical aspects. Przeglad Dermatologiczny, 2020, 107, 32-43.	0.0	1
1668	Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. RMD Open, 2020, 6, e001042.	1.8	18
1669	The Neuropathic Pain Features in Psoriatic Arthritis: A Cross-sectional Evaluation of Prevalence and Associated Factors. Journal of Rheumatology, 2020, 47, 1198-1203.	1.0	12
1670	Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet, The, 2020, 395, 1496-1505.	6.3	178
1671	Mortality in psoriatic arthritis: Risk, causes of death, predictors for death. Seminars in Arthritis and Rheumatism, 2020, 50, 571-575.	1.6	23

#	Article	IF	CITATIONS
1672	Proteoglycan loss in the articular cartilage is associated with severity of joint inflammation in psoriatic arthritis—a compositional magnetic resonance imaging study. Arthritis Research and Therapy, 2020, 22, 124.	1.6	7
1673	Fragility fractures in psoriatic arthritis patients: a matched retrospective cohort study. Clinical Rheumatology, 2020, 39, 3685-3691.	1.0	4
1674	Axial Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2020, 46, 327-341.	0.8	23
1675	Using genetics to prioritize diagnoses for rheumatology outpatients with inflammatory arthritis. Science Translational Medicine, 2020, 12, .	5.8	31
1676	Tumor necrosis factor (TNF) inhibitors for the treatment of psoriatic arthritis. The Cochrane Library, 0, , .	1.5	0
1677	Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study. Rheumatology and Therapy, 2020, 7, 553-580.	1.1	54
1678	Large joint and lower extremity involvement have higher impact on disease outcomes in oligoarticular psoriatic arthritis. International Journal of Rheumatic Diseases, 2020, 23, 1094-1099.	0.9	0
1679	The numbers of peripheral regulatory T cells are reduced in patients with psoriatic arthritis and are restored by low-dose interleukin-2. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232091601.	1.1	31
1680	The impact of fatigue on patients with psoriatic arthritis: aÂmulti-center study of the TLAR-network. Rheumatology International, 2020, 40, 1803-1815.	1.5	9
1681	Upregulation of miR-941 in Circulating CD14+ Monocytes Enhances Osteoclast Activation via WNT16 Inhibition in Patients with Psoriatic Arthritis. International Journal of Molecular Sciences, 2020, 21, 4301.	1.8	12
1682	Power Doppler Ultrasound Assessment of A1 Pulley. A New Target of Inflammation in Psoriatic Arthritis?. Frontiers in Medicine, 2020, 7, 204.	1.2	9
1683	Serum MicroRNA Signature as a Diagnostic and Therapeutic Marker in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2020, 47, 1760-1767.	1.0	29
1684	Quantifying Differences in Heritability among Psoriatic Arthritis (PsA), Cutaneous Psoriasis (PsC) and Psoriasis vulgaris (PsV). Scientific Reports, 2020, 10, 4925.	1.6	20
1685	Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial. Arthritis Research and Therapy, 2020, 22, 43.	1.6	3
1686	Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study. BMJ Open, 2020, 10, e034356.	0.8	7
1687	Enthesitis in psoriatic arthritis (Part 1): pathophysiology. Rheumatology, 2020, 59, i10-i14.	0.9	14
1688	Prevalence of extra-articular manifestations in psoriatic arthritis: a systematic review and meta-analysis. Rheumatology, 2020, 59, 2199-2206.	0.9	41
1689	Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis. Rheumatology, 2020, 59, 1818-1825.	0.9	28

#	Article	IF	CITATIONS
1690	Aspects échographiques et cliniques des atteintes de la hanche chez les patients goutteux. Revue Du Rhumatisme (Edition Francaise), 2020, 87, 106-109.	0.0	0
1691	Metabolic Syndrome and psoriatic arthritis: considerations for the clinician. Expert Review of Clinical Immunology, 2020, 16, 409-420.	1.3	21
1692	Content validity of psoriatic arthritis screening questionnaires: systematic review. International Journal of Dermatology, 2020, 59, 902-914.	0.5	1
1693	A Multimodal Eye Assessment in Psoriatic Arthritis Patients sine-Psoriasis: Evidence for a Potential Association with Systemic Inflammation. Journal of Clinical Medicine, 2020, 9, 719.	1.0	12
1694	Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2020, 395, 1126-1136.	6.3	206
1695	Enthesitis in psoriatic arthritis (Part 2): imaging. Rheumatology, 2020, 59, i15-i20.	0.9	19
1696	Role of the IL-23 pathway in the pathogenesis and treatment of enthesitis in psoriatic arthritis. Expert Opinion on Biological Therapy, 2020, 20, 787-798.	1.4	6
1697	Dépistage du rhumatisme psoriasiqueÂ: le ciblage des phénotypes pourrait améliorer la détection des cas. Revue Du Rhumatisme (Edition Francaise), 2020, 87, 309-311.	0.0	0
1698	Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis. Frontiers in Medicine, 2020, 7, 288.	1.2	12
1699	Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff. Hospital Practice (1995), 2020, 48, 213-222.	0.5	5
1700	The association between synovial fluid serine proteinase activity and response to intra-articular corticosteroid injection in psoriatic arthritis. Clinical Rheumatology, 2020, 39, 2355-2361.	1.0	1
1701	Ultrasound verified enthesophytes are associated with radiographic progression at entheses in psoriatic arthritis. Rheumatology, 2020, 59, 2893-2897.	0.9	6
1702	How does the joint dermatology–rheumatology clinic benefit both patients and dermatologists?. Dermatologic Therapy, 2020, 33, e13283.	0.8	11
1703	Association of Structural Entheseal Lesions With an Increased Risk of Progression From Psoriasis to Psoriatic Arthritis. Arthritis and Rheumatology, 2022, 74, 253-262.	2.9	40
1704	Remission in psoriatic arthritis: Definition and predictors. Seminars in Arthritis and Rheumatism, 2020, 50, 1494-1499.	1.6	7
1705	Incidence and risk of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) after tooth extraction in patients with autoimmune disease. Journal of Bone and Mineral Metabolism, 2020, 38, 581-588.	1.3	11
1706	Correlation of serum protein biomarkers with disease activity in psoriatic arthritis. Expert Review of Clinical Immunology, 2020, 16, 335-341.	1.3	11
1707	Declining levels of serum chemokine (Câ€Xâ€C motif) ligand 10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: a new biomarker?*. British Journal of Dermatology, 2020, 183, 920-927.	1.4	14

#	Article	IF	CITATIONS
1708	Immune checkpoint inhibitor–induced inflammatory arthritis as a model of autoimmune arthritis. Immunological Reviews, 2020, 294, 106-123.	2.8	24
1709	Comparison of bone structure and microstructure in the metacarpal heads between patients with psoriatic arthritis and healthy controls: an HR-pQCT study. Osteoporosis International, 2020, 31, 941-950.	1.3	9
1710	Disease Activity Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2020, 47, 1344-1353.	1.0	11
1711	Circulating micro <scp>RNA</scp> s in extracellular vesicles as potential biomarkers for psoriatic arthritis in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1248-1256.	1.3	42
1712	HDL cholesterol efflux capacity is related to disease activity in psoriatic arthritis patients. Clinical Rheumatology, 2020, 39, 1871-1880.	1.0	10
1713	Bone microstructure and volumetric bone mineral density in patients with hyperuricemia with and without psoriasis. Osteoporosis International, 2020, 31, 931-939.	1.3	4
1714	Evaluation of a special concept of physical therapy in spondyloarthritis: German multimodal rheumatologic complex treatment for spondyloarthritis. Clinical Rheumatology, 2020, 39, 1513-1520.	1.0	15
1715	Plasma gelsolin levels in patients with psoriatic arthritis: a possible novel marker. Clinical Rheumatology, 2020, 39, 1881-1888.	1.0	11
1716	Patient perspectives on the pathway to psoriatic arthritis diagnosis: results from a web-based survey of patients in the United States. BMC Rheumatology, 2020, 4, 2.	0.6	23
1717	Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis. Rheumatology International, 2020, 40, 1021-1028.	1.5	3
1718	Elevated CRP even at the first visit to a rheumatologist is associated with long-term poor outcomes in patients with psoriatic arthritis. Clinical Rheumatology, 2020, 39, 2951-2961.	1.0	12
1719	Challenges in the clinical diagnosis of psoriatic arthritis. Clinical Immunology, 2020, 214, 108390.	1.4	33
1720	Psoriatic arthritis in childhood: A commentary on the controversy. Clinical Immunology, 2020, 214, 108396.	1.4	15
1721	Cutaneous immunohistochemical expression of interleukin-23 receptor (IL-23R) in psoriasis and psoriatic arthritis patients: Relation to musculoskeletal ultrasound findings. Egyptian Rheumatologist, 2020, 42, 313-318.	0.5	6
1722	Pathway to biomarker discovery in psoriatic arthritis. Expert Review of Clinical Immunology, 2020, 16, 471-478.	1.3	5
1723	GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis. Annals of the Rheumatic Diseases, 2020, 79, 490-498.	0.5	41
1724	Secukinumab efficacy in patients with PsA is not dependent on patients' body mass index. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-217251.	0.5	25
1725	RNAseq-Based Prioritization Revealed COL6A5, COL8A1, COL10A1 and MIR146A as Common and Differential Susceptibility Biomarkers for Psoriasis and Psoriatic Arthritis: Confirmation from Genotyping Analysis of 1417 Italian Subjects. International Journal of Molecular Sciences, 2020, 21, 2740.	1.8	12

		CITATION REPORT		
#	Article		IF	CITATIONS
1726	Liver Abnormalities in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2020,	47, 847-853.	1.0	18
1727	Prevalence and severity of fatigue in psoriasis and psoriatic arthritis. Postepy Dermatol Alergologii, 2020, 37, 46-51.	ogii l	0.4	6
1728	A dermatologist perspective in the pharmacological treatment of patients with psorias arthritis. Expert Review of Clinical Pharmacology, 2020, 13, 481-491.	is and psoriatic	1.3	6
1729	Interleukinâ€17A Is Produced by CD4+ but Not CD8+ T Cells in Synovial Fluid Followin Activation and Regulates Different Inflammatory Mediators Compared to Tumor Necro Model of Psoriatic Arthritis Synovitis. Arthritis and Rheumatology, 2020, 72, 1303-131	sis Factor in a	2.9	14
1730	Effectiveness of ustekinumab in patients with psoriatic arthritis in a real-world, multice Clinical Rheumatology, 2020, 39, 2963-2971.	nter study.	1.0	5
1731	Enthesitis and joint erosions are disease traits associated with cardiovascular risk in ps arthritis. Clinical Rheumatology, 2020, 39, 2973-2979.	oriatic	1.0	8
1732	Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review. Rheumatology and Therap 271-285.	ıy, 2020, 7,	1.1	20
1733	Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatolog Medicine, 2020, 26, 974-980.	y. Nature	15.2	9
1734	Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative review Review of Clinical Pharmacology, 2020, 13, 505-519.	м. Expert	1.3	6
1735	Disease features associated with a low disease impact in patients with psoriatic arthrit cross-sectional multicenter study. Arthritis Research and Therapy, 2020, 22, 82.	is: results of a	1.6	6
1736	Secukinumab as biological treatment for psoriatic arthritis in real clinical practice. Reu ClÃnica (English Edition), 2021, 17, 203-206.	natologÃa	0.2	2
1737	The Pattern of Musculoskeletal Complaints in Patients With Suspected Psoriatic Arthri Correlation With Physical Examination and Ultrasound. Journal of Rheumatology, 2021		1.0	9
1738	Whole-body Magnetic Resonance Imaging in Psoriatic Arthritis, Rheumatoid Arthritis, a Controls: Interscan, Intrareader, and Interreader Agreement and Distribution of Lesions Rheumatology, 2021, 48, 198-206.	ind Healthy 5. Journal of	1.0	7
1739	Interleukinâ€9 serves as a key link between systemic inflammation and angiogenesis ir and Experimental Dermatology, 2021, 46, 50-57.	n psoriasis. Clinical	0.6	14
1740	Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biol aÂNordic population-based cohort study. Rheumatology, 2021, 60, 140-146.	ogics:	0.9	4
1741	Disease Characteristics, Quality of Life, and Work Productivity by Enthesitis Site: Real- From the US Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Journal of Rheumate 48, 367-375.		1.0	11
1742	Psoriatic arthritis is associated with adverse body composition predictive of greater co disease and type 2 diabetes propensity – a cross-sectional study. Rheumatology, 202		0.9	7
1743	Which ultrasound lesions contribute to dactylitis in psoriatic arthritis and their reliabili clinical setting. Clinical Rheumatology, 2021, 40, 1061-1067.	ty in a	1.0	7

#	Article	IF	CITATIONS
1744	Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study. Clinical Rheumatology, 2021, 40, 2251-2262.	1.0	10
1745	Residual Disease Burden in Patients With Axial Spondyloarthritis and Psoriatic Arthritis Despite Low Disease Activity States in a Multiethnic Asian Population. Journal of Rheumatology, 2021, 48, 677-684.	1.0	14
1747	Broad proteomic screen reveals shared serum proteomic signature in patients with psoriatic arthritis and psoriasis without arthritis. Rheumatology, 2021, 60, 751-761.	0.9	16
1748	Axial psoriatic arthritis: An update for dermatologists. Journal of the American Academy of Dermatology, 2021, 84, 92-101.	0.6	41
1749	Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. Joint Bone Spine, 2021, 88, 105062.	0.8	14
1750	Interstitial lung disease associated with psoriatic arthritis: a new disease entity?. Internal and Emergency Medicine, 2021, 16, 229-231.	1.0	6
1751	A patient-initiated DMARD self-monitoring service for people with rheumatoid or psoriatic arthritis: a cost-effectiveness analysis. Rheumatology, 2021, 60, 277-287.	0.9	3
1752	Psoriatic arthritis and depressive symptoms: does systemic inflammation play a role?. Clinical Rheumatology, 2021, 40, 1893-1902.	1.0	5
1753	Distal phalangeal bone erosions observed by HR-pQCT in patients with psoriatic onycholysis. Rheumatology, 2021, 60, 1176-1184.	0.9	5
1754	Construct validity of the ASAS health index in psoriatic arthritis: a cross-sectional analysis. Rheumatology, 2021, 60, 1465-1473.	0.9	15
1756	Fibromyalgia in patients with psoriatic arthritis: Impact on disease activity indices, fatigue and healthâ€related quality of life. International Journal of Rheumatic Diseases, 2021, 24, 189-196.	0.9	13
1757	Erectile Dysfunction in Men With Psoriatic Arthritis: A Population-based Cohort Study. Journal of Rheumatology, 2021, 48, 527-532.	1.0	0
1758	Doppler enthesitis: a potential useful outcome in the assessment of axial spondyloarthritis and psoriatic arthritis. Clinical Rheumatology, 2021, 40, 2013-2020.	1.0	10
1759	IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors. Annals of the Rheumatic Diseases, 2021, 80, 591-597.	0.5	24
1760	Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2). Rheumatology and Therapy, 2021, 8, 199-217.	1.1	8
1761	Carpal tunnel syndrome in patients with rheumatoid arthritis and psoriatic arthritis: an electrophysiological and ultrasonographic study. Rheumatology International, 2021, 41, 361-368.	1.5	10
1762	Validation of the Toronto Psoriatic Arthritis Screen II (ToPAS II) questionnaire in a Brazilian population. Clinical Rheumatology, 2021, 40, 1889-1892.	1.0	4
1763	Effect of Multidomain Disease Presentations on Patients With Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Journal of Rheumatology, 2021, 48, 698-706.	1.0	15

#	Article	IF	CITATIONS
1764	Association between inflammasome-related polymorphisms and psoriatic arthritis. Scandinavian Journal of Rheumatology, 2021, 50, 206-212.	0.6	14
1765	Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Annals of the Rheumatic Diseases, 2021, 80, 312-320.	0.5	131
1767	Axial spondyloarthritis: concept, construct, classification and implications for therapy. Nature Reviews Rheumatology, 2021, 17, 109-118.	3.5	73
1768	Potential Differences in Clinical Features, Disease Activity, Function and Impact of Disease Between Oligo and Polyarticular Psoriatic Arthritis. Journal of Psoriasis and Psoriatic Arthritis, 2021, 6, 38-42.	0.3	0
1769	Fibromyalgia in patients with psoriatic arthritis: Relationship with enthesopathy, sleep, fatigue and quality of life. International Journal of Rheumatic Diseases, 2021, 24, 183-188.	0.9	8
1770	Psychological factors associated with sleep disorders in patients with axial spondyloarthritis or psoriatic arthritis: A multicenter crossâ€sectional observational study. Journal of Clinical Nursing, 2021, 30, 266-275.	1.4	12
1771	Axial involvement in patients with early peripheral spondyloarthritis: a prospective MRI study of sacroiliac joints and spine. Annals of the Rheumatic Diseases, 2021, 80, 103-108.	0.5	11
1772	ls there any association between psoriasis, psoriatic arthritis and thyroid autoimmunity?. Australasian Journal of Dermatology, 2021, 62, e207-e211.	0.4	5
1773	Incidence and case fatality rate of COVIDâ€19 in patients with inflammatory articular diseases. International Journal of Clinical Practice, 2021, 75, e13707.	0.8	13
1774	Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Annals of the Rheumatic Diseases, 2021, 80, 185-193.	0.5	79
1775	Increased levels of plasma nucleotides in patients with rheumatoid arthritis. International Immunology, 2021, 33, 119-124.	1.8	11
1776	Axial and peripheral spondyloarthritis: does psoriasis influence the clinical expression and disease burden? Data from REGISPONSER registry. Rheumatology, 2021, 60, 1125-1136.	0.9	8
1777	Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. Rheumatology, 2021, 60, 1137-1147.	0.9	13
1778	Physical and Psychosocial Burden of Psoriatic Arthritis: Longitudinal Data From a Populationâ€Based Study in Norway. Arthritis Care and Research, 2021, 73, 138-145.	1.5	16
1779	Epidemiology of Uveitis in a Spanish Region: Prevalence and Etiology. Ophthalmic Epidemiology, 2021, 28, 227-236.	0.8	10
1781	Differentiating rheumatoid and psoriatic arthritis: a systematic analysis of high-resolution magnetic resonance imaging features—preliminary findings. Skeletal Radiology, 2021, 50, 531-541.	1.2	8
1782	Model to Determine the Costâ€Effectiveness of Screening Psoriasis Patients for Psoriatic Arthritis. Arthritis Care and Research, 2021, 73, 266-274.	1.5	6
1783	Machine Learning Techniques for Prediction of Psoriatic Arthritis Development in Patients with Psoriasis. IFMBE Proceedings, 2021, , 208-216.	0.2	0

#	Article	IF	CITATIONS
1784	LOOP, a cross-sectional, observational study investigating the clinical specialty setting as a determinant of disease management in psoriatic arthritis: Subgroup analysis results from Japan. PLoS ONE, 2021, 16, e0245954.	1.1	4
1785	Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. RMD Open, 2021, 7, e001450.	1.8	64
1786	Clinical associations of psoriasis, fibromyalgia, and enthesial-synovial inflammation. Medical Alphabet, 2021, , 38-42.	0.0	0
1787	Characterization of bone metabolism in hungarian psoriatic arthritis patients: a case–control study. BMC Musculoskeletal Disorders, 2021, 22, 70.	0.8	6
1788	Adipokines and Autoimmunity in Inflammatory Arthritis. Cells, 2021, 10, 216.	1.8	33
1789	Corticosteroid injection treatment for dactylitis in psoriatic arthritis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110418.	1.2	0
1790	Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination. RMD Open, 2021, 7, e001484.	1.8	1
1791	Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations. Annals of Dermatology, 2021, 33, 131.	0.3	2
1792	Active Latent Space Shape Model: A Bayesian Treatment of Shape Model Adaptation with an Application to Psoriatic Arthritis Radiographs. , 2021, , .		0
1793	Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Annals of the Rheumatic Diseases, 2021, 80, 884-890.	0.5	28
1794	Characteristics of patients with psoriatic arthritis treated with ustekinumab. Evidence from real-life clinical practice. Meditsinskiy Sovet, 2021, , 274-283.	0.1	0
1795	Anti-cyclic-citrullinated-protein-antibodies in psoriatic arthritis patients: how autoimmune dysregulation could affect clinical characteristics, retention rate of methotrexate monotherapy and first line biotechnological drug survival. A single center retrospective study Therapeutic Advances in Chronic Disease. 2021, 12, 204062232098672.	1.1	3
1796	The Delay of Diagnosis in Spondyloarthropathy Patients in a Tertiary Hospital in Saudi Arabia. Cureus, 2021, 13, e12629.	0.2	3
1797	Effectiveness of web-based and mobile health interventions designed to enhance adherence to physical activity for people with inflammatory arthritis: a systematic review. Rheumatology Advances in Practice, 2021, 5, rkab016.	0.3	6
1798	ls central sensitization an important determinant of functional disability in patients with chronic inflammatory arthritides?. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2199325.	1.2	18
1799	Latest Research in Nail Psoriasis. Updates in Clinical Dermatology, 2021, , 129-170.	0.1	2
1800	Evaluating the Persian versions of two psoriatic arthritis screening questionnaires early arthritis for psoriatic patients questionnaire (EARP) and psoriasis epidemiology screening tool (PEST) in Iranian psoriatic patients. Turkish Journal of Medical Sciences, 2021, 51, 159-166.	0.4	2
1801	GM-CSF Expression and Macrophage Polarization in Joints of Undifferentiated Arthritis Patients Evolving to Rheumatoid Arthritis or Psoriatic Arthritis. Frontiers in Immunology, 2020, 11, 613975.	2.2	17

#	Article	IF	CITATIONS
1802	Quality of life and its relation to periarticular bone changes in psoriatic patients with or without joint involvement. Clinical Rheumatology, 2021, 40, 3175-3183.	1.0	0
1803	Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. RMD Open, 2021, 7, e001519.	1.8	32
1804	Diagnostic Delay in Psoriatic Arthritis: A Population-based Study. Journal of Rheumatology, 2021, 48, 1410-1416.	1.0	25
1805	Health-related quality of life in early psoriatic arthritis compared with early rheumatoid arthritis and a general population. Seminars in Arthritis and Rheumatism, 2021, 51, 246-252.	1.6	10
1806	Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. Nature Reviews Rheumatology, 2021, 17, 238-243.	3.5	23
1807	Enthesitis is a clue to the diagnosis of spondyloarthritis, focus on psoriatic arthritis. Sovremennaya Revmatologiya, 2021, 15, 79-86.	0.1	0
1808	Adipokines, Cardiovascular Risk, and Therapeutic Management in Obesity and Psoriatic Arthritis. Frontiers in Immunology, 2020, 11, 590749.	2.2	13
1809	Incidence of and Risk Factors for Heart Failure in Patients With Psoriatic Disease: A Cohort Study. Arthritis Care and Research, 2022, 74, 1244-1253.	1.5	9
1810	Prevalence of Type 2 and Type 1 Diabetes in Psoriatic Arthritis. Journal of Clinical Rheumatology, 2021, Publish Ahead of Print, e324-e329.	0.5	2
1811	JAK inhibition for treatment of psoriatic arthritis in Down syndrome. Rheumatology, 2021, 60, e309-e311.	0.9	12
1812	Biologic therapies for the treatment of psoriatic arthritis. Journal of the Korean Medical Association, 2021, 64, 124-129.	0.1	0
1813	Comparative Efficacy of Different Triage Methods for Psoriatic Arthritis: Results From a Prospective Study in a Rapid Access Clinic. Arthritis Care and Research, 2022, 74, 1254-1262.	1.5	4
1814	Psoriatic arthritis associated with peliosis hepatis: characteristics and therapeutic management. Clinical Rheumatology, 2021, 40, 3827-3832.	1.0	1
1815	Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis—A Retrospective Database Study. Rheumatology and Therapy, 2021, 8, 483-497.	1.1	14
1816	Validation of Sinhala version of Psoriasis Epidemiology Screening Tool. Clinical Rheumatology, 2021, 40, 3127-3134.	1.0	1
1817	Psoriatic arthritis in patients with psoriasis: A clinicalâ€epidemiological study at a dermatology center in western Mexico. Australasian Journal of Dermatology, 2021, 62, e366-e372.	0.4	1
1818	Malignancy in psoriatic disease: Results from prospective longitudinal cohorts. Seminars in Arthritis and Rheumatism, 2021, 51, 144-149.	1.6	10
1819	Does current evidence on disease-modifying antirheumatic drugs for psoriatic arthritis reinforce an effect on radiographic progression? Results from a systematic review and meta-analysis. Clinical Rheumatology, 2021, 40, 3499-3510.	1.0	1

#	Article	IF	CITATIONS
1820	Psoriatic Arthritis Quality of Life Questionnaire: translation, cultural adaptation and validation into Brazilian Portuguese language. Advances in Rheumatology, 2021, 61, 13.	0.8	4
1821	CaracterÃsticas epidemiológicas y eventos adversos de los pacientes con artritis psoriásica en tratamiento con terapias biológicas en Galicia. ReumatologÃa ClÃnica, 2021, 17, 150-154.	0.2	0
1822	Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis—study protocol for the MONITOR-PsA study, a trials within cohorts study design. Trials, 2021, 22, 185.	0.7	5
1823	Proteinase-Mediated Macrophage Signaling in Psoriatic Arthritis. Frontiers in Immunology, 2020, 11, 629726.	2.2	8
1824	Psoriatic arthritis: the role of the nonphysician clinician in the diagnosis and treatment of patients with psoriasis. Drugs and Therapy Perspectives, 2021, 37, 162-174.	0.3	1
1825	Multispectral optoacoustic tomography might be a helpful tool for noninvasive early diagnosis of psoriatic arthritis. Photoacoustics, 2021, 21, 100225.	4.4	9
1826	Risk Factors for Progression from Subclinical to Clinical Phase of Psoriatic Arthritis: A Case–Control Study. Rheumatology and Therapy, 2021, 8, 585-597.	1.1	5
1827	ls family history a predictor of response to tumour necrosis factor inhibitors in spondyloarthritis? A Swedish nationwide cohort study. Scandinavian Journal of Rheumatology, 2022, 51, 10-20.	0.6	0
1828	Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study. Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 47-55.	0.2	6
1829	Composite Measures for Routine Clinical Practice in Psoriatic Arthritis: Testing of Shortened Versions in a UK Multicenter Study. Journal of Rheumatology, 2021, , jrheum.201675.	1.0	3
1830	Comparison of Composite Measure Remission Targets in Psoriatic Arthritis. Journal of Rheumatology, 2021, 48, 1272-1278.	1.0	2
1831	Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib. Arthritis Research and Therapy, 2021, 23, 94.	1.6	9
1832	Ultrasound, magnetic resonance imaging and radiography of the finger joints in psoriatic arthritis patients. Rheumatology, 2022, 61, 563-571.	0.9	4
1833	Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nature Reviews Rheumatology, 2021, 17, 257-269.	3.5	52
1834	Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study. Journal of Rheumatology, 2021, , jrheum.201674.	1.0	9
1835	Navigating the diverse immune landscapes of psoriatic arthritis. Seminars in Immunopathology, 2021, 43, 279-290.	2.8	7
1837	Epidemiological characteristics and adverse events of patients with psoriatic arthritis undergoing treatment with biological therapies in Galicia. ReumatologÃa ClÃnica (English Edition), 2021, 17, 150-154.	0.2	0
1838	The burden of psoriatic arthritis in the biologics era: data from the Belgian Epidemiological Psoriatic Arthritis Study. Rheumatology, 2021, 60, 5677-5685.	0.9	10

#	Article	IF	CITATIONS
1839	Assessment of enthesopathy in patients with acne vulgaris: A case ontrolled trial. Journal of Cosmetic Dermatology, 2021, 20, 3552-3562.	0.8	0
1840	Insights into the pathogenesis of psoriatic arthritis from genetic studies. Seminars in Immunopathology, 2021, 43, 221-234.	2.8	9
1841	Differential diagnostic value of rheumatic symptoms in patients with Whipple's disease. Scientific Reports, 2021, 11, 5980.	1.6	10
1842	Suspecting and Diagnosing the Patient with Spondyloarthritis and What to Expect from Therapy. Medical Clinics of North America, 2021, 105, 325-339.	1.1	3
1843	The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial. Clinical Rheumatology, 2021, 40, 3667-3677.	1.0	3
1844	Mild cognitive impairment in psoriatic arthritis. Medicine (United States), 2021, 100, e24833.	0.4	9
1845	Dactylitis: Good for diagnosis, bad for treatment. Seminars in Arthritis and Rheumatism, 2022, 52, 151817.	1.6	0
1847	Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis. Medicine (United States), 2021, 100, e25223.	0.4	7
1848	Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. New England Journal of Medicine, 2021, 384, 1227-1239.	13.9	143
1849	Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. Rheumatology, 2021, 60, 5337-5350.	0.9	18
1850	Enthesis lesions are associated with Xâ€ray progression in psoriatic arthritis. International Journal of Rheumatic Diseases, 2021, 24, 828-833.	0.9	11
1851	Clinical significance of spondyloarthritis-attended enthesites: from pathophysiology to treatment (review). Bolʹ, Sustavy, PozvonoÄnik, 2021, 11, 17-27.	0.1	0
1852	Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study. Rheumatology and Therapy, 2021, 8, 903-919.	1.1	41
1853	Artritis psoriÃisica. Medicine, 2021, 13, 1623-1634.	0.0	0
1854	Different Chronic Disorders That Fall within the Term Juvenile Idiopathic Arthritis. Life, 2021, 11, 398.	1.1	4
1855	High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry. Clinical Rheumatology, 2021, 40, 3659-3665.	1.0	2
1856	The Molecular Pathophysiology of Psoriatic Arthritis—The Complex Interplay Between Genetic Predisposition, Epigenetics Factors, and the Microbiome. Frontiers in Molecular Biosciences, 2021, 8, 662047.	1.6	29
1857	Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice. Journal of Rheumatology, 2021, 48, 1552-1558.	1.0	3

#	Article	IF	CITATIONS
1858	Synovial Immunohistological Biomarkers of the Classification of Undifferentiated Arthritis Evolving to Rheumatoid or Psoriatic Arthritis. Frontiers in Medicine, 2021, 8, 656667.	1.2	8
1859	The association between IL17, fatigue and quality of life in psoriatic arthritis patients. Expert Review of Clinical Immunology, 2021, 17, 539-544.	1.3	4
1860	Secukinumab como tratamiento biológico en la artritis psoriásica en práctica clÃnica real. ReumatologÃa ClÃnica, 2021, 17, 203-206.	0.2	8
1861	Do tender joints in active psoriatic arthritis reflect inflammation assessed by ultrasound and magnetic resonance imaging?. Rheumatology, 2022, 61, 723-733.	0.9	10
1862	Association between syndesmophyte and metabolic syndrome in patients with psoriatic arthritis or ankylosing spondylitis: a cross-sectional study. BMC Musculoskeletal Disorders, 2021, 22, 367.	0.8	3
1863	Comparison of Behavioral Risk Factors and Cardiometabolic Comorbidities of Psoriatic Arthritis and Psoriasis: A Case–Control Study in Chinese Patients. Therapeutics and Clinical Risk Management, 2021, Volume 17, 397-404.	0.9	3
1865	Tissueâ€Resident Memory CD8+ T Cells From Skin Differentiate Psoriatic Arthritis From Psoriasis. Arthritis and Rheumatology, 2021, 73, 1220-1232.	2.9	40
1866	Disease activity indices in psoriatic arthritis: current and evolving concepts. Clinical Rheumatology, 2021, 40, 4427-4435.	1.0	9
1867	Large-scale plasma-metabolome analysis identifies potential biomarkers of psoriasis and its clinical subtypes. Journal of Dermatological Science, 2021, 102, 78-84.	1.0	15
1868	Proton Pump Inhibitor and Tacrolimus Uses are Associated With Hypomagnesemia in Connective Tissue Disease: a Potential Link With Renal Dysfunction and Recurrent Infection. Frontiers in Pharmacology, 2021, 12, 616719.	1.6	4
1869	Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study. Frontiers in Medicine, 2021, 8, 679009.	1.2	27
1870	Identification of a distinct lipidomic profile in the osteoarthritic synovial membrane by mass spectrometry imaging. Osteoarthritis and Cartilage, 2021, 29, 750-761.	0.6	15
1871	Effect of interleukin-17A inhibitor in Japanese patients with psoriatic arthritis compared with tumor necrosis factor-alpha inhibitor. Journal of Orthopaedic Surgery, 2021, 29, 230949902110122.	0.4	2
1872	Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Annals of the Rheumatic Diseases, 2021, 80, 1147-1157.	0.5	43
1873	JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials. Expert Review of Clinical Immunology, 2021, 17, 701-715.	1.3	21
1874	The relationship between obesity, cardiometabolic disorders and disease activity in psoriatic arthritis patients: data from the Russian register. Terapevticheskii Arkhiv, 2021, 93, .	0.2	3
1875	Effectiveness of self-management interventions in inflammatory arthritis: a systematic review informing the 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. RMD Open, 2021, 7, e001647.	1.8	21
1876	Medication adherence and persistence of psoriatic arthritis patients treated with biological therapy in a specialty pharmacy in Brazil: a prospective observational study. Pharmacy Practice, 2021, 19, 2312.	0.8	5

#	ARTICLE	IF	CITATIONS
1877	Psoriatic arthritis. Journal of Dermatology, 2021, 48, 741-749.	0.6	13
1878	Prevalence of psoriatic arthritis among patients with plaque psoriasis: a Brazilian retrospective study. Sao Paulo Medical Journal, 2021, 139, 476-480.	0.4	4
1879	Associations of ultrasound-based inflammation patterns with peripheral innate lymphoid cell populations, serum cytokines/chemokines, and treatment response to methotrexate in rheumatoid arthritis and spondyloarthritis. PLoS ONE, 2021, 16, e0252116.	1.1	7
1880	Measuring Physical Function in Psoriatic Arthritis: Comparing the Multidimensional Health Assessment Questionnaire to the Health Assessment Questionnaire–Disability Index. Journal of Rheumatology, 2021, 48, jrheum.200927.	1.0	1
1881	The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register. BMC Rheumatology, 2021, 5, 19.	0.6	2
1882	Magnetic Resonance Imaging evidence of Inflammation at Interphalangeal joint of Thumb — A distinct entity in psoriatic arthritis. International Journal of Rheumatic Diseases, 2021, 24, 1467-1472.	0.9	1
1883	Growth factors: Do they play a role in entheseal involvement in psoriatic arthritis and undifferentiated spondyloarthritis patients?. ReumatologÃa ClÃnica, 2021, 17, 369-370.	0.2	2
1884	Long-term Outcomes and Prognosis in New-Onset Psoriasis. JAMA Dermatology, 2021, 157, 684.	2.0	18
1885	Pregnancy in women with psoriatic arthritis: A systematic literature review of disease activity and adverse pregnancy outcomes. Seminars in Arthritis and Rheumatism, 2021, 51, 530-538.	1.6	11
1886	Ultrasound Doppler enthesitis shows sensitivity to change after biological therapy in spondyloarthritis and psoriatic arthritis patients. Scandinavian Journal of Rheumatology, 2021, , 1-9.	0.6	1
1887	Real-life efficacy of guselkumab in patients with early psoriatic arthritis. Rheumatology, 2022, 61, 1217-1221.	0.9	15
1888	Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. Annals of the Rheumatic Diseases, 2021, 80, 1419-1428.	0.5	17
1889	Clinical and laboratory characteristics of psoriatic arthritis in a cohort of Egyptian patients. Egyptian Rheumatologist, 2021, 43, 229-234.	0.5	3
1890	Axial Psoriatic Disease: Clinical and Imaging Assessment of an Underdiagnosed Condition. Journal of Clinical Medicine, 2021, 10, 2845.	1.0	10
1891	The epidemiology of psoriatic arthritis: A literature review. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101692.	1.4	44
1892	Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naÃ⁻ve patients. Rheumatology, 2022, 61, 1035-1043.	0.9	6
1893	Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Annals of the Rheumatic Diseases, 2022, 81, 68-73.	0.5	53
1894	Identification and Evaluation of Serum Protein BiomarkersÂThat Differentiate Psoriatic Arthritis From Rheumatoid Arthritis. Arthritis and Rheumatology, 2022, 74, 81-91.	2.9	9

#	Article	IF	CITATIONS
1895	Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Annals of the Rheumatic Diseases, 2021, 80, 1330-1338.	0.5	503
1896	Magnetic resonance imaging (MRI) evidence of sacroiliitis in skin psoriasis patients: Relation to disease severity. Egyptian Rheumatologist, 2021, 43, 267-269.	0.5	1
1897	Growth factors: Do they play a role in entheseal involvement in psoriatic arthritis and undifferentiated spondyloarthritis patients?. ReumatologÃa ClÃnica (English Edition), 2021, 17, 369-370.	0.2	0
1898	The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2021, 51, 547-552.	1.6	11
1899	Unmet needs in psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101693.	1.4	11
1900	In Patients with Early Peripheral Psoriatic Arthritis Baseline C-Reactive Protein, Pain and Ultrasound-Detected Synovitis Predict Subsequent Treatment with ts/bDMARDs. A Retrospective Analysis. Journal of Clinical Medicine, 2021, 10, 2834.	1.0	2
1901	Performance of a Handheld Ultrasound Device to Assess Articular and Periarticular Pathologies in Patients with Inflammatory Arthritis. Diagnostics, 2021, 11, 1139.	1.3	11
1902	Clinical, laboratory, and genetic markers for the development or presence of psoriatic arthritis in psoriasis patients: a systematic review. Arthritis Research and Therapy, 2021, 23, 168.	1.6	22
1903	Diagnosis, classification, and assessment in psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101669.	1.4	10
1904	Imaging in psoriatic arthritis: Status and recent advances. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101690.	1.4	7
1905	Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease—results of the Immune Metabolic Associations in Psoriatic Arthritis study. Rheumatology, 2022, 61, 1026-1034.	0.9	15
1906	Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study. Clinical Rheumatology, 2021, 40, 4569-4580.	1.0	16
1907	Psoriatic Dactylitis: Current Perspectives and New Insights in Ultrasonography and Magnetic Resonance Imaging. Journal of Clinical Medicine, 2021, 10, 2604.	1.0	14
1908	Younger age of onset and uveitis associated with HLA-B27 and delayed diagnosis in Thai patients with axial spondyloarthritis. Scientific Reports, 2021, 11, 13536.	1.6	4
1909	Psoriatic arthritis in Africa. Clinical Rheumatology, 2021, 40, 3411-3418.	1.0	1
1910	Psoriatic disease is associated with systemic inflammation, endothelial activation,Âand altered haemostatic function. Scientific Reports, 2021, 11, 13043.	1.6	11
1911	The "Climb―Towards Minimal Disease Activity in Psoriatic Arthritis. Rheumatology and Therapy, 2021, 8, 1443-1450.	1.1	9
1912	From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases. Frontiers in Genetics, 2021, 12, 685280.	1.1	16

#	Article	IF	CITATIONS
1913	Hypochondriasis and Personality Traits of Patients with Chronic Plaque Psoriasis. Dermatology, 2022, 238, 276-282.	0.9	1
1914	Serum trough levels of adalimumab correlate inversely with disease activity in patients with inflammatory arthritis. Joint Bone Spine, 2021, 88, 105193.	0.8	0
1915	Fibromyalgia influences health-related quality of life and disease activity in psoriatic arthritis. Rheumatology International, 2022, 42, 511-517.	1.5	5
1917	Elevated serum Dickkopf-1 is a biomarker for bone erosion in patients with psoriatic arthritis. Chinese Medical Journal, 2021, 134, 2583-2588.	0.9	11
1918	Entheseal involvement in a group of psoriatic arthritis patients: An ultrasonographic study. Experimental and Therapeutic Medicine, 2021, 22, 1044.	0.8	1
1919	HLA Allele Prevalence in Disease-Modifying Antirheumatic Drugs-Responsive Enthesitis and/or Arthritis Not Fulfilling ASAS Criteria: Comparison with Psoriatic and Undifferentiated Spondyloarthritis. Journal of Clinical Medicine, 2021, 10, 3006.	1.0	1
1920	The Genetic Contribution to Drug Response in Spondyloarthritis: A Systematic Literature Review. Frontiers in Genetics, 2021, 12, 703911.	1.1	7
1921	Differences in oxylipin profile in psoriasis versus psoriatic arthritis. Arthritis Research and Therapy, 2021, 23, 200.	1.6	12
1922	Factors Associated with Health-Related Quality of Life in Psoriatic Arthritis Patients: A Longitudinal Analysis. Rheumatology and Therapy, 2021, 8, 1341-1354.	1.1	4
1923	Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. RMD Open, 2021, 7, e001600.	1.8	18
1924	Role of ultrasound for assessment of psoriatic arthritis patients with fibromyalgia. Annals of the Rheumatic Diseases, 2021, 80, 1553-1558.	0.5	13
1925	Ultrasonographic and resistance index evaluation of nails in psoriatic arthritis, psoriasis, and control groups: a cross-sectional study. Advances in Rheumatology, 2021, 61, 48.	0.8	11
1926	MicroRNAs in Axial Spondylarthritis: an Overview of the Recent Progresses in the Field with a Focus on Ankylosing Spondylitis and Psoriatic Arthritis. Current Rheumatology Reports, 2021, 23, 59.	2.1	8
1927	Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderateâ€toâ€severe plaque psoriasis: results from EXCEED, a randomized, doubleâ€blind headâ€toâ€head monotherapy study. British Journal of Dermatology, 2021, 185, 1124-1134.	1.4	21
1928	Engagement process for patients with spondyloarthritis: PANLAR early SpA clinics project — centers of excellence. Clinical Rheumatology, 2021, 40, 4759-4766.	1.0	2
1929	Gender-related differences in disease activity and clinical features in patients with peripheral psoriatic arthritis: A multi-center study. Joint Bone Spine, 2021, 88, 105177.	0.8	28
1930	Interval between symptom onset and diagnosis among patients with autoimmune rheumatic diseases in a multiâ€ethnic Asian population. International Journal of Rheumatic Diseases, 2021, 24, 1061-1070.	0.9	8
1931	Ex vivo mass cytometry analysis reveals a profound myeloid proinflammatory signature in psoriatic arthritis synovial fluid. Annals of the Rheumatic Diseases, 2021, 80, 1559-1567.	0.5	16

#	Article	IF	CITATIONS
1932	The prevalence of comorbid and concomitant diseases in psoriatic arthritis patients, data from Russian register. Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 275-281.	0.2	2
1933	Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis. Arthritis Research and Therapy, 2021, 23, 190.	1.6	13
1934	Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Annals of the Rheumatic Diseases, 2022, 81, 74-79.	0.5	55
1935	Does Disease Activity Influence the Levels of Uric Acid in Psoriatic Arthritis?. Open Rheumatology Journal, 2021, 15, 57-64.	0.1	2
1936	Circulating Mir-140 and leptin improve the accuracy of the differential diagnosis between psoriatic arthritis and rheumatoid arthritis: a case-control study. Translational Research, 2022, 239, 18-34.	2.2	13
1937	Axial involvement in psoriatic arthritis: An update for rheumatologists. Seminars in Arthritis and Rheumatism, 2021, 51, 880-887.	1.6	48
1938	The Epidemiology of Psoriatic Arthritis Over Five Decades: A Populationâ€Based Study. Arthritis and Rheumatology, 2021, 73, 1878-1885.	2.9	25
1939	Absenteeism and Presenteeism in Rheumatoid Arthritis, Axial Spondyloarthritis, and Psoriatic Arthritis: Relationship with Fatigue and Clinical Parameters. Ankara ÉÄŸitim Ve AraÅŸtırma Hastanesi Tıp Dergisi, 2021, 54, 313-320.	0.1	0
1940	Psoriatic arthritis. Nature Reviews Disease Primers, 2021, 7, 59.	18.1	113
1941	Identification of proteins associated with development of psoriatic arthritis in peripheral blood mononuclear cells: a quantitative iTRAQ-based proteomics study. Journal of Translational Medicine, 2021, 19, 331.	1.8	8
1942	Outcome measures used in psoriatic arthritis registries and cohorts: A systematic literature review of 27 registries or 16,183 patients. Seminars in Arthritis and Rheumatism, 2021, 51, 888-894.	1.6	7
1943	Inclusion of Synovial Tissue–Derived Characteristics in a Nomogram for the Prediction of Treatment Response in Treatmentâ€Naive Rheumatoid Arthritis Patients. Arthritis and Rheumatology, 2021, 73, 1601-1613.	2.9	22
1944	Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. Pain, 2022, 163, 1206-1214.	2.0	40
1945	Impact of obesity on quality of life, psychological status, and disease activity in psoriatic arthritis: a multiâ€ʿcenter study. Rheumatology International, 2022, 42, 659-668.	1.5	8
1946	Depression and Endothelial Dysfunction in Psoriatic Arthritis: Is There Any Possible Relationship?. Frontiers in Medicine, 2021, 8, 669397.	1.2	0
1947	Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Doubleâ€Blind Withdrawal Study. Arthritis and Rheumatology, 2021, 73, 1663-1672.	2.9	13
1948	Classification Criteria for Spondyloarthritis/HLA-B27-Associated Anterior Uveitis. American Journal of Ophthalmology, 2021, 228, 117-125.	1.7	22
1950	Unveiling axial involvement in psoriatic arthritis: An ancillary analysis of the ASAS-perSpA study. Seminars in Arthritis and Rheumatism, 2021, 51, 766-774.	1.6	15

#	Article	IF	CITATIONS
1951	Enthesitis in Psoriatic Arthritis, the Sonographic Perspective. Current Rheumatology Reports, 2021, 23, 75.	2.1	9
1952	CD4+LAG-3+ T cells are decreased in active psoriatic arthritis patients and their restoration <i>in vitro</i> is mediated by TNF inhibitors. Clinical and Experimental Immunology, 2021, 206, 173-183.	1.1	5
1953	Long-term effectiveness and drug survival of golimumab in patients affected by psoriatic arthritis with cutaneous involvement. Clinical Rheumatology, 2021, , 1.	1.0	3
1954	Role of diagnostic imaging in psoriatic arthritis: how, when, and why. Insights Into Imaging, 2021, 12, 121.	1.6	11
1955	Anti-Citrullinated Protein Antibodies in Patients with Psoriatic Arthritis. Rheumatology, 2021, , .	0.9	1
1956	Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study. Clinical Rheumatology, 2022, 41, 85-94.	1.0	4
1957	Psoriatic arthritis—What we know now?. Dermatological Reviews, 2021, 2, 229.	0.3	0
1958	Differentiating Psoriatic Arthritis from Osteoarthritis and Rheumatoid Arthritis: A Narrative Review and Guide for Advanced Practice Providers. Rheumatology and Therapy, 2021, 8, 1493-1517.	1.1	13
1959	Realâ€World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study. ACR Open Rheumatology, 2021, , .	0.9	5
1960	Novel application of optical coherence tomography and capillaroscopy in psoriatic arthritis in relationship to psoriasis and hand osteoarthritis. Rheumatology Advances in Practice, 2021, 5, rkab065.	0.3	5
1961	Adult-onset Still's disease or systemic-onset juvenile idiopathic arthritis and spondyloarthritis: overlapping syndrome or phenotype shift?. Rheumatology, 2022, 61, 2535-2547.	0.9	10
1963	Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions: results of the cross-sectional ASAS-COMOSPA study. RMD Open, 2021, 7, e001752.	1.8	11
1964	Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials. Clinical Rheumatology, 2022, 41, 499-511.	1.0	3
1966	JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis. Autoimmunity Reviews, 2021, 20, 102902.	2.5	24
1967	Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis. Rheumatology and Therapy, 2021, 8, 1519-1534.	1.1	42
1968	Incidence, sociodemographic factors and treatment penetration of rheumatoid arthritis and psoriatic arthritis in Norway. Seminars in Arthritis and Rheumatism, 2021, 51, 1081-1088.	1.6	10
1969	Kinase activity profiling reveals contribution of G-protein signaling modulator 2 deficiency to impaired regulatory T cell migration in rheumatoid arthritis. Journal of Autoimmunity, 2021, 124, 102726.	3.0	13
1970	Health-Related Quality of Life in Psoriatic Arthritis: Findings and Implications. Value in Health Regional Issues, 2021, 26, 135-141.	0.5	8

#	Article	IF	CITATIONS
1971	Comparative analysis between ankylosing spondylitis and axial psoriatic arthritis patients. Egyptian Rheumatologist, 2022, 44, 25-29.	0.5	5
1972	Ustekinumab-induced chronic lymphocytic leukemia in aÂpatient with psoriatic arthritis. Reumatologia, 2021, 59, 58-61.	0.5	2
1973	Association of C-reactive protein and non-steroidal anti-inflammatory drugs with cardiovascular events in patients with psoriatic arthritis: a time-dependent Cox regression analysis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110277.	1.2	8
1974	Multimodal imaging of psoriatic arthritis triggered by Chikungunya fever. International Journal of Case Reports and Images, 2021, 12, 1-7.	0.0	0
1975	Effect of significant weight loss on disease activity: reason to implement this non-pharmaceutical intervention in daily clinical practice. RMD Open, 2021, 7, e001498.	1.8	14
1976	Psychometric validation of a patient-reported outcome questionnaire (Qualipsosex) assessing the impact of psoriasis and psoriatic arthritis on patient perception of sexuality. Medicine (United States), 2021, 100, e24168.	0.4	0
1977	Plasma heat shock protein 90 levels in patients with spondyloarthritis and their relation to structural changes: a cross-sectional study. Biomarkers in Medicine, 2021, 15, 5-13.	0.6	3
1978	Prevalence of Nonradiographic Sacroiliitis in Patients With Psoriatic Arthritis: A Real-life Observational Study. Journal of Rheumatology, 2021, 48, 1014-1021.	1.0	5
1979	Distribution of comorbidities in spondyloarthritis with regard to the phenotype and psoriasis: data from the ASAS-COMOSPA study. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110452.	1.2	7
1980	Assessment of Widespread and Extraarticular Pain in Psoriatic Arthritis: A Case-control Study. Journal of Rheumatology, 2021, 48, 1405-1409.	1.0	3
1981	Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. Turkish Journal of Medical Sciences, 2021, 51, 1615-1623.	0.4	6
1984	Clinical Evaluation. , 2008, , 25-38.		1
1986	Epidemiology of Psoriasis and Psoriatic Arthritis. , 2016, , 27-38.		2
1988	Magnetic resonance imaging (MRI) of feet demonstrates subclinical inflammatory joint disease in cutaneous psoriasis patients without clinical arthritis. Clinical Rheumatology, 2018, 37, 383-388.	1.0	13
1989	Rapidly progressive destructive arthritis in psoriatic arthritis sine psoriasis: do bone resorption marker levels predict outcome of bone destruction in psoriatic arthritis?. Modern Rheumatology, 2011, 21, 106-108.	0.9	2
1990	Clinical features of psoriatic arthritis. , 2011, , 1183-1193.e2.		1
1992	Reactive Arthritis and Undifferentiated Spondyloarthritis. , 2013, , 1221-1231.		2
1993	Juvenile-Versus Adult-Onset Spondyloarthritis. Rheumatic Disease Clinics of North America, 2020, 46, 241-257.	0.8	11

# 1994	ARTICLE Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients. Seminars in Arthritis and Rheumatism, 2020, 50, 608-615.	IF 1.6	Citations 31
1996	Comorbidities, pain and fatigue in psoriatic arthritis, psoriasis and healthy controls: a clinical cohort study. Rheumatology, 2021, 60, 3289-3300.	0.9	13
1997	Sensitivity to change and clinical correlations of the novel DACtylitis glObal Sonographic (DACTOS) score in psoriatic arthritis. Rheumatology, 2021, 60, 4103-4111.	0.9	5
1998	Metabolic Syndrome, Disease Activity, and Adipokines in Patients With Newly Diagnosed Inflammatory Joint Diseases. Journal of Clinical Rheumatology, 2021, 27, e349-e356.	0.5	8
1999	Inflammatory and Noninflammatory Synovial Fluids Exhibit New and Distinct Tribological Endotypes. Journal of Biomechanical Engineering, 2020, 142, .	0.6	4
2000	Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices. RMD Open, 2020, 6, e001170.	1.8	20
2001	TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis. Journal of Clinical Investigation, 2020, 130, 1863-1878.	3.9	51
2002	Improving sensitivity of the connective tissue disease screening questionnaire: A comparative study of various scoring methods. Lupus, 2021, 30, 35-44.	0.8	3
2003	Difficult airway management of a patient with limited range of motion in the temporomandibular joint and cervical extension caused by psoriatic arthritis: a case report. JA Clinical Reports, 2020, 6, 44.	0.2	4
2004	Psoriatic arthritis. F1000Research, 2019, 8, 1665.	0.8	105
2005	High Frequency Ultrasonography of the Hand in Rheumatoid Arthritis, Psoriatic Arthritis, Gout and Osteoarthritis Patients. Current Health Sciences Journal, 2016, 42, 35-39.	0.2	6
2006	Downregulation of Immunoglobulin-Like Transcript-4 (ILT4) in Patients with Psoriatic Arthritis. PLoS ONE, 2014, 9, e92018.	1.1	9
2007	Moesin and Stress-Induced Phosphoprotein-1 Are Possible Sero-Diagnostic Markers of Psoriasis. PLoS ONE, 2014, 9, e101773.	1.1	19
2008	Divergent Gene Activation in Peripheral Blood and Tissues of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis following Infliximab Therapy. PLoS ONE, 2014, 9, e110657.	1.1	15
2009	A Comparison of Disease Burden in Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis. PLoS ONE, 2015, 10, e0123582.	1.1	94
2010	Smelling the Diagnosis: The Electronic Nose as Diagnostic Tool in Inflammatory Arthritis. A Case-Reference Study. PLoS ONE, 2016, 11, e0151715.	1.1	27
2011	Effect of Vitamin D on Peripheral Blood Mononuclear Cells from Patients with Psoriasis Vulgaris and Psoriatic Arthritis. PLoS ONE, 2016, 11, e0153094.	1.1	16
2012	Antibodies Directed against a Peptide Epitope of a Klebsiella pneumoniae-Derived Protein Are Present in Ankylosing Spondylitis. PLoS ONE, 2017, 12, e0171073.	1.1	14

#	Article	IF	CITATIONS
2013	C5a and C5aR are elevated in joints of rheumatoid and psoriatic arthritis patients, and C5aR blockade attenuates leukocyte migration to synovial fluid. PLoS ONE, 2017, 12, e0189017.	1.1	34
2014	Genetics in TNF-TNFR pathway: A complex network causing spondyloarthritis and conditioning response to anti-TNFI± therapy. PLoS ONE, 2018, 13, e0194693.	1.1	17
2015	A Study of Intima Media Thickness and Their Cardiovascular Risk Factors in Patients with Psoriatic Arthritis. Acta Medica (Hradec Kralove), 2009, 52, 107-116.	0.2	20
2016	Conceitos atuais e relevantes sobre artrite psoriásica. Revista Brasileira De Reumatologia, 2012, 52, 98-106.	0.8	16
2017	The prognostic value of clinical and anamnestic markers of psoriatic arthritis. Klinicheskaya Dermatologiya I Venerologiya, 2016, 15, 23.	0.0	4
2018	<i>KIF3A</i> and <i>IL-4</i> are disease-specific biomarkers for psoriatic arthritis susceptibility. Oncotarget, 2017, 8, 95401-95411.	0.8	12
2020	Serum levels of angiogenic cytokines in psoriatic arthritis and SAPHO syndrome. Polish Archives of Internal Medicine, 2013, 123, 297-302.	0.3	21
2021	Infliximab (Remicade) in the treatment of psoriatic arthritis. Therapeutics and Clinical Risk Management, 2006, 2, 389-400.	0.9	8
2022	Role of Protein Tyrosine Phosphatase (PTPN22) Gene [C1858T] Functional Variant in Genetic Susceptibility of Psoriatic Arthritis in Kuwaiti Arabs. Open Rheumatology Journal, 2020, 14, 15-21.	0.1	2
2023	Mobile Health Usage, Preferences, Barriers, and eHealth Literacy in Rheumatology: Patient Survey Study. JMIR MHealth and UHealth, 2020, 8, e19661.	1.8	121
2025	Standardizing the monitoring of outcome measures: imaging in psoriatic arthritis. International Journal of Clinical Rheumatology, 2011, 6, 77-86.	0.3	5
2026	The impact of different rheumatic diseases on health-related quality of life: a comparison with a selected sample of healthy individuals using SF-36 questionnaire, EQ-5D and SF-6D utility values. Acta Biomedica, 2019, 89, 541-557.	0.2	35
2027	Psoriasin: a novel marker linked obesity with psoriasis. Disease Markers, 2013, 34, 33-9.	0.6	12
2028	Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Health Technology Assessment, 2017, 21, 1-326.	1.3	21
2029	Evaluation of Hearing and Outer Hair Cell Function of Cochlea in Patients With Psoriatic Arthritis. Clinical and Experimental Otorhinolaryngology, 2015, 8, 183.	1.1	8
2030	Musculoskeletal Ultrasound in Monitoring Clinical Response to Treatment in Acute Symptomatic Psoriatic Dactylitis: Results from a Multicentre Prospective Observational Study. Journal of Clinical Medicine, 2020, 9, 3127.	1.0	6
2031	Psoriatic arthritis: A permanent new challenge for dermatologists (Review). Experimental and Therapeutic Medicine, 2020, 20, 47-51.	0.8	9
2032	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. Journal of Rheumatology, 2018, 94, 17-25.	1.0	10

	CHAIION		
#	Article	IF	CITATIONS
2033	Juvenile Idiopathic Arthritis: An Idea Whose Time Has Gone?. Journal of Rheumatology, 2019, 46, 124-126.	1.0	16
2034	Psoriatic arthritis. When the heterogeneity requires normality. Reumatismo, 2012, 64, 59-65.	0.4	3
2035	Epidemiology of psoriatic arthritis. Reumatismo, 2012, 64, 66-70.	0.4	42
2036	Classification and clinical assessment. Reumatismo, 2012, 64, 79-87.	0.4	1
2037	Biomarkers and prognostic stratification in psoriatic arthritis. Reumatismo, 2012, 64, 88-98.	0.4	7
2038	Prevalence of metabolic syndrome in south Indian patients with psoriasis vulgaris and the relation between disease severity and metabolic syndrome: A hospital-based case-control study. Indian Journal of Dermatology, 2012, 57, 353.	0.1	47
2039	Genetics of psoriasis and psoriatic arthritis. Indian Journal of Dermatology, 2010, 55, 151.	0.1	14
2040	Psoriatic arthritis as a distinct disease entity. Journal of Postgraduate Medicine, 2007, 53, 63-71.	0.2	38
2041	The pattern of psoriatic arthritis in Kashmir: A 6-year prospective study. North American Journal of Medical Sciences, 2015, 7, 356.	1.7	2
2042	Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatology Online Journal, 2016, 7, 471.	0.2	62
2043	Study of serum sclerostin levels in association to entheseal ultrasonography in Egyptian psoriatic arthritis patients. Egyptian Rheumatology and Rehabilitation, 2017, 44, 45-51.	0.2	3
2044	Reactive Arthritis: From Clinical Features to Pathogenesis. International Journal of Clinical Medicine, 2013, 04, 20-30.	0.1	1
2045	Specific features of axial involvement in psoriatic arthritis: data from real clinical practice. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 401-406.	0.2	5
2046	Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 480-488.	0.2	10
2047	Pathogenesis of psoriasis in the "omic―era. Part IV. Epidemiology, genetics, immunopathogenesis, clinical manifestation and treatment of psoriatic arthritis. Postepy Dermatologii I Alergologii, 2020, 37, 625-634.	0.4	8
2048	Rheumatological Findings in Patients with Breast Cancer. The Journal of Breast Health, 2020, 16, 55-60.	0.4	4
2049	Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with Psoriatic Arthritis. European Journal of Rheumatology, 2017, 4, 40-45.	1.3	23
2050	Real-life experience of using conventional disease-modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA). Retrospective analysis of the efficacy of methotrexate, sulfasalazine, and leflunomide in PsA in comparison to spondyloarthritides other than PsA and literature review of the use of conventional DMARDs in PsA. European lournal of Rheumatology, 2017, 4, 1-10.	1.3	11

#	Article	IF	CITATIONS
2051	Tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy. European Journal of Rheumatology, 2019, 6, 19-22.	1.3	5
2052	Are there any differences among psoriasis, psoriatic arthritis and rheumatoid arthritis in terms of metabolic syndrome and cardiovascular risk factors?. European Journal of Rheumatology, 2019, 6, 174-178.	1.3	12
2054	The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis. Clinics, 2013, 68, 1189-1196.	0.6	5
2055	Association of C-Reactive Protein (rs1205) Gene Polymorphism with Susceptibility to Psoriasis in South Indian Tamils. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, GC01-GC04.	0.8	4
2056	Ultrasound in Psoriatic Arthritis. , 2021, , 367-381.		0
2057	Nomogram for accurate and quantitative prediction of the risk of psoriatic arthritis in Chinese adult patients with moderate and severe plaque psoriasis. European Journal of Dermatology, 2021, 31, 499-507.	0.3	2
2058	Risk factors associated with osteoporosis and fracture in psoriatic arthritis. Chinese Medical Journal, 2021, Publish Ahead of Print, 2564-2572.	0.9	2
2059	Inflammatory Foot Involvement in Spondyloarthritis: From Tarsitis to Ankylosing Tarsitis. Frontiers in Medicine, 2021, 8, 730273.	1.2	3
2060	The role of tender and swollen joints for the assessment of inflammation in PsA using ultrasound. Rheumatology, 2022, 61, SI92-SI96.	0.9	2
2061	Inconsistencies of the Disease Activity Assessment Tools for Psoriatic Arthritis: Challenges to Rheumatologists. Joint Bone Spine, 2022, 89, 105296.	0.8	10
2062	Ultrasound Effectiveness of Steroid Injection for hand Psoriatic Dactylitis: Results from a Longitudinal Observational Study. Rheumatology and Therapy, 2021, 8, 1809-1826.	1.1	3
2063	Clinical Characteristics of Psoriatic Arthritis in Chinese Patients: A Cross-Sectional Study. Rheumatology and Therapy, 2021, 8, 1845-1857.	1.1	8
2064	The Effect of TNF-α Inhibitors on Nail Psoriasis and Psoriatic Arthritis—Real-World Data from Dermatology Practice. Journal of Personalized Medicine, 2021, 11, 1083.	1.1	0
2065	Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1. Rheumatology and Therapy, 2021, 8, 1789-1808.	1.1	14
2066	Psychological Stress and Salivary Cortisol Levels in Patients with Plaque Psoriasis. Journal of Personalized Medicine, 2021, 11, 1069.	1.1	4
2067	Diagnostic Criteria of Psoriatic Arthritis. , 2007, , 19-28.		0
2068	Psoriatic Arthropathy. , 2008, , 359-363.		0
2070	The Diagnosis. , 2008, , 291-1268.		0

#	Article	IF	CITATIONS
2071	Spondyloarthritis. , 2008, , 837-857.		1
2074	An Overview of Psoriasis. , 2008, , 1-25.		0
2075	Gelenkschmerzen und ihre Differenzialdiagnose. , 2009, , 81-169.		0
2076	Miscellaneous Disorders With Prominent Features Involving the Skin and the Joints. , 2009, , 39-51.		0
2077	Artritis psoriásica. SÃndrome SAPHO. , 2010, , 295-302.		0
2078	Psoriatic Arthritis Significantly Improved by Methotrexate. Nishinihon Journal of Dermatology, 2010, 72, 447-451.	0.0	1
2081	Psoriasis Vulgaris and Arthopathica. , 2011, , 325-348.		0
2082	Muskuloskelettale Erkrankungen und Autoimmunopathien. , 2011, , 877-966.		0
2086	Psoriatic Arthritis of TMJ Presenting as a First Articular Complaint in Psoriasis. Journal of Indian Academy of Oral Medicine and Radiology, 2011, 23, 245-247.	0.1	2
2088	Spondyloarthritiden. , 2012, , 59-101.		0
2089	Spondyloarthritis. , 2013, , 676-692.		1
2091	Clinical Manifestations and Diagnosis of Psoriatic Arthritis. Korean Journal of Medicine, 2013, 85, 250.	0.1	1
2092	Imaging Modalities in Rheumatic Diseases. , 2013, , 830-869.e6.		0
2093	Schwere Psoriasis – immer Biologics?*. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2013, , 6-11.	0.0	0
2096	Clinical Presentation of Sine Syndrome in Psoriatic Arthritis. , 2014, , 81-85.		0
2097	Spondyloarthritis: Psoriatic Arthritis. , 2014, , 1110-1115.		0
2098	Acute onset small joint affliction in ankylosing spondylitis: A red herring. International Journal of Case Reports and Images, 2014, 5, 576.	0.0	0
2099	Psoriatic Arthritis: Clinical Review and Update. , 2014, , 39-61.		0

#	Article	IF	CITATIONS
2100	Clinical Assessment of Spondyloarthritis. , 2014, , 3-7.		0
2101	Serological Evaluation of Anti-CCP, ANCA and ANA Autoantibodies in Patients with Psoriasis Vulgaris and Psoriatic Arthritis. Turkiye Klinikleri Journal of Medical Sciences, 2014, 34, 40-46.	0.1	0
2102	Anti-Saccharomyces cerevisiae antibodies and its relationship with radiological damage in ankylosing spondylitis. Egyptian Rheumatology and Rehabilitation, 2014, 41, 45-50.	0.2	0
2103	Features of Pain Syndrome and Psychoemotional State in Patients with Psoriatic Arthritis Depending on Whether They Have Symptoms of Autonomic Dysfunction. Bolʹ, Sustavy, PozvonoÄnik, 2014, .	0.1	0
2104	Clinical features of psoriatic arthritis. , 2015, , 989-997.		1
2106	Rheumatoid Arthritis and Related Disorders. , 2015, , 1-20.		0
2107	Inflammatory Arthropathy of the Knee. , 2015, , 39-49.		0
2108	Pied inflammatoire. , 2015, , 748-758.		1
2109	Clinical Patterns of Psoriatic Arthritis in Jordanian Patients with Psoriasis in a Single Center from Jordan. Journal of the Royal Medical Services, 2015, 22, 18-23.	0.0	0
2110	An Overview of Inflammatory Arthritis. , 2015, , 1-11.		0
2111	A case of temporomandibular joint ankylosis caused by psoriatic arthritis. Nihon Koku Geka Gakkai Zasshi, 2015, 61, 518-523.	0.0	1
2112	Bewegungsapparat. , 2015, , 101-144.		1
2113	Psoriasis-Arthritis. , 2015, , 1-6.		0
2114	Etiology and pathogenesis of psoriatic arthritis. , 2015, , 998-1007.		0
2115	Epidemiologic concepts and classification of rheumatic and musculoskeletal conditions. , 2015, , 1-8.		0
2116	Specific features of axial spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, in persons of different genders. Sovremennaya Revmatologiya, 2015, , 35.	0.1	0
2117	PALLIATIVE CARE IN SPONDYLOARTHRITIS: IS THERE A NEED FOR THIS?. Nauchno-Prakticheskaya Revmatologiya, 2015, , 220.	0.2	2
2118	Assessment of serum antimutated citrullinated vimentin antibodies in rheumatoid arthritis. Egyptian Rheumatology and Rehabilitation, 2015, 42, 62-67.	0.2	2

# 2119	ArticLe 乾癬性é−¢ç⁻€ç,Žã®3例. Orthopedics & Traumatology, 2016, 65, 599-602.	IF 0.0	Citations
2121	PROMs for Spondyloarthritis. , 2016, , 121-147.		0
2122	Comorbidities, Metabolic and Malignancy Risk Profile in Patients with Psoriasis. West Indian Medical Journal, 0, , .	0.4	0
2123	Melanocortin 1 receptor MC1R as a genetic factor in the development of psoriasis. Russian Journal of Skin and Venereal Diseases, 2016, 19, 173-177.	0.0	0
2124	Abordagem fisioterapêutica da dor crônica nas espondiloartropatias soronegativas. ConScientiae Saúde, 2016, 15, 161-166.	0.1	0
2125	Rheumatoid Arthritis and Related Disorders. , 2017, , 1525-1543.		0
2126	Evaluation of the Involvement of the Tempromandibular Joint in Patients with Psoriasis using Computed Tomography for Detection of Psoriatic Arthritis Changes. Iraqi Dental Journal, 2016, 38, 113.	0.1	0
2127	Nail manifestations in Hong Kong Chinese patients with psoriatic arthropathy (PsA). Hong Kong Bulletin on Rheumatic Diseases, 2016, 16, 48-53.	0.1	0
2129	Implementing Shared Decision Making In Clinical Practice: Outcomes of a New Shared Decision Making Aid for Chronic Inflammatory Arthritis Patients. Journal of Patient Care, 2017, 02, .	0.1	2
2130	Arthropathy in dermatology: A comprehensive review. Indian Dermatology Online Journal, 2017, 8, 79.	0.2	2
2131	Spondyloarthritiden. , 2017, , 41-73.		0
2132	Cambios radiográficos en el penacho de la falange distal de las manos en pacientes con psoriasis o artritis psoriásica. Revisión sistemática. Revista Facultad De Medicina, 2017, 65, 349-357.	0.0	0
2135	Psöriatik artrit hastalarında metabolik sendrom sıklığı. SdÜ SaĞlik Bİlİmlerİ Dergİsİ, 0, , .	0.1	0
2137	Spondyloarthrites. , 2018, , 471-488.		0
2139	Biological treatment of psoriatic arthritis. Vnitrni Lekarstvi, 2018, 64, 127-135.	0.1	1
2140	ENTHESITIS AND PSORIATIC ONYCHOPATHY AS A FACTOR FOR PREDICTION OF PSORIATIC ARTHRITIS IN PSORIASIS. Vestnik Dermatologii I Venerologii, 2018, 94, 38-50.	0.2	2
2141	PatologÃa de la aponeurosis plantar. EMC - PodologÃa, 2018, 20, 1-13.	0.1	0
2143	Juvenile Psoriatic Arthritis: A Report from the GRAPPA 2017 Annual Meeting. Journal of Rheumatology, 2018, 94, 11-16.	1.0	19

#	Article	IF	CITATIONS
2145	Apremilast: target synthetic drug for the treatment of psoriatic arthritis and psoriasis. Meditsinskiy Sovet, 2018, , 136-141.	0.1	0
2146	Gelenk- und Muskelschmerzen. Springer Reference Medizin, 2019, , 1-27.	0.0	0
2148	Concurrence of systemic lupus erythematosus and psoriatic arthritis: literature data and a case report. Sovremennaya Revmatologiya, 2018, 12, 123-128.	0.1	2
2150	Gelenk- und Muskelschmerzen. Springer Reference Medizin, 2019, , 347-373.	0.0	0
2151	Use of a multidimensional RAPID3 questionnaire to assess the achievement of remission and minimal disease activity in patients with early psoriatic arthritis treated according to Treat-to-target strategy. Nauchno-Prakticheskaya Revmatologiya, 2019, 56, 739-745.	0.2	0
2152	New opportunities in the treatment of psoriasis and psoriatic arthritis. Nauchno-Prakticheskaya Revmatologiya, 2019, 56, 722-726.	0.2	5
2153	Gelenkschmerzen und ihre Differenzialdiagnose. , 2019, , 105-211.		0
2154	Ultrasonography greatly improves the ability of clinicians to diagnose psoriatic arthritis. Journal of Medical Ultrasound, 2019, 27, 167.	0.2	1
2155	Psoriatic Arthritis: A Current Vision. , 2019, , 105-105.		0
2156	Psoriatic onychodystrophy: clinical manifestations (part 1). Vestnik Dermatologii I Venerologii, 2019, 94, 7-14.	0.2	4
2157	Recent recommendations on psoriatic arthritis treatment in accordance with 2018 American College of Rheumatology and National Psoriasis Foundation guidelines. Bolʹ, Sustavy, PozvonoÄnik, 2019, 9, 46-58.	0.1	0
2158	Quality of life in spondyloarthritis patients receiving biological therapy. Sovremennaya Revmatologiya, 2019, 13, 36-40.	0.1	1
2159	Detectability of the peripheral and axial manifestations of psoriatic arthritis in patients with psoriasis in dermatological practice. Sovremennaya Revmatologiya, 2019, 13, 48-54.	0.1	1
2161	The use of subcutaneous methotrexate from various manufacturers in real clinical practice: a comparative study. Alʹmanah KliniÄeskoj Mediciny, 2019, 47, 383-392.	0.2	2
2162	Clinical Assessment of Spondyloarthritis. , 2020, , 3-8.		0
2163	Comparative characteristics of early psoriatic arthritis with and without axial skeleton injury (a) Tj ETQq1 1 0.784 Revmatologiya, 2019, 57, 636-641.	314 rgBT 0.2	Overlock 10 6
2164	Psöriatik Artritli Hastaların Yaşam Kalitesinde Emosyonel Durumun Önemi. Sakarya Medical Journal, 0, ,	0.1	0
2165	Inflammatory Arthritis: Psoriatic Arthritis. , 2020, , 697-704.		0

#	Article	IF	CITATIONS
2166	Biological therapy safety in chronic inflammatory arthropathy patients. European Journal of Rheumatology, 2020, 7, 53-59.	1.3	0
2167	SAT0433â€TRIAL SIMULATION TO INFORM ENROLLMENT CRITERIA AND OUTCOME MEASURES FOR PRAGMATI TRIALS IN PsA. Annals of the Rheumatic Diseases, 2020, 79, 1173.2-1173.	С _{0.5}	0
2168	SAT0435â€SECUKINUMAB EFFICACY In PsA PATIENTS IS DEPENDENT ON PATIENTS' BODY MASS INDEX. An of the Rheumatic Diseases, 2020, 79, 1174-1174.	nals 0.5	2
2171	Assessment of serum levels of anti‑cyclic citrullinated peptide antibodies in patients with psoriatic arthritis: A cross‑sectional study in a Brazilian cohort. Biomedical Reports, 2020, 13, 1-1.	0.9	8
2172	Consensus-based recommendations on the diagnosis, referral and clinical management of patients with psoriatic arthritis. Rheumatology International, 2022, 42, 391-401.	1.5	5
2173	Spondyloarthritides. Emergency Medicine Clinics of North America, 2021, 40, 159-178.	0.5	2
2174	Influence of perceived barriers and facilitators for physical activity on physical activity levels in patients with rheumatoid arthritis or spondyloarthritis: a cross-sectional study of 150 patients. BMC Musculoskeletal Disorders, 2021, 22, 915.	0.8	10
2175	A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. Journal of Autoimmunity, 2021, 125, 102743.	3.0	45
2176	IL-22 increases the production of sFRP3 by FLS in inflammatory joint diseases. Brazilian Journal of Medical and Biological Research, 2020, 53, e9880.	0.7	3
2177	RHEUMATISCHE ERKRANKUNGEN. , 2020, , I-1-18-7.		0
2178	CD74 auto-antibodies display little clinical value in Chinese Han population with axial spondyloarthritis. Medicine (United States), 2020, 99, e23433.	0.4	6
2179	Comparing the Visual Analog Scale and the Numerical Rating Scale in Patient-reported Outcomes in Psoriatic Arthritis. Journal of Rheumatology, 2021, 48, 836-840.	1.0	5
2180	A Brazilian Cohort of Patients With Immuno-Mediated Chronic Inflammatory Diseases Infected by SARS-CoV-2 (ReumaCoV-Brasil Registry): Protocol for a Prospective, Observational Study. JMIR Research Protocols, 2020, 9, e24357.	0.5	13
2181	Cytokine status in patients with psoriasis. Ukrainian Journal of Dermatology Venerology Cosmetology, 2020, .	0.0	0
2182	Assessment of loneliness in patients with inflammatory arthritis. International Journal of Rheumatic Diseases, 2021, 24, 223-230.	0.9	4
2183	Program extracorporeal photophoresis in complex treatment of psoriatic arthritis. Vestnik of Russian Military Medical Academy, 2020, 22, 95-99.	0.1	0
2185	High Prevalence of Metabolic Syndrome in Patients With Psoriatic Arthritis From Northeastern Brazil. Journal of Clinical Rheumatology, 2021, 27, S186-S192.	0.5	3
2186	Serum Biomarkers of Inflammation and Turnover of Joint Cartilage Can Help Differentiate Psoriatic Arthritis (PsA) Patients from Osteoarthritis (OA) Patients. Diagnostics, 2021, 11, 52.	1.3	7

#	Article	IF	Citations
2187	Ultrasound detected synovitis, tenosynovitis and erosions in hand and wrist joints: aÂcomparative study between rheumatoid and psoriatic arthritis. Reumatologia, 2021, 59, 313-322.	0.5	1
2188	Pseudo NLP Joint Spam Classification Technique for Big Data Cluster. Computers, Materials and Continua, 2022, 71, 517-535.	1.5	9
2189	Patterns of dyslipidemia in young patients with seronegative spondyloarthropathies without cardiovascular diseases. Reumatologia, 2021, 59, 285-291.	0.5	3
2190	Rheumatoid Arthritis and Related Disorders. , 2020, , 1-20.		0
2191	Psoriatic Arthropathy. , 2020, , 293-310.		0
2192	Spondyloarthritis and related conditions. , 2020, , 4441-4456.		0
2193	Rheumatic Diseases. , 2020, , 222-260.		0
2194	ϴΫϴϿϫϴ;ϴϔϴ·ϴϔϴϷ;ϿͺϔϴϿϫϿϨϿ;ϿϿϿϿ·ϴϴͼϴϷ϶ϴϿ϶ϴϴ϶ϴϴ;ϴϿͼϴ;ϴͼϴ;ϴͼϴ;ϴͼϴ;ϴͼϴ;ϴͼϴ;ϴͼϴ;ϴͼ	П Ð.Ð ~ БE	ŀªÐðГÐÐÐ <mark>;€</mark>
2195	Value of ultrasound examination of the Leeds Enthesitis Index in assessment of disease activity in psoriatic arthritis. Rheumatica Acta Open Access, 2020, 4, 001-006.	0.0	0
2196	Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study. RMD Open, 2021, 7, e001728.	1.8	5
2197	Clinical and Social Aspects of Psoriatic Arthritis in Pediatrics. Voprosy Sovremennoi Pediatrii - Current Pediatrics, 2021, 20, 426-429.	0.1	0
2198	Clinical joints manifestations in patients with psoriatic arthritis on musculoskeletal ultrasound. Clinical Rheumatology, 2022, 41, 1211-1218.	1.0	2
2199	Ultrasound features of Achilles enthesitis in psoriatic arthritis: a systematic review. Rheumatology Advances in Practice, 2021, 5, ii19-ii34.	0.3	1
2200	Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort study. Rheumatology Advances in Practice, 2021, 5, rkab076.	0.3	4
2201	Successful treatment of psoriatic arthritis with apremilast in a mixed connective tissue disease patient. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 373-375.	0.8	0
2202	Biologic Agents in Psoriatic Arthritis. , 2007, , 97-110.		3
2203	Bewegungsapparat. , 2008, , 69-110.		0
2204	Effects of adalimumab therapy on musculoskeletal manifestations and health-related quality of life in patients with active psoriatic arthritis. Modern Rheumatology, 2013, 23, 529-537.	0.9	0

#	Article	IF	CITATIONS
2205	Manifestations of psoriatic arthritis in patients with psoriasis. Dermatologie Pro Praxi, 2020, 14, 142-146.	0.1	0
2206	Successful use of Netakimab in the treatment of psoriasis accompanied by the psoriatic onychodystrophy. Meditsinskiy Sovet, 2020, , 64-70.	0.1	3
2207	Psoriatic arthritis is associated with myocardial repolarization dysregulation as assessed by the QTc interval and the Tp-e/QTc ratio. Journal of Surgery and Medicine, 2020, 4, 887-890.	0.0	0
2208	Compromiso Axial en Artritis Psoriásica. Análisis de sus caracterÃstica en grupo de pacientes con diagnóstico temprano en Sudamérica Clobal Rheumatology, 0, , .	0.0	0
2210	Clinical comparison of early-onset psoriatic and non-psoriatic oligoarticular juvenile idiopathic arthritis. Clinical and Experimental Rheumatology, 2011, 29, 582-8.	0.4	22
2211	Heel pain due to psoriatic arthritis in a 50 year old recreational male athlete: case report. Journal of the Canadian Chiropractic Association, 2011, 55, 288-93.	0.2	0
2212	Anti-cyclic citrullinated peptide antibodies in psoriatic arthritiscross-sectional study and literature review. Journal of Medicine and Life, 2013, 6, 376-82.	0.4	18
2213	Which Psoriasis Patients Develop Psoriatic Arthritis?. Psoriasis Forum, 2010, 16, 17-25.	0.1	19
2214	Macrophage migration inhibitory factor (MIF) promoter polymorphisms (-794 CATT5-8 and -173 G>C): association with MIF and TNF1± in psoriatic arthritis. International Journal of Clinical and Experimental Medicine, 2014, 7, 2605-14.	1.3	17
2215	Cardiovascular risk in psoriatic arthritis - a cross-sectional study. Mædica, 2014, 9, 19-24.	0.4	4
2216	Diagnosing Psoriatic Arthritis from the Dermatologist's View. Journal of Lifestyle Medicine, 2013, 3, 85-90.	0.3	0
2217	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting. Journal of Clinical and Aesthetic Dermatology, 2015, 8, S4-S26.	0.1	1
2218	Psoriasis and Psoriatic Arthritis. Journal of Clinical and Aesthetic Dermatology, 2017, 10, S16-S25.	0.1	3
2219	Arthritis, Infectious Tenosynovitis, and Tendon Rupture in a Patient With Rheumatoid Arthritis and Psoriasis. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2015, 32, 31-35.	0.6	0
2220	Management of Psoriasis and Psoriatic Arthritis in a Multidisciplinary Rheumatology/Dermatology Clinic. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2015, 32, 14S-20S.	0.6	2
2222	Facing the Unseen - Metabolic Syndrome in Psoriatic Arthritis. Current Health Sciences Journal, 2020, 46, 280-284.	0.2	0
2225	Role of endothelial cell specific molecule-1 (endocan) and cardiac imaging in early detection of cardiac involvement in psoriatic patients with or without arthritis. Egyptian Rheumatologist, 2022, 44, 159-164.	0.5	1
2227	Obesity and Clinical Activity in Psoriatic Arthritis Patients Treated with Synthetic Disease-Modifying Antirheumatic Drugs. Clinical Medical Reviews and Reports, 2021, 3, 01-09.	0.1	0

#	Article	IF	Citations
2228	Autoimmune conditions in the World Trade Center general responder cohort: A nested caseâ€control and standardized incidence ratio analysis. American Journal of Industrial Medicine, 2022, 65, 117-131.	1.0	2
2229	Peripheral manifestations are major determinants of disease phenotype and outcome in new onset spondyloarthritis. Rheumatology, 2022, 61, 3279-3288.	0.9	13
2231	Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis. Advances in Rheumatology, 2021, 61, 69.	0.8	7
2232	Efficacy of tofacitinib in reduction of inflammation detected on MRI in patients with Psoriatic ArthritiS presenTing with axial involvement (PASTOR): protocol of a randomised, double-blind, placebo-controlled, multicentre trial. BMJ Open, 2021, 11, e048647.	0.8	8
2233	Copy Number Variation Analysis of IL22 and LCE3C in Different Subtypes of Psoriasis in a Chinese Han Population. Medical Science Monitor, 2021, 27, e934927.	0.5	3
2234	Performance of 4 methods for screening of latent tuberculosis infection in patients with chronic inflammatory arthritis under TNFα inhibitors: a 24-month prospective study. Advances in Rheumatology, 2021, 61, 71.	0.8	3
2235	Effect of psoriatic arthritis on the strength, proprioception, skill, coordination, and functional condition of the hand. International Journal of Rheumatic Diseases, 2022, 25, 47-55.	0.9	6
2237	Musculoskeletal pain in psoriasis – relation to inflammation and additional value of ultrasound in psoriatic arthritis classification. Rheumatology, 2021, , .	0.9	4
2238	Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population. Biologics: Targets and Therapy, 2021, Volume 15, 463-470.	3.0	5
2239	Relationship between iodineâ€enhanced dual energyâ€computed tomographic findings and ultrasonographic findings for psoriatic arthritis. Journal of Dermatology, 2021, , .	0.6	Ο
2240	Cardiovascular risk reclassification according to six cardiovascular risk algorithms and carotid ultrasound in psoriatic arthritis patients. Clinical Rheumatology, 2022, 41, 1413-1420.	1.0	5
2241	Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER): Protocol for a Longitudinal Observational Study. JMIR Research Protocols, 2021, 10, e31647.	0.5	3
2242	DNA Methylation Signature in Monozygotic Twins Discordant for Psoriatic Disease. Frontiers in Cell and Developmental Biology, 2021, 9, 778677.	1.8	6
2243	Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models. Scientific Reports, 2021, 11, 23335.	1.6	10
2244	ls a fat thumb another sign of psoriatic arthritis?. International Journal of Rheumatic Diseases, 2021, 24, 1447-1448.	0.9	0
2245	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Therapeutic Advances in Musculoskeletal Disease. 2021. 13. 1759720X2110579.	1.2	30
2246	Clinical effectiveness of symptomatic therapy compared with standard step-up care for the treatment of low-impact psoriatic oligoarthritis: the two-arm parallel group randomised POISE feasibility study. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2110576.	1.2	0
2247	Evaluation of cytokine gene expression in psoriasis. Postepy Dermatologii I Alergologii, 2021, 38, 858-863.	0.4	4

#	Article	IF	CITATIONS
2248	Ultrasound shows swollen joints are the better proxy for synovitis than tender joints in DMARD-naÃ ⁻ ve early psoriatic arthritis. Rheumatology Advances in Practice, 2021, 5, rkab086.	0.3	2
2249	Lumbar Canal Stenosis Caused by Spondylolisthesis and Intraspinal Canal Calcifications Associated with Psoriatic Arthritis: A Case Report. NMC Case Report Journal, 2021, 8, 793-798.	0.2	0
2250	Absence of metacarpophalangeal synovitis by high-resolution ultrasonography distinguishes psoriatic arthritis from rheumatoid arthritis – A cross-sectional study. Indian Journal of Rheumatology, 2021, 16, 415.	0.2	0
2251	Band acro-osteolysis in a Black woman: a case report and review of the literature. Archives of Hand and Microsurgery, 2022, 27, 62-67.	0.1	0
2252	Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors. RMD Open, 2022, 8, e001847.	1.8	19
2253	Role of musculoskeletal ultrasound, magnetic resonance imaging, and serum chemokine C-X-C motif ligand 10 in early detection of arthritis in patients with psoriasis. Egyptian Rheumatologist, 2022, 44, 219-224.	0.5	0
2255	Radial tunnel syndrome in psoriatic enthesitis: Complication or coincidence?. Mediterranean Journal of Rheumatology, 2021, 32, 373.	0.3	0
2256	Spondyloarthritis (SpA). , 2021, , 503-517.		2
2257	Psoriatic arthritis among Egyptian patients with psoriasis attending the dermatology clinic: prevalence, comorbidities, and clinical predictors. Reumatologia, 2021, 59, 394-401.	0.5	0
2259	Functional study of TNF-Î \pm promoter polymorphisms in psoriasis. Italian Journal of Dermatology and Venereology, 2021, , .	0.1	0
2261	Monoartritlerin değerlendirilmesi, bir yıllık, retrospektif tek merkez deneyimi. Ankara Eğitim Ve Araştırm Hastanesi Tıp Dergisi, 0, , .	^{1a} 0.1	0
2262	Perceptions of Rheumatologists on Diagnosis of Psoriatic Arthritis in China. Frontiers in Immunology, 2021, 12, 733708.	2.2	2
2263	Rheumatoid Arthritis and Related Disorders. , 2022, , 1615-1634.		0
2264	Tumor Necrosis Factor Alpha -308G/A Gene Polymorphisms Combined with Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio Predicts the Efficacy and Safety of Anti-TNF-α Therapy in Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Arthritis. Frontiers in Pharmacology, 2021, 12, 811719.	1.6	11
2265	Characterising axial psoriatic arthritis: correlation between whole spine MRI abnormalities and clinical, laboratory and radiographic findings. RMD Open, 2022, 8, e002011.	1.8	5
2266	Advances of Genomic Medicine in Psoriatic Arthritis. Journal of Personalized Medicine, 2022, 12, 35.	1.1	3
2267	Association of Gender, Diagnosis, and Obesity With Retention Rate of Secukinumab in Spondyloarthropathies: Results Form a Multicenter Real-World Study. Frontiers in Medicine, 2021, 8, 815881.	1.2	6
2268	Psoriatic Spondylitis: A Disease Manifestation in Debate. Journal of Clinical Rheumatology, 2022, 28, 38-43.	0.5	4

#	Article	IF	CITATIONS
2269	Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritis. Rheumatology, 2022, , .	0.9	2
2270	The value of SPARCC sacroiliac MRI scoring in axial psoriatic arthritis and its association with other disease parameters. International Journal of Rheumatic Diseases, 2022, 25, 433-439.	0.9	3
2272	The Conundrum of Psoriatic Arthritis: a Pathogenetic and Clinical Pattern at the Midpoint of Autoinflammation and Autoimmunity. Clinical Reviews in Allergy and Immunology, 2022, , .	2.9	5
2273	Associations of IL-18 with Altered Cardiovascular Risk Profile in Psoriatic Arthritis and Ankylosing Spondylitis. Journal of Clinical Medicine, 2022, 11, 766.	1.0	6
2274	Patient-Support Program in Diabetes Care During the Covid-19 Pandemic: An Italian Multicentric Experience. Patient Preference and Adherence, 2022, Volume 16, 113-122.	0.8	4
2275	Successful IL-17A inhibitor cycling in psoriatic arthritis patient: a case report and a literature review. Rheumatology International, 2022, 42, 365-370.	1.5	3
2276	Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis. Biomedicines, 2022, 10, 324.	1.4	4
2278	Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents. Scandinavian Journal of Rheumatology, 2023, 52, 42-50.	0.6	11
2279	High Dimensional Analyses of Circulating Immune Cells in Psoriatic Arthritis Detects Elevated Phosphorylated STAT3. Frontiers in Immunology, 2021, 12, 758418.	2.2	4
2280	Potential Differences in the Cardiometabolic Risk Profile of Patients with Psoriatic Disease according to Their HLA-C $ â^— $ 06 Status. BioMed Research International, 2022, 2022, 1-7.	0.9	5
2281	Case report of Osteopoikilosis in patient with psoriatic arthritis. Clinical Case Reports (discontinued), 2022, 10, e05263.	0.2	0
2282	Prevalence and consequences of psoriasis in recent axial spondyloarthritis: an analysis of the DESIR cohort over 6 years. RMD Open, 2022, 8, e001986.	1.8	7
2283	The Clinical Characteristics and Treatment Status of Psoriatic Arthritis. , 0, , .		0
2284	Psoriatic arthritis and other spondyloarthritides. Medicine, 2022, , .	0.2	0
2285	Pain catastrophizing in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: biopsychosocial perspective and impact on health-related quality of life. Rheumatology International, 2022, 42, 669-682.	1.5	8
2286	Doppler Signal and Bone Erosions at the Enthesis Are Independently Associated With Ultrasound Joint Erosive Damage in Psoriatic Arthritis. Journal of Rheumatology, 2023, 50, 70-75.	1.0	4
2287	Time to transition from psoriasis to psoriatic arthritis: A population-based study. Seminars in Arthritis and Rheumatism, 2022, 52, 151949.	1.6	6
2288	Enthesitis in patients with psoriatic arthritis and axial spondyloarthritis – data from the Danish nationwide DANBIO registry. Seminars in Arthritis and Rheumatism, 2022, 52, 151948.	1.6	7

#	Article	IF	CITATIONS
2289	Defining imaging sub-phenotypes of psoriatic arthritis: integrative analysis of imaging data and gene expression in a PsA patient cohort. Rheumatology, 2022, 61, 4952-4961.	0.9	3
2290	Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies. Journal of Endocrinological Investigation, 2022, 45, 1277-1288.	1.8	26
2291	Psoriasis and family history of psoriasis may not affect disease severity of rheumatoid arthritis. Reumatismo, 2021, 73, .	0.4	0
2292	Systematic review of the use of CRP in clinical trials for psoriatic arthritis: a concern for clinical practice?. RMD Open, 2022, 8, e001756.	1.8	6
2293	Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients. Journal of Applied Physiology, 2022, 132, 682-688.	1.2	2
2294	Evaluation of the prevalence of musculoskeletal conditions in consecutive patients with skin psoriasis: a descriptive cross-sectional study. Rheumatology International, 2022, , 1.	1.5	1
2295	Development of a Predictive Model for Screening Patients with Psoriasis at Increased Risk of Psoriatic Arthritis. Dermatology and Therapy, 2022, 12, 419-433.	1.4	9
2296	Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis. Annals of the Rheumatic Diseases, 2022, 81, 490-495.	0.5	10
2297	Seroprevalence of SARS-CoV-2 antibodies in patients with autoimmune inflammatory rheumatic diseases. Clinical and Experimental Rheumatology, 0, , .	0.4	2
2298	Psoriatic arthritis: prospects for the future. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210867.	1.2	4
2300	Unequal relevance between different subtypes of fingernail psoriasis and psoriatic arthritis. Clinical Rheumatology, 2022, , 1.	1.0	0
2301	Realâ€world blood examination screening data before initiation of biologics for psoriasis patients. Journal of Dermatology, 2022, 49, 534-538.	0.6	3
2302	Cardiovascular Risks and Risk Stratification in Inflammatory Joint Diseases: A Cross-Sectional Study. Frontiers in Medicine, 2022, 9, 786776.	1.2	6
2303	Epidemiology and Characteristics of Spondyloarthritis in the Predominantly Afro-Descendant Population of Martinique, a French Caribbean Island. Journal of Clinical Medicine, 2022, 11, 1299.	1.0	0
2304	Tofacitinib combined with leflunomide for treatment of psoriatic arthritis with IgA nephropathy: a case report with literature review. Clinical Rheumatology, 2022, , 1.	1.0	1
2305	Frequency of Renal Function Parameter Abnormalities in Patients with Psoriatic Arthritis and Rheumatoid Arthritis: Real-World Evidence from Clinical Practice. Journal of Clinical Medicine, 2022, 11, 1029.	1.0	2
2306	A Seven-Joint Ultrasound Score for Differentiating Between Rheumatoid and Psoriatic Arthritis. Current Rheumatology Reviews, 2022, 18, 329-337.	0.4	2
2307	Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induced activation of intermediate monocytes in synovial fluid mononuclear cells from patients with inflammatory arthritis. Arthritis Research and Therapy, 2022, 24, 43.	1.6	4

#	Article	IF	CITATIONS
2308	Multimodal imaging of the distal interphalangeal-joint synovio-entheseal complex in psoriatic arthritis (MIDAS): a cross-sectional study on the diagnostic accuracy of different imaging modalities comparing psoriatic arthritis to psoriasis and osteoarthritis. RMD Open, 2022, 8, e002109.	1.8	3
2309	The synovial and blood monocyte DNA methylomes mirror prognosis, evolution, and treatment in early arthritis. JCI Insight, 2022, 7, .	2.3	11
2310	Psoriatic arthritis: Ultrasound peculiarities with particular emphasis on enthesitis. Journal of Clinical Ultrasound, 2022, 50, 556-560.	0.4	2
2311	Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study. Frontiers in Immunology, 2022, 13, 846248.	2.2	19
2312	Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study. Arthritis and Rheumatology, 2022, 74, 1184-1192.	2.9	5
2313	Diagnostik per Power-Ultraschall: Psoriasis-Arthritis – exakte Diagnose, gezielte Therapie. , 0, , .		0
2314	The structured delegation of medical care services for patients with inflammatory rheumatic diseases. Deutsches Ärzteblatt International, 2022, , .	0.6	2
2315	The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast. Journal of Internal Medicine, 2022, 291, 676-693.	2.7	11
2316	Assessment of autonomic dysfunction with the COMPASS-31 and its relationship with disease activity and cardiovascular risks in patients with psoriatic arthritis. Rheumatology International, 2022, 42, 1539-1548.	1.5	2
2317	Deep Learning-Based Classification of Inflammatory Arthritis by Identification of Joint Shape Patterns—How Neural Networks Can Tell Us Where to "Deep Dive―Clinically. Frontiers in Medicine, 2022, 9, 850552.	1.2	12
2318	A Comparison of International League of Associations for Rheumatology and Pediatric Rheumatology International Trials Organization Classification Systems for Juvenile Idiopathic Arthritis Among Children in a Canadian Arthritis Cohort. Arthritis and Rheumatology, 2022, 74, 1409-1419.	2.9	7
2319	Osteo-Proliferative Lesions of the Phalanges on Radiography: Associations with Sex, Age, and Osteoarthritis. Diagnostics, 2022, 12, 618.	1.3	0
2320	Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Annals of the Rheumatic Diseases, 2022, 81, 815-822.	0.5	88
2321	Degenerative and Inflammatory Osteoproliferations in Lumbar Radiographs in Psoriatic Arthritis Patients. Journal of Clinical Medicine, 2022, 11, 2009.	1.0	0
2322	Diagnosis and Intervention in Early Psoriatic Arthritis. Journal of Clinical Medicine, 2022, 11, 2051.	1.0	7
2323	Enabling work participation for people with musculoskeletal conditions: lessons from work changes imposed by COVID-19: a mixed-method study. BMJ Open, 2022, 12, e057919.	0.8	1
2324	Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study. Lancet Rheumatology, The, 2022, 4, e262-e273.	2.2	8
2325	Dietetic intervention in psoriatic arthritis: the DIETA trial. Advances in Rheumatology, 2022, 62, 12.	0.8	6

#	Article	IF	CITATIONS
2326	Suspecting and Diagnosing the Patient with Spondyloarthritis and What to Expect from Therapy. Rheumatic Disease Clinics of North America, 2022, 48, 507-521.	0.8	4
2327	Hand functions and joint position sense in patients with psoriatic arthritis- a comparison with rheumatoid arthritis and healthy controls. Clinical Biomechanics, 2022, 95, 105640.	0.5	5
2328	Comparison of Clinical Manifestations in Rheumatoid Arthritis vs. Spondyloarthritis: A Systematic Literature Review. Rheumatology and Therapy, 2022, 9, 331-378.	1.1	13
2329	Clinical Specialty Setting as Determinant of Management of Psoriatic Arthritis. Journal of Clinical Rheumatology, 2022, 28, 120-125.	0.5	1
2330	Single cell analysis of spondyloarthritis regulatory T cells identifies distinct synovial gene expression patterns and clonal fates. Communications Biology, 2021, 4, 1395.	2.0	27
2331	Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection. Journal of Inflammation Research, 2021, Volume 14, 6975-6991.	1.6	6
2332	New Perspectives on Diagnosing Psoriatic Arthritis by Imaging Techniques. Open Access Rheumatology: Research and Reviews, 2021, Volume 13, 343-352.	0.8	1
2333	Assessment of physical function, quality of life, and medication adherence in elderly patients with rheumatic diseases. Egyptian Rheumatology and Rehabilitation, 2021, 48, .	0.2	0
2334	Using the patientâ€acceptable symptom state to evaluate patients' perspectives of living with psoriasis: A crossâ€sectional study. Australasian Journal of Dermatology, 2022, 63, .	0.4	1
2335	The use of guselkumab in psoriatic arthritis: evidence from real clinical practice. Sovremennaya Revmatologiya, 2021, 15, 91-94.	0.1	0
2336	Use of Ultrasonography to Discriminate Psoriatic Arthritis from Fibromyalgia: A Post-Hoc Analysis of the ULISSE Study. Journal of Clinical Medicine, 2022, 11, 180.	1.0	4
2337	Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib. Rheumatology and Therapy, 2022, 9, 411-433.	1.1	1
2338	Non-Alcoholic Fatty Liver Disease Is Associated With Reduced Glomerular Filtration Rate in Patients With Chronic Plaque Psoriasis. Journal of Cutaneous Medicine and Surgery, 2021, , 120347542110669.	0.6	1
2339	The Complex Role of C-Reactive Protein in Systemic Lupus Erythematosus. Journal of Clinical Medicine, 2021, 10, 5837.	1.0	27
2340	Recurrent and refractory lower limbs lymphedema in psoriatic arthritis: a case description and literature review. Veins and Lymphatics, 2021, 10, .	0.1	0
2341	Multicentre study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test results. RMD Open, 2022, 8, e002099.	1.8	12
2342	Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA Trial. Journal of Rheumatology, 2022, 49, 885-893.	1.0	12
2343	Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naÃ-ve Patients With Psoriatic Arthritis. Journal of Rheumatology, 2022, 49, 694-699.	1.0	4

#	Article	IF	CITATIONS
2344	Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy. Immunotherapy, 2022, 14, 593-598.	1.0	15
2345	The value of ultrasound-defined tenosynovitis and synovitis in the prediction of persistent arthritis. Rheumatology, 2023, 62, 1057-1068.	0.9	4
2346	The Immunogenicity and Safety of Three Types of SARS-CoV-2 Vaccines in Adult Patients with Immune-Mediated Inflammatory Diseases: A Longitudinal Cohort Study. Biomedicines, 2022, 10, 911.	1.4	9
2347	Patient characteristics, treatment patterns and disease outcomes in patients with psoriatic arthritis followed in a combined Dermatology–Rheumatology clinic: a retrospective real-world study. Rheumatology International, 2022, , 1.	1.5	1
2364	Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials. Rheumatology and Therapy, 2021, 8, 1677-1691.	1.1	1
2365	The impact of psoriasis on the clinical characteristics, disease burden and treatment patterns of peripheral spondyloarthritis. Rheumatology, 2022, 62, 135-146.	0.9	1
2366	Assessment of four screening tools and retrieval of key questions to detect undiagnosed psoriatic arthritis in Chinese patients with psoriasis: A multicenter study. Journal of Dermatology, 2022, 49, 615-623.	0.6	3
2367	Concise report: a minimal-invasive method to retrieve and identify entheseal tissue from psoriatic arthritis patients. Annals of the Rheumatic Diseases, 2022, 81, 1131-1135.	0.5	6
2370	Rheumatologie. , 2022, , 541-606.		0
2371	Fatigue and Associated Factors in an Immune-Mediated Inflammatory Disease Population: A Cross-Sectional Study. Journal of Clinical Medicine, 2022, 11, 2455.	1.0	4
2372	Response to: Correspondence on †No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related †physician-reported spondylitis'?' by Braun and Landewé. Annals of the Rheumatic Diseases, 2022, , annrheumdis-2022-222359.	0.5	2
2373	Sex-Based Medicine Meets Psoriatic Arthritis: Lessons Learned and to Learn. Frontiers in Immunology, 2022, 13, 849560.	2.2	4
2374	Artritis psoriásica. Medicina ClÃnica, 2022, 159, 40-46.	0.3	9
2375	Dactylitis is associated with more severe axial joint damage and higher disease activity in axial psoriatic arthritis. Journal of Rheumatology, 2022, , jrheum.220098.	1.0	3
2376	Clinical characteristics of patients with spondyloarthritis and inflammatory bowel disease versus inflammatory bowel disease-related arthritis. Rheumatology International, 2022, 42, 1751-1766.	1.5	5
2377	Psoriatic arthritis from a mechanistic perspective. Nature Reviews Rheumatology, 2022, 18, 311-325.	3.5	49
2378	Autoantibody Landscape Revealed by Wet Protein Array: Sum of Autoantibody Levels Reflects Disease Status. Frontiers in Immunology, 2022, 13, .	2.2	7
2379	Erythema nodosum after COVID-19 vaccine. Reumatismo, 2022, 74, .	0.4	4

#	Article	IF	CITATIONS
2380	Psoriatic arthritis mutilans: a descriptive study from a Brazilian tertiary center. Advances in Rheumatology, 2022, 62, 14.	0.8	0
2381	Increased erythrocyte mean corpuscular volume by methotrexate predicts clinical response in psoriatic arthritis. Rheumatology, 2022, , .	0.9	0
2382	Axial psoriatic arthritis: New entity or clinical form only?. Joint Bone Spine, 2022, 89, 105409.	0.8	4
2383	Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling. Arthritis and Rheumatology, 2022, 74, 1535-1543.	2.9	15
2384	Validity and reliability of the Turkish version of Psoriasis Epidemiology Screening Tool for the detection of psoriatic arthritis in patients with psoriasis. Archives of Rheumatology, 0, , .	0.3	0
2385	Severe Disease in Patients With Recent-Onset Psoriatic Arthritis. Prediction Model Based on Machine Learning. Frontiers in Medicine, 2022, 9, 891863.	1.2	5
2386	Correlation of enthesial and synovial inflammation in patients with psoriatic arthritis: Data of clinical and ultrasonographic study. Nauchno-Prakticheskaya Revmatologiya, 2022, 60, 174-180.	0.2	0
2387	Exploring the Association Between History of Psoriasis (PSO) and Disease Activity in Patients with Psoriatic Arthritis (PsA). Rheumatology and Therapy, 2022, , .	1.1	2
2388	Total-Body ¹⁸ F-FDG PET/CT in Autoimmune Inflammatory Arthritis at Ultra-Low Dose: Initial Observations. Journal of Nuclear Medicine, 2022, 63, 1579-1585.	2.8	13
2389	Clinical Characteristics of Potential "Difficult-to-treat―Patients with Psoriatic Arthritis: A Retrospective Analysis of a Longitudinal Cohort. Rheumatology and Therapy, 2022, 9, 1193-1201.	1.1	17
2390	Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials. Rheumatology and Therapy, 0, , .	1.1	3
2392	A multilocus genetic study evidences the association of autoimmune-related genes with Psoriatic Arthritis in Italian patients. Immunobiology, 2022, 227, 152232.	0.8	3
2393	Satisfaction with Social Roles and Physical Function in Immune-mediated Inflammatory Diseases: A Cross-Sectional Study. Reviews on Recent Clinical Trials, 2022, 17, 177-186.	0.4	2
2394	New Insights on Juvenile Psoriatic Arthritis. Frontiers in Pediatrics, 2022, 10, .	0.9	9
2395	Increased Cardiovascular Risk in Psoriatic Arthritis: Results From a Case-Control Monocentric Study. Frontiers in Medicine, 2022, 9, .	1.2	5
2396	The differences of Matrix Metalloproteinases (MMP-9 and MMP-13) in chronic inflammatory rheumatic diseases. , 2022, 125, 325-329.		0
2398	Effectiveness of Disease Modifying Anti-Rheumatic Drugs for Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort. Journal of Rheumatology, 0, , jrheum.211231.	1.0	1
2399	The impact of a structured weight-loss treatment on physical fitness in patients with psoriatic arthritis and obesity compared to matched controls: a prospective interventional study. Clinical Rheumatology, 2022, 41, 2745-2754.	1.0	3

#	Article	IF	Citations
" 2400	Validity and psychometric characteristics of the self-administered comorbidity questionnaire in patients with psoriatic arthritis. Rheumatology International, 2022, 42, 2061-2067.	1.5	2
2401	Juvenile Psoriasisarthritis. Springer Reference Medizin, 2022, , 403-412.	0.0	1
2402	Clinical profiling of psoriatic arthritis: an observational cross-sectional study from Karnataka Psoriatic Arthritis Cohort. Indian Journal of Rheumatology, 2022, 17, 340.	0.2	0
2403	Spondyloarthritis in familial Mediterranean fever: a cohort study. Rheumatology International, 2022, 42, 1729-1739.	1.5	7
2404	VEGF Profile in Early Undifferentiated Arthritis Cohort. Medicina (Lithuania), 2022, 58, 833.	0.8	4
2405	Validity of clinical psoriatic arthritis diagnoses made by rheumatologists in the Swedish National Patient Register. Scandinavian Journal of Rheumatology, 2023, 52, 374-384.	0.6	7
2406	Evaluating the Impact of High Intensity Interval Training on Axial Psoriatic Arthritis Based on MR Images. Diagnostics, 2022, 12, 1420.	1.3	3
2407	Comorbidity in Adult Psoriasis: Considerations for the Clinician. Psoriasis: Targets and Therapy, 0, Volume 12, 139-150.	1.2	10
2408	Risk of Autoimmune Diseases Following Optic Neuritis: A Nationwide Population-Based Cohort Study. Frontiers in Medicine, 0, 9, .	1.2	12
2409	Minimal disease activity (MDA) in patients with recent-onset psoriatic arthritis: predictive model based on machine learning. Arthritis Research and Therapy, 2022, 24, .	1.6	10
2410	NETosis in Psoriatic Arthritis: Serum MPO–DNA Complex Level Correlates With Its Disease Activity. Frontiers in Immunology, 0, 13, .	2.2	3
2411	Dactylitis and Early Onset Psoriasis in Psoriatic Arthritis: Are they Markers of Disease Severity? A Clinical Study. Rheumatology and Therapy, 0, , .	1.1	0
2412	Analysis of 5-year clinical and radiological outcomes in patients with psoriatic arthritis observed as part of the Treat to target strategy. Preliminary data. Sovremennaya Revmatologiya, 2022, 16, 14-20.	0.1	0
2413	Psoriatic arthritis and psoriasis severity as metabolic syndrome and insulin resistance predictors. Srpski Arhiv Za Celokupno Lekarstvo, 2022, 150, 456-461.	0.1	0
2414	NEUROMETABOLIC STRATEGY OF PHARMACOTHERAPY FOR PATIENTS WITH SERONEGATIVE ARTHRITIS. WiadomoÅvci Lekarskie, 2022, 75, 1477-1480.	0.1	0
2415	Patient and learner experience in a new set up of a multidisciplinary dermatologyâ€rheumatology clinic care model for psoriatic arthritis. International Journal of Rheumatic Diseases, 0, , .	0.9	1
2416	Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. Rheumatology, 2023, 62, 606-616.	0.9	6
2417	The reliability, validity, and responsiveness of Cognitive Exercise Therapy Approach: Biopsychosocial Questionnaire for patients with psoriatic arthritis. Rheumatology International, 2022, 42, 1973-1981.	1.5	2

#	Article	IF	CITATIONS
2418	Dysregulation of Bile Acids, Lipids, and Nucleotides in Psoriatic Arthritis Revealed by Unbiased Profiling of Serum Metabolites. Arthritis and Rheumatology, 2023, 75, 53-63.	2.9	13
2420	Proteomic Changes of Osteoclast Differentiation in Rheumatoid and Psoriatic Arthritis Reveal Functional Differences. Frontiers in Immunology, 0, 13, .	2.2	3
2421	Apremilast retention rate in clinical practice: observations from an Italian multi-center study. Clinical Rheumatology, 2022, 41, 3219-3225.	1.0	3
2422	Finding Gene Regulatory Networks in Psoriasis: Application of a Tree-Based Machine Learning Approach. Frontiers in Immunology, 0, 13, .	2.2	5
2423	Successful treatment of refractory erythrodermic psoriasis with traditional Thai herbal medicine. Explore: the Journal of Science and Healing, 2022, , .	0.4	0
2424	Acute joint swelling in psoriatic arthritis: Flare or "psoutâ€â€"A 10-year-monocentric study on synovial fluid. Experimental Biology and Medicine, 2022, 247, 1650-1656.	1.1	1
2425	Biological treatment usage in patients with HIV and rheumatic disease, 2003–2021: long-term safety and follow-up. RMD Open, 2022, 8, e002282.	1.8	5
2426	Serum interleukin-23 levels: relation to depression, anxiety, and disease activity in psoriatic arthritis patients. Clinical Rheumatology, 2022, 41, 3391-3399.	1.0	8
2427	Clinical Characteristics of Patients With Psoriatic Spondylitis Versus Those With Ankylosing Spondylitis: Features at Baseline Before Biologic Therapy. Journal of Korean Medical Science, 2022, 37, .	1.1	5
2429	Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study. Journal of Clinical Medicine, 2022, 11, 4178.	1.0	6
2430	The Effect of Guselkumab on Work Productivity in Biologic-NaÃ⁻ve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial. Advances in Therapy, 2022, 39, 4613-4631.	1.3	2
2431	Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis. Psoriasis: Targets and Therapy, 0, Volume 12, 213-220.	1.2	13
2432	Associations of Polypharmacy With Clinical Parameters, Function, and Health-Related Quality of Life in Psoriatic Arthritis. Journal of Clinical Rheumatology, 0, Publish Ahead of Print, .	0.5	2
2433	VIP/VPAC Axis Expression in Immune-Mediated Inflammatory Disorders: Associated miRNA Signatures. International Journal of Molecular Sciences, 2022, 23, 8578.	1.8	4
2435	Isolated axial disease in psoriatic arthritis and ankylosing spondylitis with psoriasis. Annals of the Rheumatic Diseases, 2022, 81, 1678-1684.	0.5	10
2436	Single-cell RNA sequencing to decipher the immunogenicity of ChAdOx1 nCoV-19/AZD1222 and mRNA-1273 vaccines in patients with autoimmune rheumatic diseases. Frontiers in Immunology, 0, 13, .	2.2	1
2437	Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials. Lancet Rheumatology, The, 2022, 4, e755-e764.	2.2	16
2438	MAPK activated kinase 2 inhibition shifts the chemokine signature in arthritis synovial fluid mononuclear cells from CXCR3 to CXCR2. International Immunopharmacology, 2022, 112, 109267.	1.7	1

#	Article	IF	CITATIONS
2439	Characteristics associated with the perception of high-impact disease (PsAID ≥4) in patients with recent-onset psoriatic arthritis. Machine learning-based model. Seminars in Arthritis and Rheumatism, 2022, 57, 152097.	1.6	1
2440	The length of stay and inpatient burden in inpatients with different psoriasis subtypes. International Journal of Medical Sciences, 2022, 19, 1519-1524.	1.1	2
2441	Prevention and risk assessment of cardiovascular events in a population of patients with psoriasis and psoriatic arthritis. Reumatologia, 2022, 60, 266-274.	0.5	2
2442	Palmoplantar plaque psoriasis is associated with diabetes, hypertension, obesity, and metabolic syndrome—A Case–control study. Indian Dermatology Online Journal, 2022, 13, 606.	0.2	1
2443	Normal C-reactive protein in active psoriatic arthritis: results from real-world clinical practice. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2211224.	1.2	5
2444	Relationship between onset of psoriasis and spondyloarthritis symptoms with clinical phenotype and diagnosis: data from REGISPONSER registry. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2211180.	1.2	1
2445	PSÖRİYATİK ARTRİTLİ HASTALARDA ANTİ-SİKLİK SİTRÜLİNLİ PEPTİT POZİTİFLİĞİ İLI ARASINDAKİ İLİŞKİ. Sakarya Medical Journal, 0, , .	E KLİNİ 0.1	K/RADYOLOJ
2446	Gut microbiota differences between psoriatic arthritis and other undifferentiated arthritis: A pilot study. Medicine (United States), 2022, 101, e29870.	0.4	5
2447	Epidemiology and clinical characteristics of psoriatic arthritis-related uveitis in Madrid, Spain. International Ophthalmology, 2023, 43, 771-777.	0.6	2
2448	Clinical and instrumental characteristics of axial involvement in psoriatic arthritis in real-life clinical practice. Nauchno-Prakticheskaya Revmatologiya, 2022, 60, 465-472.	0.2	2
2449	Is vitamin D status relevant to psoriasis and psoriatic arthritis? A retrospective cross-sectional study. Sao Paulo Medical Journal, 2023, 141, .	0.4	1
2450	The impact of nail psoriasis on disease activity, quality of life, and clinical variables in patients with psoriatic arthritis: A crossâ€sectional multicenter study. International Journal of Rheumatic Diseases, 2023, 26, 43-50.	0.9	2
2451	Comparison of Homologous and Heterologous Booster SARS-CoV-2 Vaccination in Autoimmune Rheumatic and Musculoskeletal Patients. International Journal of Molecular Sciences, 2022, 23, 11411.	1.8	2
2453	Combined – whole blood and skin fibroblasts- transcriptomic analysis in Psoriatic Arthritis reveals molecular signatures of activity, resistance and early response to treatment. Frontiers in Immunology, 0, 13, .	2.2	7
2455	Efficacy and safety of a mobile app intervention in patients with inflammatory arthritis: a prospective pilot study. Rheumatology International, 2022, 42, 2177-2190.	1.5	6
2456	Identification of variants in genes associated with autoinflammatory disorders in a cohort of patients with psoriatic arthritis. RMD Open, 2022, 8, e002561.	1.8	7
2457	Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study. Frontiers in Medicine, 0, 9, .	1.2	7
2458	Pathogenesis, multi-omics research, and clinical treatment of psoriasis. Journal of Autoimmunity, 2022, 133, 102916.	3.0	21

#	Article	IF	CITATIONS
2459	Analysis of rheumatoid- vs psoriatic arthritis synovial fluid reveals differential macrophage (CCR2) and T helper subsets (STAT3/4 and FOXP3) activation Autoimmunity Reviews, 2022, 21, 103207.	2.5	9
2460	Improved diagnostic performance of CASPAR criteria with integration of ultrasound. Frontiers in Immunology, 0, 13, .	2.2	5
2461	Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Drugs - Real World Outcomes, 2022, 9, 617-628.	0.7	4
2462	Longitudinal Follow-Up Using the Heel Enthesitis Magnetic Resonance Imaging Scoring System (HEMRIS) Shows Minimal Changes in Heel Enthesitis Assessed in Spondyloarthritis and Psoriasis Patients. Journal of Personalized Medicine, 2022, 12, 1765.	1.1	0
2463	HLA-B27 and its role of the pathogenesis of psoriatic arthritis. Vestnik Dermatologii I Venerologii, 0, , .	0.2	1
2464	Nail and enthesis assessment in patients with psoriatic disease by high frequency ultrasonography: findings from a single-centre cross-sectional study. Radiologia Medica, 2022, 127, 1400-1406.	4.7	7
2465	Sex-Based Differences in Sonographic and Clinical Findings Among Patients With Psoriatic Arthritis. Journal of Rheumatology, 2023, 50, 197-203.	1.0	2
2466	Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study. Rheumatology and Therapy, 0, , .	1.1	12
2467	Burden of enthesitis on the quality of life and work productivity in psoriatic arthritis patients. Egyptian Rheumatology and Rehabilitation, 2022, 49, .	0.2	0
2468	TCR repertoire profiling revealed antigen-driven CD8+ T cell clonal groups shared in synovial fluid of patients with spondyloarthritis. Frontiers in Immunology, 0, 13, .	2.2	7
2469	Galectin-1: A Potential Biomarker Differentiating between Early Rheumatoid Arthritis and Spondyloarthritis. Journal of Clinical Medicine, 2022, 11, 6313.	1.0	1
2470	Clinical Variations of Uveitis in Immuno-Inflammatory Diseases. Review of the Literature. Part 1. Oftalmologiya, 2022, 19, 465-474.	0.2	2
2471	Ultrasound Can Be Usefully Integrated with the Clinical Assessment of Nail and Enthesis Involvement in Psoriasis and Psoriatic Arthritis. Journal of Clinical Medicine, 2022, 11, 6296.	1.0	4
2473	Serum Calprotectin as a Promising Inflammatory Biomarker in Psoriatic Arthritis: a 1-Year Longitudinal Study. Rheumatology and Therapy, 0, , .	1.1	2
2474	Utilization of the Psoriasis Epidemiology Screening Tool (PEST): A Risk Stratification Strategy for Early Referral of Psoriatic Arthritis Patients to Minimize Irreversible Erosive Joint Damage. Journal of Cutaneous Medicine and Surgery, 0, , 120347542211287.	0.6	3
2475	Reduced prescription of TNF-inhibitors in chronic arthritis based on therapeutic drug monitoring: A randomized controlled trial. Scandinavian Journal of Rheumatology, 2023, 52, 468-480.	0.6	4
2476	Real-World Safety Profile of Biologics Used in Rheumatology: A Six-Year Observational Pharmacovigilance Study in the Calabria Region. Pharmaceutics, 2022, 14, 2328.	2.0	2
2477	Advanced genomics and clinical phenotypes in psoriatic arthritis. Seminars in Immunology, 2021, 58, 101665.	2.7	1

#	Article	IF	CITATIONS
2478	TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA). BMJ Open, 2022, 12, e064338.	0.8	2
2479	Ultrasound Enthesitis in Psoriasis Patients with or without Psoriatic Arthritis, a Cross-Sectional Analysis. Medicina (Lithuania), 2022, 58, 1557.	0.8	3
2480	Prologue: Evidence Informing the GRAPPA 2021 Treatment Recommendations, by Domain. Journal of Rheumatology, 2023, 50, 117-118.	1.0	0
2481	Tenderness and radiographic progression in rheumatoid arthritis and psoriatic arthritis. Annals of the Rheumatic Diseases, 2023, 82, 344-350.	0.5	5
2482	Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cross-sectional study. RMD Open, 2022, 8, e002626.	1.8	0
2483	Management of Dactylitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. Journal of Rheumatology, 2023, 50, 265-278.	1.0	4
2484	Diagnosis of subclinical psoriatic arthritis in patients with psoriasis using CASPAR criteria: a sonographic study. Egyptian Rheumatology and Rehabilitation, 2022, 49, .	0.2	0
2485	Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis epidemiology in England from 2004 to 2020: An observational study using primary care electronic health record data. Lancet Regional Health - Europe, The, 2022, 23, 100519.	3.0	10
2486	Tackling the Inflammatory Burden of Psoriasis: A Multidisciplinary Approach. European Medical Journal (Chelmsford, England), 0, , 27-35.	3.0	0
2487	18F-sodium fluoride PET-CT visualizes both axial and peripheral new bone formation in psoriatic arthritis patients. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 756-764.	3.3	2
2488	Ex vivo cytokine production in psoriatic disease: Towards specific signatures in cutaneous psoriasis and peripheral psoriatic arthritis. Frontiers in Immunology, 0, 13, .	2.2	1
2489	Multiple Cytokine Analysis of Th1/Th2/Th9/Th17/Th22/Treg Cytokine Pathway for Individual Immune Profile Assessment in Patients with Psoriasis. Medical Science Monitor, 0, 28, .	0.5	7
2490	Association of female sex with increased risk of sleep disturbance in adult patients with moderate to severe psoriasis: a Chinese cross-sectional study. International Journal of Dermatology and Venereology, 0, Publish Ahead of Print, .	0.1	0
2491	Peripheral spondyloarthritis and psoriatic arthritis <i>sine psoriase</i> : are we dealing with semantics or clinically meaningful differences?. RMD Open, 2022, 8, e002592.	1.8	2
2492	An overview of psoriatic arthritis including clinical manifestations, assessment, diagnostic criteria, investigations, drug management and GRAPPA guidelines. Musculoskeletal Care, 2022, 20, .	0.6	0
2493	Musculoskeletal Surgery in Psoriatic Arthritis: Prevalence and Risk Factors. Journal of Rheumatology, 2023, 50, 497-503.	1.0	2
2494	Morphologic, dynamic and high-resolution microscopy MRI in early-onset spondyloarthritis finger dactylitis. Skeletal Radiology, 0, , .	1.2	2
2495	DNA methylation markers in peripheral blood for psoriatic arthritis. Journal of Dermatological Science, 2022, 108, 39-47.	1.0	4

#	Article	IF	CITATIONS
2496	Carotid ultrasound for assessing the subclinical atherosclerosis in psoriatic arthritis patients: A propensity scores matching analysis. Journal of Radiation Research and Applied Sciences, 2022, 15, 100481.	0.7	0
2497	First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study. Sao Paulo Medical Journal, 2022, 140, 787-797.	0.4	1
2498	Evaluation of subclinical atherosclerosis by ultrasound radiofrequency data technology in patients with psoriatic arthritis. Revista Da Associação Médica Brasileira, 2022, 68, 1645-1650.	0.3	1
2499	Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial. Lancet Rheumatology, The, 2023, 5, e14-e23.	2.2	7
2500	Smoking and alcohol consumption are associated with peripheral musculoskeletal involvement in patients with spondyloarthritis (including psoriatic arthritis). Results from the ASAS-PerSpA study. Seminars in Arthritis and Rheumatism, 2023, 58, 152146.	1.6	1
2501	Clinical Overview of Psoriasis and Psoriatic Arthritis. , 2022, , 345-365.		0
2502	Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study). Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2211422.	1.2	2
2503	Le patient présentant des lésions du revêtement cutané et muqueux. , 2022, , 267-278.		0
2504	Platelet to albumin ratio is an independent indicator for disease activity in ankylosing spondylitis. Clinical Rheumatology, 2023, 42, 407-413.	1.0	1
2505	Risks of malignancies among patients with psoriasis: A cohort study of 360 patients. Journal of Dermatology, 2023, 50, 615-621.	0.6	3
2506	Drug Retention and Safety of Secukinumab in a Real-World Cohort of Ankylosing Spondylitis and Psoriatic Arthritis Patients. International Journal of Environmental Research and Public Health, 2022, 19, 15861.	1.2	1
2507	Impairment in cognitive function in patients with axial spondyloarthritis and psoriatic arthritis. Rheumatology International, 2023, 43, 89-97.	1.5	2
2508	COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data. Advances in Rheumatology, 2022, 62, .	0.8	2
2509	Utility of nailfold capillary assessment for predicting psoriatic arthritis based on a prospective observational cohort study. Rheumatology, 2023, 62, 2418-2425.	0.9	9
2510	Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ Open, 2022, 12, e063650.	0.8	10
2511	Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-î± inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet, The, 2023, 401, 38-48.	6.3	57
2512	Importance of quick attainment of minimal disease activity for a positive impact on lives of patients with psoriatic arthritis. RMD Open, 2022, 8, e002706.	1.8	4
2514	Psoriatic Arthritis: Differential Features at the Time of Clinical Presentation in a Large Cohort of Patients with Polyarthralgia. , 2023, 10, 12-17.		0

#	Article	IF	CITATIONS
2515	Residual inflammation in psoriatic arthritis patients in stable minimal disease activity. Frontiers in Medicine, 0, 9, .	1.2	3
2516	Multiâ€omics integration reveals a core network involved in host defence and hyperkeratinization in psoriasis. Clinical and Translational Medicine, 2022, 12, .	1.7	4
2517	Relevance of studying axial syndrome in spondyloarthritis (review of literature). Medical Alphabet, 2022, , 44-48.	0.0	0
2518	Characterising the axial phenotype of psoriatic arthritis: a study comparing axial psoriatic arthritis and ankylosing spondylitis with psoriasis from the REGISPONSER registry. RMD Open, 2022, 8, e002513.	1.8	13
2519	Exploiting Signal Joint T Cell Receptor Excision Circle to Investigate the Impact of COVID-19 and Autoimmune Diseases on Age Prediction and Immunosenescence. Biomedicines, 2022, 10, 3193.	1.4	0
2520	In-Office Needle Arthroscopic Synovial Biopsy Is an Effective Diagnostic Tool in Patients With Inflammatory Arthritis. Arthroscopy, Sports Medicine, and Rehabilitation, 2022, 4, e2099-e2106.	0.8	0
2521	Fluorescence-optical imaging as a promising easy-to-use imaging biomarker to increase early psoriatic arthritis detection in patients with psoriasis: a cross-sectional cohort study with follow-up. RMD Open, 2022, 8, e002682.	1.8	2
2522	Primary antibody deficiency-associated arthritis shares features with spondyloarthritis and enteropathic arthritis. RMD Open, 2022, 8, e002664.	1.8	3
2523	Alterations in the cutaneous microbiome of patients with psoriasis and psoriatic arthritis reveal similarities between non-lesional and lesional skin. Annals of the Rheumatic Diseases, 2023, 82, 507-514.	0.5	6
2524	Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet, The, 2023, 401, 25-37.	6.3	55
2525	Prospective double-blind study on the value of musculoskeletal ultrasound by dermatologists as a screening instrument for psoriatic arthritis. Rheumatology, 2023, 62, 2724-2731.	0.9	4
2526	Temporomandibular Joint Disorders Associated With Psoriatic Arthritis: A Report of Three Cases. Cureus, 2022, , .	0.2	0
2527	Current treatment strategies and recommendations in psoriatic arthritis. International Journal of Rheumatic Diseases, 2023, 26, 8-10.	0.9	7
2528	Real-World Experience of Apremilast in Treating Psoriatic Arthritis Patients with Comorbidities. European Medical Journal Rheumatology, 0, , 134-139.	0.0	1
2529	Secukinumab in the Management of Psoriatic Arthritis: Current Perspectives. European Medical Journal Rheumatology, 0, , 112-121.	0.0	0
2530	Sporadic hypophosphatemic osteomalacia combined with psoriasis: A rare case report and a brief review of the literature. International Journal of Rheumatic Diseases, 2023, 26, 968-972.	0.9	2
2532	Juvenile Psoriatic Arthritis: Myth or Reality? An Unending Debate. Journal of Clinical Medicine, 2023, 12, 367.	1.0	3
2533	Pembrolizumab-induced psoriatic arthritis treated with disease-modifying anti-rheumatic drugs in a patient with gastric cancer: A case report. World Journal of Clinical Cases, 0, 11, 218-224.	0.3	3

#	Article	IF	CITATIONS
2534	Increase in axial spondyloarthritis diagnoses after the introduction of the ASAS criteria: a systematic review. Rheumatology International, 0, , .	1.5	0
2535	Clinical significance of plasma markers of angiogenesis in patients with psoriasis. Russian Journal of Skin and Venereal Diseases, 2023, 25, 409-418.	0.0	0
2536	Acute and Chronic Systemic Inflammation: Features and Differences in the Pathogenesis, and Integral Criteria for Verification and Differentiation. International Journal of Molecular Sciences, 2023, 24, 1144.	1.8	8
2537	Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience. Journal of Clinical Medicine, 2023, 12, 467.	1.0	4
2538	Psoriatic arthritis and its special features predispose not only for osteoporosis but also for fractures and falls. Journal of Dermatology, 0, , .	0.6	0
2539	Psoriatic arthritis of the temporomandibular joint: A systematic review. Journal of Oral Rehabilitation, 2023, 50, 243-255.	1.3	5
2540	Exploring pain catastrophizing and its associations with low disease activity in rheumatic inflammatory disorders. Rheumatology International, 2023, 43, 687-694.	1.5	0
2541	Paraneoplastic arthritides: an up-to-date case-based systematic review. Reumatologia, 2022, 60, 422-436.	0.5	4
2543	Clinical and psychological characteristics associated with negative beliefs and concerns about treatment necessity in rheumatic diseases. Scientific Reports, 2022, 12, .	1.6	2
2544	PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis. Rheumatology and Therapy, 2023, 10, 489-505.	1.1	1
2545	Acute Ischemic Stroke in the Patients with Inflammatory Arthritis: An Analysis of Data from National Health Insurance Service. Korean Journal of Clinical Geriatrics, 2022, 23, 96-114.	0.3	0
2546	Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis. Arthritis Research and Therapy, 2022, 24, .	1.6	0
2547	Evaluation of Subclinical Hand Joint Synovitis by Ultrasonography in Patients with Psoriatic Arthritis and Cutaneous Psoriasis: A Case-Control Study. Mediterranean Journal of Rheumatology, 2022, 33, 421.	0.3	2
2548	Effectiveness and safety of generic tofacitinib in spondyloarthritis: A realâ€world retrospective analysis from India. International Journal of Rheumatic Diseases, 2023, 26, 487-492.	0.9	3
2549	Diagnostic criteria in dermatology. Indian Journal of Dermatology, Venereology and Leprology, 0, .	0.2	0
2550	Moderate-High Disease Activity in Patients with Recent-Onset Psoriatic Arthritis—Multivariable Prediction Model Based on Machine Learning. Journal of Clinical Medicine, 2023, 12, 931.	1.0	1
2551	Autoantibodies to <scp>Diseaseâ€Related</scp> Proteins in Joints as Novel Biomarkers for the Diagnosis of Rheumatoid Arthritis. Arthritis and Rheumatology, 2023, 75, 1110-1119.	2.9	10
2553	Association of Transition of Laboratory Markers with Transition of Disease Activity in Psoriasis Patients Treated with Biologics. Journal of Nippon Medical School, 2022, 89, 587-593.	0.3	5

#	Article	IF	CITATIONS
2554	IL-17 Inhibition in Spondyloarthritis: A Targeted Approach in Psoriatic Arthritis. European Medical Journal Rheumatology, 0, , 55-64.	0.0	0
2555	Hepatic failure in a patient with rheumatoid arthritis treated with methotrexate: A case report. Medicine (United States), 2023, 102, e32711.	0.4	2
2556	Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA. RMD Open, 2023, 9, e002837.	1.8	7
2557	The use of ultrasound to detect enthesitis as a potential guide for intervention in patients with psoriasis at risk of psoriatic arthritis: a systematic review. International Journal of Dermatology, 2023, 62, 973-979.	0.5	1
2558	Serum Interleukin-34 in Psoriatic arthritis patients and its correlation with disease 1 activity, and subclinical atherosclerosis. Egyptian Rheumatology and Rehabilitation, 2023, 50, .	0.2	0
2559	Patient reported outcomes in early vs late diagnosis of psoriatic arthritis. Revista Colombiana De ReumatologÃa, 2023, 30, S27-S33.	0.0	Ο
2560	Vitamin D in psoriatic arthritis – A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 2023, 60, 152200.	1.6	3
2562	Rheumatoid factor and anti-citrullinated protein antibodies (ACPA) in psoriatic arthritis (PsA), and skin psoriasis: Relevance and clinical implications. Egyptian Rheumatologist, 2023, 45, 145-151.	0.5	1
2563	Comprehensive assessment of the dynamics of angiogenesis in patients with psoriasis treated with methotrexate. Vestnik Dermatologii I Venerologii, 2023, 99, 37-47.	0.2	0
2564	Multi-modality data-driven analysis of diagnosis and treatment of psoriatic arthritis. Npj Digital Medicine, 2023, 6, .	5.7	0
2565	Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study. Biomedicines, 2023, 11, 433.	1.4	1
2566	The association of psoriasis and psoriatic arthritis with periodontitis: A hospital-based case-control study. Indian Journal of Dermatology, Venereology and Leprology, 0, .	0.2	2
2567	Atteintes axiales du rhumatisme psoriasique. , 2022, , 3-9.		0
2568	Anti-inflammatory effect of biologic therapy in patients with psoriatic disease: A prospective cohort FDG PET study. Journal of Nuclear Cardiology, 2023, 30, 1642-1652.	1.4	4
2569	Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Clinical Rheumatology, 2023, 42, 1593-1605.	1.0	4
2570	The Clinical Characteristics of Psoriatic Arthritis: A Cross-Sectional Study Based on the Psoriatic Arthritis Cohort of West China Hospital. Rheumatology and Therapy, 2023, 10, 775-784.	1.1	1
2571	Psoriatic Arthritis in Males and Females: Differences and Similarities. Rheumatology and Therapy, 2023, 10, 589-599.	1.1	9
2572	Rheumatic aspects of arthralgias associated with aromatase inhibitor therapy (analysis of a clinical) Tj ETQq1	1 0.784314 r 0.1	gBT /Overloc

#	Article	IF	CITATIONS
2573	Development of Autoantibodies Following BNT162b2 mRNA COVID-19 Vaccination and Their Association with Disease Flares in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) and the General Population: Results of 1-Year Prospective Follow-Up Study. Vaccines, 2023, 11, 476.	2.1	6
2574	Ixekizumab therapy following secukinumab inadequate response in psoriatic arthritis: a case series focusing on axial disease. Rheumatology International, 2023, 43, 969-973.	1.5	1
2575	Histone deacetylase inhibitors as a potential new treatment for psoriatic disease and other inflammatory conditions. Critical Reviews in Clinical Laboratory Sciences, 2023, 60, 300-320.	2.7	2
2576	Apremilast for biologic-naÃ ⁻ ve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study. Rheumatology International, 2023, 43, 889-902.	1.5	2
2577	Impact of biological and non-biological treatment on hematological indices in patients with ankylosing spondylitis and psoriatic arthritis. Egyptian Rheumatology and Rehabilitation, 2023, 50, .	0.2	1
2578	The role of ultrasound in screening subclinical psoriatic arthritis in patients with moderate to severe psoriasis. European Radiology, 2023, 33, 3943-3953.	2.3	4
2579	Value of Hands Ultrasonography in the Differential Diagnosis Between Psoriatic Arthritis and Rheumatoid Arthritis. Journal of Ultrasound in Medicine, 0, , .	0.8	0
2581	Association between triglyceride-glucose index and carotid atherosclerosis in patients with psoriatic arthritis. Rheumatology, 0, , .	0.9	0
2582	Vitamin D Status and Psoriatic Arthritis: Association with the Risk for Sacroiliitis and Influence on the Retention Rate of Methotrexate Monotherapy and First Biological Drug Survival—A Retrospective Study. International Journal of Molecular Sciences, 2023, 24, 5368.	1.8	1
2583	Leucocyte Abnormalities in Synovial Fluid of Degenerative and Inflammatory Arthropathies. International Journal of Molecular Sciences, 2023, 24, 5450.	1.8	1
2584	No Relationship Between Blood Groups and Psoriatic arthritis. Ahi Evran Medical Journal, 0, , .	0.1	0
2585	Late-Onset Psoriatic Arthritis: Are There Any Distinct Characteristics? A Retrospective Cohort Data Analysis. Life, 2023, 13, 792.	1.1	2
2586	Prevalence and clinical associations of ultrasound-confirmed enthesitis in systemic lupus erythematosus. Rheumatology, 0, , .	0.9	1
2587	Characterization of the inflammatory proteome of synovial fluid from patients with psoriatic arthritis: Potential treatment targets. Frontiers in Immunology, 0, 14, .	2.2	4
2588	Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension. RMD Open, 2023, 9, e002718.	1.8	8
2589	Optical spectral transmission to assess glucocorticoid therapy response in patients with arthritis: a longitudinal follow-up comparison with joint ultrasound. Arthritis Research and Therapy, 2023, 25, .	1.6	0
2590	Arthroscopic synovectomy versus intra-articular injection of corticosteroids for the management of refractory psoriatic or rheumatoid arthritis of the wrist: study protocol for a randomized controlled trial (ARCTIC trial). Trials, 2023, 24, .	0.7	0
2591	Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort. Advances in Rheumatology, 2023, 63, .	0.8	3

#	Article	IF	CITATIONS
2592	Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational Study. Vaccines, 2023, 11, 740.	2.1	4
2593	Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study. Life, 2023, 13, 877.	1.1	3
2594	Central Pain Sensitization in Patients with Chronic Plaque Psoriasis. Dermatology and Therapy, 2023, 13, 1149-1156.	1.4	1
2596	Same, same or different? Commonalities and differences between spondyloarthritis and its subsets of axial and peripheral spondyloarthritis with psoriatic arthritis and its diverse phenotypes. RMD Open, 2023, 9, e002872.	1.8	4
2598	Foot and Ankle Inflammatory Arthritis. Medical Radiology, 2023, , 355-390.	0.0	0
2599	Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies. Arthritis Research and Therapy, 2023, 25, .	1.6	1
2600	Sleep disturbances in patients with psoriatic arthritis. Revista Colombiana De Reumatolog $ ilde{A}$ a, 2023, , .	0.0	0
2601	Ultrasonographic Evaluation of Entheseal Fibrocartilage in Patients with Psoriatic Arthritis, Athletes and Healthy Controls: A Comparison Study. Diagnostics, 2023, 13, 1446.	1.3	0
2602	Evaluation of clinical efficacy of tumor necrosis factorâ€Î± inhibitors in treatment of distal extremity swelling with pitting edema in psoriatic arthritis of inadequate response to conventional therapy: A 10â€'year retrospective study. Experimental and Therapeutic Medicine, 2023, 25, .	0.8	0
2606	Autoantibodies in psoriatic disease. Advances in Clinical Chemistry, 2023, , .	1.8	0
2615	Do Biologic Treatments for Psoriasis Lower the Risk of Psoriatic Arthritis? A Systematic Review. American Journal of Clinical Dermatology, 0, , .	3.3	1
2754	Drug- or Vaccine-Induced/Aggravated Psoriatic Arthritis: A Systematic Review. Dermatology and Therapy, 2024, 14, 59-81.	1.4	0
2761	The Saudi consensus recommendations for the management of psoriatic arthritis (2023). Clinical Rheumatology, 2024, 43, 879-894.	1.0	0
2767	Exploration desÂspondyloarthrites enÂIRM. , 2023, , 85-102.		0